

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/48015 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/705

MI 49024 (US). HIEBSCH, Ronald, R.; 917 Lane Boulevard, Kalamazoo, MI 49001 (US). RUFF, Valerie; Portage, MI (US).

(21) International Application Number: PCT/US00/35456

(22) International Filing Date:  
28 December 2000 (28.12.2000)

(74) Agents: DELUCA, Mark et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(25) Filing Language: English

(81) Designated States (national): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

60/173,339	28 December 1999 (28.12.1999)	US
60/184,305	23 February 2000 (23.02.2000)	US
60/188,880	13 March 2000 (13.03.2000)	US
60/200,534	27 April 2000 (27.04.2000)	US
60/219,492	20 July 2000 (20.07.2000)	US
60/224,321	11 August 2000 (11.08.2000)	US
60/239,062	9 October 2000 (09.10.2000)	US

(71) Applicant: PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/48015 A2

(54) Title: NOVEL G PROTEIN-COUPLED RECEPTORS

(57) Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

## NOVEL G PROTEIN-COUPLED RECEPTORS

### CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority of Application Serial No. 60/173,339, filed 5 1999 December 28; Serial No. 60/184,305, filed 2000 February 23; Serial No. 60/224,321, filed 2000 August 11; Serial No. 60/200,534, filed 2000 April 27; Serial No. 60/239,062, filed 2000 October 9; Serial No. 60/188,880, filed 2000 March 13; Serial No. 60/219,492, filed 2000 July 20, each of which is hereby incorporated by reference in its entirety.

10

### FIELD OF THE INVENTION

The present invention relates generally to the fields of genetics and cellular and molecular biology. More particularly, the invention relates to novel G protein coupled receptors, to polynucleotides that encode such novel receptors, to reagents such as 15 antibodies, probes, primers and kits comprising such antibodies, probes, primers related to the same, and to methods which use the novel G protein coupled receptors, polynucleotides or reagents.

### BACKGROUND OF THE INVENTION

20 The G protein-coupled receptors (GPCRs) form a vast superfamily of cell surface receptors which are characterized by an amino-terminal extracellular domain, a carboxyl-terminal intracellular domain, and a serpentine structure that passes through the cell membrane seven times. Hence, such receptors are sometimes also referred to as seven transmembrane (7TM) receptors. These seven transmembrane domains define three 25 extracellular loops and three intracellular loops, in addition to the amino- and carboxy-terminal domains. The extracellular portions of the receptor have a role in recognizing and binding one or more extracellular binding partners (e.g., ligands), whereas the intracellular portions have a role in recognizing and communicating with downstream molecules in the signal transduction cascade.

30 The G protein-coupled receptors bind a variety of ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants,

and even photons, and are important in the normal (and sometimes the aberrant) function of many cell types. [See generally Strosberg, *Eur. J. Biochem.* 196:1-10 (1991) and Bohm *et al.*, *Biochem J.* 322:1-18 (1997).] When a specific ligand binds to its corresponding receptor, the ligand typically stimulates the receptor to activate a specific 5 heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) that is coupled to the intracellular portion of the receptor. The G protein in turn transmits a signal to an effector molecule within the cell, by either stimulating or inhibiting the activity of that effector molecule. These effector molecules include adenylate cyclase, phospholipases and ion channels. Adenylate cyclase and phospholipases are enzymes that are involved in 10 the production of the second messenger molecules cAMP, inositol triphosphate and diacyglycerol. It is through this sequence of events that an extracellular ligand stimuli exerts intracellular changes through a G protein-coupled receptor. Each such receptor has its own characteristic primary structure, expression pattern, ligand-binding profile, and intracellular effector system.

15 Because of the vital role of G protein-coupled receptors in the communication between cells and their environment, such receptors are attractive targets for therapeutic intervention, for example by activating or antagonizing such receptors. For receptors having a known ligand, the identification of agonists or antagonists may be sought specifically to enhance or inhibit the action of the ligand. Some G protein-coupled 20 receptors have roles in disease pathogenesis (e.g., certain chemokine receptors that act as HIV co-receptors may have a role in AIDS pathogenesis), and are attractive targets for therapeutic intervention even in the absence of knowledge of the natural ligand of the receptor. Other receptors are attractive targets for therapeutic intervention by virtue of their expression pattern in tissues or cell types that are themselves attractive targets for 25 therapeutic intervention. Examples of this latter category of receptors include receptors expressed in immune cells, which can be targeted to either inhibit autoimmune responses or to enhance immune responses to fight pathogens or cancer; and receptors expressed in the brain or other neural organs and tissues, which are likely targets in the treatment of mental disorder, depression, bipolar disease, or other neurological disorders. This latter 30 category of receptor is also useful as a marker for identifying and/or purifying (e.g., via

fluorescence-activated cell sorting) cellular subtypes that express the receptor. Unfortunately, only a limited number of G protein receptors from the central nervous system (CNS) are known. Thus, a need exists for G protein-coupled receptors that have been identified and show promise as targets for therapeutic intervention in a variety of 5 animals, including humans.

## SUMMARY OF THE INVENTION

The present invention relates to an isolated nucleic acid molecule that comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence 10 homologous to sequences selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or a fragment thereof. The nucleic acid molecule encodes at least a portion of nGPCR-x. In some embodiments, the nucleic acid molecule comprises a sequence that encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ 15 ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a sequence selected from the group consisting of SEQ 20 ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, and fragments thereof.

According to some embodiments, the present invention provides vectors which comprise the nucleic acid molecule of the invention. In some embodiments, the vector is an expression vector.

25 According to some embodiments, the present invention provides host cells which comprise the vectors of the invention. In some embodiments, the host cells comprise expression vectors.

The present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the 30 group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, said portion comprising at least 10 nucleotides.

The present invention provides a method of producing a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or a homolog or fragment thereof. The method comprising the steps of introducing a recombinant expression vector that includes

5 a nucleotide sequence that encodes the polypeptide into a compatible host cell, growing the host cell under conditions for expression of the polypeptide and recovering the polypeptide.

The present invention provides an isolated antibody which binds to an epitope on a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or a homolog or fragment thereof.

The present invention provides a method of inducing an immune response in a mammal against a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or a homolog or fragment thereof. The method comprises administering to a mammal an amount of the polypeptide sufficient to induce said immune response.

The present invention provides a method for identifying a compound which binds nGPCR-x. The method comprises the steps of: contacting nGPCR-x with a compound and determining whether the compound binds nGPCR-x.

20 The present invention provides a method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x. The method comprises the steps of contacting said nucleic acid molecule encoding nGPCR-x with a compound and determining whether said compound binds said nucleic acid molecule.

The present invention provides a method for identifying a compound which 25 modulates the activity of nGPCR-x. The method comprises the steps of contacting nGPCR-x with a compound and determining whether nGPCR-x activity has been modulated.

The present invention provides a method of identifying an animal homolog of nGPCR-x. The method comprises the steps screening a nucleic acid database of the 30 animal with a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID

NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or a portion thereof and determining whether a portion of said library or database is homologous to said sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or portion thereof.

5 The present invention provides a method of identifying an animal homolog of nGPCR-x. The methods comprises the steps screening a nucleic acid library of the animal with a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or a portion thereof; and determining whether a portion of said library or database

10 10 is homologous to said sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or a portion thereof.

Another aspect of the present invention relates to methods of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor. The

15 15 methods comprise the steps of assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR that is expressed in the brain. The nGPCR comprise an amino acid sequence selected from the group consisting of: SEQ ID NO:25, and SEQ ID NO:46, and allelic variants thereof. A diagnosis of the disorder or

20 20 predisposition is made from the presence or absence of the mutation. The presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

The present invention further relates to methods of screening for a nGPCR-1002 or nGPCR-1007 hereditary mental disorder genotype in a human patient. The methods

25 25 comprise the steps of providing a biological sample comprising nucleic acid from the patient, in which the nucleic acid includes sequences corresponding to alleles of nGPCR-1002 or nGPCR-1007. The presence of one or more mutations in the nGPCR-1002 allele or the nGPCR-1007 allele is detected indicative of a hereditary mental disorder genotype.

The present invention provides kits for screening a human subject to diagnose

30 30 mental disorder or a genetic predisposition therefor. The kits include an oligonucleotide

useful as a probe for identifying polymorphisms in a human nGPCR-1002 gene or a human nGPCR-1007 gene. The oligonucleotide comprises 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-1002 or nGPCR-1007 gene sequence or nGPCR-1002 or nGPCR-1007 coding sequence, 5 except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution. The kit also includes a media packaged with the oligonucleotide. The media contains information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

10 The present invention further relates to methods of identifying nGPCR allelic variants that correlates with mental disorders. The methods comprise the steps of providing biological samples that comprise nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny, and detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is 15 expressed in the brain. The nGPCR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, and SEQ ID NO:46, and allelic variants thereof. The nucleic acid includes sequences corresponding to the gene or genes encoding nGPCR. The one or more mutations detected indicate an allelic variant that correlates with a mental disorder.

20 The present invention further relates to purified polynucleotides comprising nucleotide sequences encoding alleles of nGPCR-1002 or nGPCR-1007 from a human with mental disorder. The polynucleotide hybridizes to the complement of SEQ ID NO:12 or of SEQ ID NO:45 under the following hybridization conditions: (a) hybridization for 16 hours at 42°C in a hybridization solution comprising 50% 25 formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS. The polynucleotide that encodes nGPCR-1002 or nGPCR-1007 amino acid sequence of the human differs from SEQ ID NO:25 or SEQ ID NO:46 by at least one residue.

30 The present invention also provides methods for identifying a modulator of biological activity of nGPCR-1002 or nGPCR-1007 comprising the steps of contacting a

cell that expresses nGPCR-1002 or nGPCR-1007 in the presence and in the absence of a putative modulator compound and measuring nGPCR-1002 or nGPCR-1007 biological activity in the cell. The decreased or increased nGPCR-1002 or nGPCR-1007 biological activity in the presence versus absence of the putative modulator is indicative of a 5 modulator of biological activity.

The present invention further provides methods to identify compounds useful for the treatment of mental disorders. The methods comprise the steps of contacting a composition comprising nGPCR-1002 with a compound suspected of binding nGPCR-1002 or contacting a composition comprising nGPCR-1007 with a compound suspected 10 of binding nGPCR-1007. The binding between nGPCR-1002 and the compound suspected of binding nGPCR-1002 or between nGPCR-1007 and the compound suspected of binding nGPCR-1007 is detected. Compounds identified as binding nGPCR-1002 or nGPCR-1007 are candidate compounds useful for the treatment of mental disorder.

15 The present invention further provides methods for identifying a compound useful as a modulator of binding between nGPCR-1002 and a binding partner of nGPCR-1002 or between nGPCR-1007 and a binding partner of nGPCR-1007. The methods comprise the steps of contacting the binding partner and a composition comprising nGPCR-1002 or nGPCR-1007 in the presence and in the absence of a putative modulator compound and 20 detecting binding between the binding partner and nGPCR-1002 or nGPCR-1007. Decreased or increased binding between the binding partner and nGPCR-1002 or nGPCR-1007 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a related disease or disorder.

25 Another aspect of the present invention relates to methods of purifying a G protein from a sample containing a G protein. The methods comprise the steps of contacting the sample with an nGPCR for a time sufficient to allow the G protein to form a complex with the nGPCR; isolating the complex from remaining components of the sample; maintaining the complex under conditions which result in dissociation of the G 30 protein from the nGPCR; and isolating said G protein from the nGPCR.

## DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

### Definitions

Various definitions are made throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole and as are typically understood by those skilled in the art.

"Synthesized" as used herein and understood in the art, refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. "Wholly" synthesized DNA sequences are therefore produced entirely by chemical means, and "partially" synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means.

By the term "region" is meant a physically contiguous portion of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous portion of the amino acid sequence of that protein.

The term "domain" is herein defined as referring to a structural part of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains may be co-extensive with regions or portions thereof; domains may also incorporate a portion of a biomolecule that is distinct from a particular region, in addition to all or part of that region. Examples of GPCR protein domains include, but are not limited to, the extracellular (*i.e.*, N-terminal), transmembrane and cytoplasmic (*i.e.*, C-terminal) domains, which are co-extensive with like-named regions of GPCRs; each of the seven transmembrane segments of a GPCR; and each of the loop segments (both extracellular and intracellular loops) connecting adjacent transmembrane segments.

As used herein, the term "activity" refers to a variety of measurable indicia suggesting or revealing binding, either direct or indirect; affecting a response, *i.e.* having a measurable affect in response to some exposure or stimulus, including, for example, the affinity of a compound for directly binding a polypeptide or polynucleotide of the invention, or, for example, measurement of amounts of upstream or downstream proteins or other similar functions after some stimulus or event.

Unless indicated otherwise, as used herein, the abbreviation in lower case (gpcr) refers to a gene, cDNA, RNA or nucleic acid sequence, while the upper case version (GPCR) refers to a protein, polypeptide, peptide, oligopeptide, or amino acid sequence. The term "nGPCR-x" refers to any of the nGPCRs taught herein, while specific reference 5 to a nGPCR (for example nGPCR-5) refers only to that specific nGPCR.

As used herein, the term "antibody" is meant to refer to complete, intact antibodies, and Fab, Fab', F(ab)2, and other fragments thereof. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies.

10 As used herein, the term "binding" means the physical or chemical interaction between two proteins or compounds or associated proteins or compounds or combinations thereof. Binding includes ionic, non-ionic, Hydrogen bonds, Van der Waals, hydrophobic interactions, etc. The physical interaction, the binding, can be either direct or indirect, indirect being through or due to the effects of another protein or 15 compound. Direct binding refers to interactions that do not take place through or due to the effect of another protein or compound but instead are without other substantial chemical intermediates. Binding may be detected in many different manners. As a non-limiting example, the physical binding interaction between a nGPCR-x of the invention and a compound can be detected using a labeled compound. Alternatively, functional 20 evidence of binding can be detected using, for example, a cell transfected with and expressing a nGPCR-x of the invention. Binding of the transfected cell to a ligand of the nGPCR that was transfected into the cell provides functional evidence of binding. Other methods of detecting binding are well-known to those of skill in the art.

As used herein, the term "compound" means any identifiable chemical or 25 molecule, including, but not limited to, small molecule, peptide, protein, sugar, nucleotide, or nucleic acid, and such compound can be natural or synthetic.

As used herein, the term "complementary" refers to Watson-Crick basepairing between nucleotide units of a nucleic acid molecule.

As used herein, the term "contacting" means bringing together, either directly or 30 indirectly, a compound into physical proximity to a polypeptide or polynucleotide of the

invention. The polypeptide or polynucleotide can be in any number of buffers, salts, solutions etc. Contacting includes, for example, placing the compound into a beaker, microtiter plate, cell culture flask, or a microarray, such as a gene chip, or the like, which contains the nucleic acid molecule, or polypeptide encoding the nGPCR or fragment 5 thereof.

As used herein, the phrase "homologous nucleotide sequence," or "homologous amino acid sequence," or variations thereof, refers to sequences characterized by a homology, at the nucleotide level or amino acid level, of at least the specified percentage. Homologous nucleotide sequences include those sequences coding for isoforms of 10 proteins. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. Homologous nucleotide sequences include nucleotide sequences encoding for a protein of a species other than humans, including, but not limited to, mammals. Homologous nucleotide sequences also include, but are not limited 15 to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the nucleotide sequence encoding other known GPCRs. Homologous amino acid sequences include those amino acid sequences which contain conservative amino acid substitutions and which polypeptides have the same binding and/or activity. A homologous amino 20 acid sequence does not, however, include the amino acid sequence encoding other known GPCRs. Percent homology can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using the default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489, which is 25 incorporated herein by reference in its entirety).

As used herein, the term "isolated" nucleic acid molecule refers to a nucleic acid molecule (DNA or RNA) that has been removed from its native environment. Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a

heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules.

As used herein, the terms "modulates" or "modifies" means an increase or decrease in the amount, quality, or effect of a particular activity or protein.

5 As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR). This short sequence is based on (or designed from) a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise  
10 portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30 nucleotides. They are chemically synthesized and may be used as probes.

As used herein, the term "probe" refers to nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides,  
15 depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single- or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, or ELISA-like technologies.

20 The term "preventing" refers to decreasing the probability that an organism contracts or develops an abnormal condition.

The term "treating" refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

25 The term "therapeutic effect" refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of cells; (b) inhibition (*i.e.*, slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some  
30 extent one or more of the symptoms associated with the abnormal condition; and (e)

enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.

The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, cell signaling, or cell survival. An abnormal condition may also include obesity, diabetic complications such as retinal degeneration, and irregularities in glucose uptake and metabolism, and fatty acid uptake and metabolism.

Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

Abnormal differentiation conditions include, but are not limited to, neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates. Abnormal cell signaling conditions include, but are not limited to, psychiatric disorders involving excess neurotransmitter activity.

Abnormal cell survival conditions may also relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

The term "administering" relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques and carrier techniques.

The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an

organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig or goat, more preferably a monkey or ape, and most preferably a human.

By "amplification" it is meant increased numbers of DNA or RNA in a cell 5 compared with normal cells. "Amplification" as it refers to RNA can be the detectable presence of RNA in cells, since in some normal cells there is no basal expression of RNA. In other normal cells, a basal level of expression exists, therefore in these cases amplification is the detection of at least 1 to 2-fold, and preferably more, compared to the basal level.

10 As used herein, the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions under which a probe, primer, or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected 15 to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present in excess, at  $T_m$ , 50% of the probes are occupied at 20 equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g. 10 to 50 nucleotides) and at least about 60°C for longer probes, primers or oligonucleotides. Stringent conditions may also be achieved with the addition 25 of destabilizing agents, such as formamide.

The amino acid sequences are presented in the amino to carboxy direction, from left to right. The amino and carboxy groups are not presented in the sequence. The nucleotide sequences are presented by single strand only, in the 5' to 3' direction, from left to right. Nucleotides and amino acids are represented in the manner recommended by

the IUPAC-IUB Biochemical Nomenclature Commission or (for amino acids) by three letters code.

### Polynucleotides

The present invention provides purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, both single- and double-stranded, including splice variants thereof) that encode unknown G protein-coupled receptors heretofore termed novel GPCRs, or nGPCRs. These genes are described herein and designated herein collectively as nGPCR-x (where x is 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, or 1010). That is, these genes are described herein and designated herein as nGPCR-1001, nGPCR-1002 (also referred to as "seq63" or "nGPCR-63"), nGPCR-1003, nGPCR-1004, nGPCR-1005, nGPCR-1006, nGPCR-1007, nGPCR-1008, nGPCR-1009, and nGPCR-1010. Table 1 below identifies the novel gene sequence nGPCR-x designation, the SEQ ID NO: of the gene sequence, the SEQ ID NO: of the polypeptide encoded thereby, and the U.S. Provisional Application in which the gene sequence has been disclosed.

**Table 1**

nGPCR	Nucleotide Sequence (SEQ ID NO:)	Amino acid Sequence (SEQ ID NO:)	Originally filed in:
1001	1	14	A
1002	2	15	A
1002	41	42	E
1002	43	44	F
1002	45	46	G
1003	3	16	A
1003	11	24	B
1004	4	17	A
1005	5	18	A
1006	6	19	A
1006	13	26, 27	C
1007	7	20	A
1007	12	25	D
1008	8	21	A
1009	9	22	A
1010	10	23	A

**Legend**

A= Ser. No. 60/173,339

B= Ser. No. 60/200,534

C=

Ser. No. 60/239,062

D= Ser. No. 60/224,321

E= Ser. No. 60/184,305

F= Ser. No. 60/188,880

G= Ser. No. 60/219,492

When a specific nGPCR is identified (for example nGPCR-1003), it is understood that only that specific nGPCR is being referred to.

As described in Example 5 below, the genes encoding nGPCR-1002 (nucleic acid sequence SEQ ID NO:2, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, amino acid sequence SEQ ID NO:15, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46), and nGPCR-1007 (nucleic acid sequence SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:12, amino acid sequence SEQ ID NO:20, SEQ ID NO:25) have been detected in brain tissue indicating that these nGPCR-x proteins are neuroreceptors.

The invention provides purified and isolated polynucleotides (e.g., cDNA, genomic DNA, synthetic DNA, RNA, or combinations thereof, whether single- or double-stranded) that comprise a nucleotide sequence encoding the amino acid sequence of the polypeptides of the invention. Such polynucleotides are useful for recombinantly expressing the receptor and also for detecting expression of the receptor in cells (e.g., using Northern hybridization and *in situ* hybridization assays). Such polynucleotides also are useful in the design of antisense and other molecules for the suppression of the expression of nGPCR-x in a cultured cell, a tissue, or an animal; for therapeutic purposes; or to provide a model for diseases or conditions characterized by aberrant nGPCR-x expression. Specifically excluded from the definition of polynucleotides of the invention are entire isolated, non-recombinant native chromosomes of host cells. A preferred polynucleotide has a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, which correspond to naturally occurring nGPCR-x sequences. It will be appreciated that numerous other polynucleotide sequences exist that also encode nGPCR-x having the sequence selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, due to the well-known degeneracy of the universal genetic code.

The invention also provides a purified and isolated polynucleotide comprising a nucleotide sequence that encodes a mammalian polypeptide, wherein the polynucleotide hybridizes to a polynucleotide having the sequence set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID

NO:43, and SEQ ID NO:45, or the non-coding strand complementary thereto, under the following hybridization conditions:

(a) hybridization for 16 hours at 42 °C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate; and

5 (b) washing 2 times for 30 minutes each at 60 °C in a wash solution comprising 0.1% SSC, 1% SDS. Polynucleotides that encode a human allelic variant are highly preferred.

The present invention relates to molecules which comprise the gene sequences that encode the nGPCRs; constructs and recombinant host cells incorporating the gene 10 sequences; the novel GPCR polypeptides encoded by the gene sequences; antibodies to the polypeptides and homologs; kits employing the polynucleotides and polypeptides, and methods of making and using all of the foregoing. In addition, the present invention relates to homologs of the gene sequences and of the polypeptides and methods of making and using the same.

15 Genomic DNA of the invention comprises the protein-coding region for a polypeptide of the invention and is also intended to include allelic variants thereof. It is widely understood that, for many genes, genomic DNA is transcribed into RNA transcripts that undergo one or more splicing events wherein intron (*i.e.*, non-coding regions) of the transcripts are removed, or "spliced out." RNA transcripts that can be 20 spliced by alternative mechanisms, and therefore be subject to removal of different RNA sequences but still encode a nGPCR-x polypeptide, are referred to in the art as splice variants which are embraced by the invention. Splice variants comprehended by the invention therefore are encoded by the same original genomic DNA sequences but arise from distinct mRNA transcripts. Allelic variants are modified forms of a wild-type gene 25 sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are naturally occurring sequences (as opposed to non-naturally occurring variants that arise from *in vitro* manipulation).

The invention also comprehends cDNA that is obtained through reverse transcription of an RNA polynucleotide encoding nGPCR-x (conventionally followed by second strand synthesis of a complementary strand to provide a double-stranded DNA).

Preferred DNA sequences encoding human nGPCR-x polypeptides are selected

5 from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45. A preferred DNA of the invention comprises a double stranded molecule along with the complementary molecule (the "non-coding strand" or "complement") having a sequence unambiguously deducible from the coding strand according to Watson-Crick base-pairing rules for DNA. Also preferred are other

10 polynucleotides encoding the nGPCR-x polypeptide selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, which differ in sequence from the polynucleotides selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, by virtue of the well-known degeneracy of the universal nuclear genetic code.

15 The invention further embraces other species, preferably mammalian, homologs of the human nGPCR-x DNA. Species homologs, sometimes referred to as "orthologs," in general, share at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homology with human DNA of the invention.

20 Generally, percent sequence "homology" with respect to polynucleotides of the invention may be calculated as the percentage of nucleotide bases in the candidate sequence that are identical to nucleotides in the nGPCR-x sequence set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, after aligning the sequences and introducing gaps, if necessary, to

25 achieve the maximum percent sequence identity.

Polynucleotides of the invention permit identification and isolation of polynucleotides encoding related nGPCR-x polypeptides, such as human allelic variants and species homologs, by well-known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related

30 polynucleotides include human and non-human genomic sequences, including allelic

variants, as well as polynucleotides encoding polypeptides homologous to nGPCR-x and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of nGPCR-x. Non-human species genes encoding proteins homologous to nGPCR-x can also be identified by Southern and/or PCR analysis and are 5 useful in animal models for nGPCR-x disorders. Knowledge of the sequence of a human nGPCR-x DNA also makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding nGPCR-x expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. Polynucleotides of the invention are also useful in hybridization 10 assays to detect the capacity of cells to express nGPCR-x. Polynucleotides of the invention may also provide a basis for diagnostic methods useful for identifying a genetic alteration(s) in a nGPCR-x locus that underlies a disease state or states, which information is useful both for diagnosis and for selection of therapeutic strategies.

According to the present invention, the nGPCR-x nucleotide sequences disclosed 15 herein may be used to identify homologs of the nGPCR-x, in other animals, including but not limited to humans and other mammals, and invertebrates. Any of the nucleotide sequences disclosed herein, or any portion thereof, can be used, for example, as probes to screen databases or nucleic acid libraries, such as, for example, genomic or cDNA libraries, to identify homologs, using screening procedures well known to those skilled in 20 the art. Accordingly, homologs having at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 100% homology with nGPCR-x sequences can be identified.

The disclosure herein of full-length polynucleotides encoding nGPCR-x 25 polypeptides makes readily available to the worker of ordinary skill in the art every possible fragment of the full-length polynucleotide.

One preferred embodiment of the present invention provides an isolated nucleic acid molecule comprising a sequence homologous sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ 30 ID NO:45, and fragments thereof. Another preferred embodiment provides an isolated

nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, and fragments thereof.

As used in the present invention, fragments of nGPCR-x-encoding

- 5 polynucleotides comprise at least 10, and preferably at least 12, 14, 16, 18, 20, 25, 50, or 75 consecutive nucleotides of a polynucleotide encoding nGPCR-x. Preferably, fragment polynucleotides of the invention comprise sequences unique to the nGPCR-x-encoding polynucleotide sequence, and therefore hybridize under highly stringent or moderately stringent conditions only (*i.e.*, "specifically") to polynucleotides encoding nGPCR-x (or
- 10 fragments thereof). Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full-length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be
- 15 identified through use of alignment programs routinely utilized in the art, *e.g.*, those made available in public sequence databases. Such sequences also are recognizable from Southern hybridization analyses to determine the number of fragments of genomic DNA to which a polynucleotide will hybridize. Polynucleotides of the invention can be labeled in a manner that permits their detection, including radioactive, fluorescent, and enzymatic
- 20 labeling.

Fragment polynucleotides are particularly useful as probes for detection of full-length or fragments of nGPCR-x polynucleotides. One or more polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding nGPCR-x, or used to detect variations in a polynucleotide sequence encoding nGPCR-x.

- 25 The invention also embraces DNAs encoding nGPCR-x polypeptides that hybridize under moderately stringent or high stringency conditions to the non-coding strand, or complement, of the polynucleotides set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45.

Exemplary highly stringent hybridization conditions are as follows: hybridization at 42 °C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% Dextran sulfate, and washing twice for 30 minutes at 60 °C in a wash solution comprising 0.1 X SSC and 1% SDS. It is understood in the art that conditions of 5 equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausubel *et al.* (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage 10 of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, *et al.*, (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

With the knowledge of the nucleotide sequence information disclosed in the present invention, one skilled in the art can identify and obtain nucleotide sequences 15 which encode nGPCR-x from different sources (*i.e.*, different tissues or different organisms) through a variety of means well known to the skilled artisan and as disclosed by, for example, Sambrook et al., "Molecular cloning: a laboratory manual", Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), which is incorporated herein by reference in its entirety.

20 For example, DNA that encodes nGPCR-x may be obtained by screening of mRNA, cDNA, or genomic DNA with oligonucleotide probes generated from the nGPCR-x gene sequence information provided herein. Probes may be labeled with a detectable group, such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with procedures known to the skilled artisan and used in 25 conventional hybridization assays, as described by, for example, Sambrook *et al.*

A nucleic acid molecule comprising any of the nGPCR-x nucleotide sequences described above can alternatively be synthesized by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers produced from the nucleotide sequences provided herein. See U.S. Patent Numbers 4,683,195 to Mullis *et al.* and 30 4,683,202 to Mullis. The PCR reaction provides a method for selectively increasing the

concentration of a particular nucleic acid sequence even when that sequence has not been previously purified and is present only in a single copy in a particular sample. The method can be used to amplify either single- or double-stranded DNA. The essence of the method involves the use of two oligonucleotide probes to serve as primers for the 5 template-dependent, polymerase mediated replication of a desired nucleic acid molecule.

A wide variety of alternative cloning and *in vitro* amplification methodologies are well known to those skilled in the art. Examples of these techniques are found in, for example, Berger *et al.*, *Guide to Molecular Cloning Techniques*, Methods in Enzymology 152, Academic Press, Inc., San Diego, CA (Berger), which is incorporated herein by 10 reference in its entirety.

Automated sequencing methods can be used to obtain or verify the nucleotide sequence of nGPCR-x. The nGPCR-x nucleotide sequences of the present invention are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by automated methods may contain some errors. Nucleotide sequences 15 determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in a sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in 20 translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation.

The nucleic acid molecules of the present invention, and fragments derived therefrom, are useful for screening for restriction fragment length polymorphism (RFLP) 25 associated with certain disorders, as well as for genetic mapping.

The polynucleotide sequence information provided by the invention makes possible large-scale expression of the encoded polypeptide by techniques well known and routinely practiced in the art.

#### **Vectors**

Another aspect of the present invention is directed to vectors, or recombinant expression vectors, comprising any of the nucleic acid molecules described above. Vectors are used herein either to amplify DNA or RNA encoding nGPCR-x and/or to express DNA which encodes nGPCR-x. Preferred vectors include, but are not limited to,

5 plasmids, phages, cosmids, episomes, viral particles or viruses, and integratable DNA fragments (*i.e.*, fragments integratable into the host genome by homologous recombination). Preferred viral particles include, but are not limited to, adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses. Preferred expression vectors include,

10 but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). Other expression vectors include, but are not limited to, pSPORT™ vectors, pGEM™ vectors (Promega), pPROEXvectors™ (LTI, Bethesda, MD), Bluescript™ vectors (Stratagene), pQET™ vectors (Qiagen), pSE420™ (Invitrogen), and pYES2™(Invitrogen).

Expression constructs preferably comprise GPCR-x-encoding polynucleotides operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator. Expression control DNA sequences include promoters, enhancers, operators, and regulatory element binding sites generally, and are typically selected based on the expression systems in which the expression construct is to be utilized. Preferred promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression. Expression constructs of the invention may also include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also include sequences that facilitate, and preferably promote, homologous recombination in a host cell. Preferred constructs of the invention also include sequences necessary for replication in a host cell.

Expression constructs are preferably utilized for production of an encoded protein, but may also be utilized simply to amplify a nGPCR-x-encoding polynucleotide sequence. In preferred embodiments, the vector is an expression vector wherein the polynucleotide of the invention is operatively linked to a polynucleotide comprising an expression control sequence. Autonomously replicating recombinant expression

constructs such as plasmid and viral DNA vectors incorporating polynucleotides of the invention are also provided. Preferred expression vectors are replicable DNA constructs in which a DNA sequence encoding nGPCR-x is operably linked or connected to suitable control sequences capable of effecting the expression of the nGPCR-x in a suitable host.

- 5 DNA regions are operably linked or connected when they are functionally related to each other. For example, a promoter is operably linked or connected to a coding sequence if it controls the transcription of the sequence. Amplification vectors do not require expression control domains, but rather need only the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of
- 10 transforms. The need for control sequences in the expression vector will vary depending upon the host selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding and sequences which control the termination of transcription and translation.

- 15 Preferred vectors preferably contain a promoter that is recognized by the host organism. The promoter sequences of the present invention may be prokaryotic, eukaryotic or viral. Examples of suitable prokaryotic sequences include the  $P_R$  and  $P_L$  promoters of bacteriophage lambda (The bacteriophage Lambda, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1973), which is incorporated herein by reference in its entirety; Lambda II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1980), which is incorporated herein by reference in its entirety); the *trp*, *recA*, heat shock, and *lacZ* promoters of *E. coli* and the SV40 early promoter (Benoist *et al.* *Nature*, 1981, 290, 304-310, which is incorporated herein by reference in its entirety). Additional promoters include, but are not limited to, mouse
- 20 mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.

Additional regulatory sequences can also be included in preferred vectors.

- 30 Preferred examples of suitable regulatory sequences are represented by the Shine-

Dalgarno of the replicase gene of the phage MS-2 and of the gene cII of bacteriophage lambda. The Shine-Dalgarno sequence may be directly followed by DNA encoding nGPCR-x and result in the expression of the mature nGPCR-x protein.

Moreover, suitable expression vectors can include an appropriate marker that 5 allows the screening of the transformed host cells. The transformation of the selected host is carried out using any one of the various techniques well known to the expert in the art and described in Sambrook *et al.*, *supra*.

An origin of replication can also be provided either by construction of the vector to include an exogenous origin or may be provided by the host cell chromosomal 10 replication mechanism. If the vector is integrated into the host cell chromosome, the latter may be sufficient. Alternatively, rather than using vectors which contain viral origins of replication, one skilled in the art can transform mammalian cells by the method of co-transformation with a selectable marker and nGPCR-x DNA. An example of a suitable marker is dihydrofolate reductase (DHFR) or thymidine kinase (see, U.S. Patent 15 No. 4,399,216).

Nucleotide sequences encoding GPCR-x may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable 20 joining, and ligation with appropriate ligases. Techniques for such manipulation are disclosed by Sambrook *et al.*, *supra* and are well known in the art. Methods for construction of mammalian expression vectors are disclosed in, for example, Okayama *et al.*, *Mol. Cell. Biol.*, 1983, 3, 280, Cosman *et al.*, *Mol. Immunol.*, 1986, 23, 935, Cosman *et al.*, *Nature*, 1984, 312, 768, EP-A-0367566, and WO 91/18982, each of which is 25 incorporated herein by reference in its entirety.

#### Host cells

According to another aspect of the invention, host cells are provided, including prokaryotic and eukaryotic cells, comprising a polynucleotide of the invention (or vector of the invention) in a manner that permits expression of the encoded nGPCR-x 30 polypeptide. Polynucleotides of the invention may be introduced into the host cell as part

of a circular plasmid, or as linear DNA comprising an isolated protein coding region or a viral vector. Methods for introducing DNA into the host cell that are well known and routinely practiced in the art include transformation, transfection, electroporation, nuclear injection, or fusion with carriers such as liposomes, micelles, ghost cells, and protoplasts.

5 Expression systems of the invention include bacterial, yeast, fungal, plant, insect, invertebrate, vertebrate, and mammalian cells systems.

The invention provides host cells that are transformed or transfected (stably or transiently) with polynucleotides of the invention or vectors of the invention. As stated above, such host cells are useful for amplifying the polynucleotides and also for

10 expressing the nGPCR-x polypeptide or fragment thereof encoded by the polynucleotide.

In still another related embodiment, the invention provides a method for producing a nGPCR-x polypeptide (or fragment thereof) comprising the steps of growing a host cell of the invention in a nutrient medium and isolating the polypeptide or variant thereof from the cell or the medium. Because nGPCR-x is a seven transmembrane

15 receptor, it will be appreciated that, for some applications, such as certain activity assays, the preferable isolation may involve isolation of cell membranes containing the polypeptide embedded therein, whereas for other applications a more complete isolation may be preferable.

According to some aspects of the present invention, transformed host cells having

20 an expression vector comprising any of the nucleic acid molecules described above are provided. Expression of the nucleotide sequence occurs when the expression vector is introduced into an appropriate host cell. Suitable host cells for expression of the polypeptides of the invention include, but are not limited to, prokaryotes, yeast, and eukaryotes. If a prokaryotic expression vector is employed, then the appropriate host cell

25 would be any prokaryotic cell capable of expressing the cloned sequences. Suitable prokaryotic cells include, but are not limited to, bacteria of the genera *Escherichia*, *Bacillus*, *Salmonella*, *Pseudomonas*, *Streptomyces*, and *Staphylococcus*.

If an eukaryotic expression vector is employed, then the appropriate host cell would be any eukaryotic cell capable of expressing the cloned sequence. Preferably,

30 eukaryotic cells are cells of higher eukaryotes. Suitable eukaryotic cells include, but are

not limited to, non-human mammalian tissue culture cells and human tissue culture cells. Preferred host cells include, but are not limited to, insect cells, HeLa cells, Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (COS cells), human 293 cells, and murine 3T3 fibroblasts. Propagation of such cells in cell culture has 5 become a routine procedure (see, *Tissue Culture*, Academic Press, Kruse and Patterson, eds. (1973), which is incorporated herein by reference in its entirety).

In addition, a yeast host may be employed as a host cell. Preferred yeast cells include, but are not limited to, the genera *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Preferred yeast vectors can 10 contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replication sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Shuttle vectors for replication in both yeast and *E. coli* are also included herein.

Alternatively, insect cells may be used as host cells. In a preferred embodiment, 15 the polypeptides of the invention are expressed using a baculovirus expression system (see, Luckow *et al.*, *Bio/Technology*, 1988, 6, 47, *Baculovirus Expression Vectors: A Laboratory Manual*, O'Rielly *et al.* (Eds.), W.H. Freeman and Company, New York, 1992, and U.S. Patent No. 4,879,236, each of which is incorporated herein by reference in its entirety). In addition, the MAXBAC™ complete baculovirus expression system 20 (Invitrogen) can, for example, be used for production in insect cells.

Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with nGPCR-x. Host cells of the invention are also useful in methods for the large-scale production of nGPCR-x polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are 25 isolated from the cells, or from the medium in which the cells are grown, by purification methods known in the art, e.g., conventional chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusion filtration, cation or anion exchange chromatography, high pressure liquid chromatography (HPLC), 30 reverse phase HPLC, and the like. Still other methods of purification include those

methods wherein the desired protein is expressed and purified as a fusion protein having a specific tag, label, or chelating moiety that is recognized by a specific binding partner or agent. The purified protein can be cleaved to yield the desired protein, or can be left as an intact fusion protein. Cleavage of the fusion component may produce a form of the 5 desired protein having additional amino acid residues as a result of the cleavage process.

Knowledge of nGPCR-x DNA sequences allows for modification of cells to permit, or increase, expression of endogenous nGPCR-x. Cells can be modified (e.g., by homologous recombination) to provide increased expression by replacing, in whole or in part, the naturally occurring nGPCR-x promoter with all or part of a heterologous 10 promoter so that the cells express nGPCR-x at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to endogenous nGPCR-x encoding sequences. (See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955.) It is also contemplated that, in addition to heterologous 15 promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamoyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the nGPCR-x coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the nGPCR-x coding 20 sequences in the cells.

#### **Knock-outs**

The DNA sequence information provided by the present invention also makes possible the development (e.g., by homologous recombination or "knock-out" strategies; see Capecchi, *Science* 244:1288-1292 (1989), which is incorporated herein by reference) 25 of animals that fail to express functional nGPCR-x or that express a variant of nGPCR-x. Such animals (especially small laboratory animals such as rats, rabbits, and mice) are useful as models for studying the *in vivo* activities of nGPCR-x and modulators of nGPCR-x.

#### **Antisense**

Also made available by the invention are anti-sense polynucleotides that recognize and hybridize to polynucleotides encoding nGPCR-x. Full-length and fragment anti-sense polynucleotides are provided. Fragment antisense molecules of the invention include (i) those that specifically recognize and hybridize to nGPCR-x RNA (as 5 determined by sequence comparison of DNA encoding nGPCR-x to DNA encoding other known molecules). Identification of sequences unique to nGPCR-x encoding polynucleotides can be deduced through use of any publicly available sequence database, and/or through use of commercially available sequence comparison programs. After identification of the desired sequences, isolation through restriction digestion or 10 amplification using any of the various polymerase chain reaction techniques well known in the art can be performed. Anti-sense polynucleotides are particularly relevant to regulating expression of nGPCR-x by those cells expressing nGPCR-x mRNA.

Antisense nucleic acids (preferably 10 to 30 base-pair oligonucleotides) capable of specifically binding to nGPCR-x expression control sequences or nGPCR-x RNA are 15 introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the nGPCR-x target nucleotide sequence in the cell and prevents transcription and/or translation of the target sequence.

Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention. The antisense oligonucleotides may 20 be further modified by adding poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5' end. Suppression of nGPCR-x expression at either the transcriptional or translational level is useful to generate cellular or animal models for diseases/conditions characterized by aberrant nGPCR-x expression.

Antisense oligonucleotides, or fragments of sequences selected from the group 25 consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or sequences complementary or homologous thereto, derived from the nucleotide sequences of the present invention encoding nGPCR-x are useful as diagnostic tools for probing gene expression in various tissues. For example, tissue can be probed *in situ* with oligonucleotide probes carrying detectable groups by conventional 30 autoradiography techniques to investigate native expression of this enzyme or

pathological conditions relating thereto. Antisense oligonucleotides are preferably directed to regulatory regions of sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45, or mRNA corresponding thereto, including, but not limited to, the initiation codon, TATA box, 5 enhancer sequences, and the like.

#### **Transcription factors**

The nGPCR-x sequences taught in the present invention facilitate the design of novel transcription factors for modulating nGPCR-x expression in native cells and animals, and cells transformed or transfected with nGPCR-x polynucleotides. For 10 example, the Cys<sub>2</sub>-His<sub>2</sub> zinc finger proteins, which bind DNA via their zinc finger domains, have been shown to be amenable to structural changes that lead to the recognition of different target sequences. These artificial zinc finger proteins recognize specific target sites with high affinity and low dissociation constants, and are able to act as gene switches to modulate gene expression. Knowledge of the particular nGPCR-x 15 target sequence of the present invention facilitates the engineering of zinc finger proteins specific for the target sequence using known methods such as a combination of structure-based modeling and screening of phage display libraries (Segal *et al.*, Proc. Natl. Acad. Sci. (USA) 96:2758-2763 (1999); Liu *et al.*, Proc. Natl. Acad. Sci. (USA) 94:5525-5530 (1997); Greisman *et al.*, Science 275:657-661 (1997); Choo *et al.*, J. Mol. Biol. 273:525-20 532 (1997)). Each zinc finger domain usually recognizes three or more base pairs. Since a recognition sequence of 18 base pairs is generally sufficient in length to render it unique in any known genome, a zinc finger protein consisting of 6 tandem repeats of zinc fingers would be expected to ensure specificity for a particular sequence (Segal *et al.*) The 25 artificial zinc finger repeats, designed based on nGPCR-x sequences, are fused to activation or repression domains to promote or suppress nGPCR-x expression (Liu *et al.*) Alternatively, the zinc finger domains can be fused to the TATA box-binding factor (TBP) with varying lengths of linker region between the zinc finger peptide and the TBP to create either transcriptional activators or repressors (Kim *et al.*, Proc. Natl. Acad. Sci. (USA) 94:3616-3620 (1997)). Such proteins and polynucleotides that encode them, have 30 utility for modulating nGPCR-x expression *in vivo* in both native cells, animals and

humans; and/or cells transfected with nGPCR-x-encoding sequences. The novel transcription factor can be delivered to the target cells by transfecting constructs that express the transcription factor (gene therapy), or by introducing the protein. Engineered zinc finger proteins can also be designed to bind RNA sequences for use in therapeutics 5 as alternatives to antisense or catalytic RNA methods (McColl *et al.*, Proc. Natl. Acad. Sci. (USA) 96:9521-9526 (1997); Wu *et al.*, Proc. Natl. Acad. Sci. (USA) 92:344-348 (1995)). The present invention contemplates methods of designing such transcription factors based on the gene sequence of the invention, as well as customized zinc finger proteins, that are useful to modulate nGPCR-x expression in cells (native or transformed) 10 whose genetic complement includes these sequences.

### **Polypeptides**

The invention also provides purified and isolated mammalian nGPCR-x polypeptides encoded by a polynucleotide of the invention. Presently preferred is a human nGPCR-x polypeptide comprising the amino acid sequence set out in sequences 15 selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, or fragments thereof comprising an epitope specific to the polypeptide. By "epitope specific to" is meant a portion of the nGPCR receptor that is recognizable by an antibody that is specific for the nGPCR, as defined in detail below.

20 Although the sequences provided are particular human sequences, the invention is intended to include within its scope other human allelic variants; non-human mammalian forms of nGPCR-x, and other vertebrate forms of nGPCR-x.

It will be appreciated that extracellular epitopes are particularly useful for generating and screening for antibodies and other binding compounds that bind to 25 receptors such as nGPCR-x. Thus, in another preferred embodiment, the invention provides a purified and isolated polypeptide comprising at least one extracellular domain (e.g., the N-terminal extracellular domain or one of the three extracellular loops) of nGPCR-x. Purified and isolated polypeptides comprising the N-terminal extracellular domain of nGPCR-x are highly preferred. Also preferred is a purified and isolated 30 polypeptide comprising a nGPCR-x fragment selected from the group consisting of the

N-terminal extracellular domain of nGPCR-x, transmembrane domains of nGPCR-x, an extracellular loop connecting transmembrane domains of nGPCR-x, an intracellular loop connecting transmembrane domains of nGPCR-x, the C-terminal cytoplasmic region of nGPCR-x, and fusions thereof. Such fragments may be continuous portions of the native receptor. However, it will also be appreciated that knowledge of the nGPCR-x gene and protein sequences as provided herein permits recombining of various domains that are not contiguous in the native protein. Using a FORTRAN computer program called "tmrest.all" [Parodi *et al.*, *Comput. Appl. Biosci.* 5:527-535 (1994)], nGPCR-x was shown to contain transmembrane-spanning domains.

The invention also embraces polypeptides that have at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% identity and/or homology to the preferred polypeptide of the invention. Percent amino acid sequence "identity" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence "homology" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.

In one aspect, percent homology is calculated as the percentage of amino acid residues in the smaller of two sequences which align with identical amino acid residue in the sequence being compared, when four gaps in a length of 100 amino acids may be introduced to maximize alignment [Dayhoff, in Atlas of Protein Sequence and Structure, Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972), incorporated herein by reference].

Polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Glycosylated and non-glycosylated forms of nGPCR-x polypeptides are embraced by the invention.

The invention also embraces variant (or analog) nGPCR-x polypeptides. In one example, insertion variants are provided wherein one or more amino acid residues 10 supplement a nGPCR-x amino acid sequence. Insertions may be located at either or both termini of the protein, or may be positioned within internal regions of the nGPCR-x amino acid sequence. Insertional variants with additional residues at either or both termini can include, for example, fusion proteins and proteins including amino acid tags or labels.

15 Insertion variants include nGPCR-x polypeptides wherein one or more amino acid residues are added to a nGPCR-x acid sequence or to a biologically active fragment thereof.

Variant products of the invention also include mature nGPCR-x products, *i.e.*, nGPCR-x products wherein leader or signal sequences are removed, with additional 20 amino terminal residues. The additional amino terminal residues may be derived from another protein, or may include one or more residues that are not identifiable as being derived from specific proteins. nGPCR-x products with an additional methionine residue at position -1 (Met<sup>1</sup>-nGPCR-x) are contemplated, as are variants with additional methionine and lysine residues at positions -2 and -1 (Met<sup>2</sup>-Lys<sup>1</sup>-nGPCR-x). Variants of 25 nGPCR-x with additional Met, Met-Lys, Lys residues (or one or more basic residues in general) are particularly useful for enhanced recombinant protein production in bacterial host cells.

The invention also embraces nGPCR-x variants having additional amino acid residues that result from use of specific expression systems. For example, use of 30 commercially available vectors that express a desired polypeptide as part of a

glutathione-S-transferase (GST) fusion product provides the desired polypeptide having an additional glycine residue at position -1 after cleavage of the GST component from the desired polypeptide. Variants that result from expression in other vector systems are also contemplated.

5 Insertional variants also include fusion proteins wherein the amino terminus and/or the carboxy terminus of nGPCR-x is/are fused to another polypeptide.

In another aspect, the invention provides deletion variants wherein one or more amino acid residues in a nGPCR-x polypeptide are removed. Deletions can be effected at one or both termini of the nGPCR-x polypeptide, or with removal of one or more non-10 terminal amino acid residues of nGPCR-x. Deletion variants, therefore, include all fragments of a nGPCR-x polypeptide.

The invention also embraces polypeptide fragments of sequences selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, wherein the fragments maintain biological (e.g., ligand 15 binding and/or intracellular signaling) immunological properties of a nGPCR-x polypeptide.

In one preferred embodiment of the invention, an isolated nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of SEQ ID NO:14 20 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, and fragments thereof, wherein the nucleic acid molecule encoding at least a portion of nGPCR-x. In a more preferred embodiment, the isolated nucleic acid molecule comprises a sequence that encodes a polypeptide comprising sequences selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, and 25 fragments thereof.

As used in the present invention, polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, or 40 consecutive amino acids of sequences selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46. Preferred polypeptide fragments display antigenic properties unique to, 30 or specific for, human nGPCR-x and its allelic and species homologs. Fragments of the

invention having the desired biological and immunological properties can be prepared by any of the methods well known and routinely practiced in the art.

In still another aspect, the invention provides substitution variants of nGPCR-x polypeptides. Substitution variants include those polypeptides wherein one or more 5 amino acid residues of a nGPCR-x polypeptide are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature; however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may be defined as set out in Tables 2, 3, or 4 below.

Variant polypeptides include those wherein conservative substitutions have been 10 introduced by modification of polynucleotides encoding polypeptides of the invention. Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are set out in Table 2 (from WO 97/09433, page 10, 15 published March 13, 1997 (PCT/GB96/02197, filed 9/6/96), immediately below.

Table 2  
Conservative Substitutions I

	<u>SIDE CHAIN</u>	<u>CHARACTERISTIC</u>	<u>AMINO ACID</u>
		Aliphatic	
		Non-polar	G A P I L V
25		Polar - uncharged	C S T M N Q
		Polar - charged	D E K R
		Aromatic	H F W Y
30		Other	N Q D E

Alternatively, conservative amino acids can be grouped as described in Lehninger, [Biochemistry, Second Edition; Worth Publishers; Inc. NY, NY (1975), pp.71-77] as set out in Table 3, below.

Table 3  
Conservative Substitutions II

	<u>SIDE CHAIN</u>	<u>CHARACTERISTIC</u>	<u>AMINO ACID</u>
40		Non-polar (hydrophobic)	
		A. Aliphatic:	A L I V P

	B. Aromatic:	F W
	C. Sulfur-containing:	M
	D. Borderline:	G
	Uncharged-polar	
5	A. Hydroxyl:	S T Y
	B. Amides:	N Q
	C. Sulfhydryl:	C
	D. Borderline:	G
10	Positively Charged (Basic):	K R H
	Negatively Charged (Acidic):	D E

As still another alternative, exemplary conservative substitutions are set out in Table 4, below.

15

**Table 4**  
**Conservative Substitutions III**

	Original Residue	Exemplary Substitution
20	Ala (A)	Val, Leu, Ile
25	Arg (R)	Lys, Gln, Asn
	Asn (N)	Gln, His, Lys, Arg
	Asp (D)	Glu
30	Cys (C)	Ser
	Gln (Q)	Asn
35	Glu (E)	Asp
	His (H)	Asn, Gln, Lys, Arg
	Ile (I)	Leu, Val, Met, Ala, Phe,
40	Leu (L)	Ile, Val, Met, Ala, Phe
	Lys (K)	Arg, Gln, Asn
45	Met (M)	Leu, Phe, Ile
	Phe (F)	Leu, Val, Ile, Ala
	Pro (P)	Gly
50	Ser (S)	Thr
	Thr (T)	Ser
55	Trp (W)	Tyr
	Tyr (Y)	Trp, Phe, Thr, Ser
	Val (V)	Ile, Leu, Met, Phe, Ala

60 It should be understood that the definition of polypeptides of the invention is intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues. By way of example, the modifications may be covalent in nature, and include for example, chemical bonding with polymers, lipids,

other organic, and inorganic moieties. Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the targeting capacity of the polypeptide for desired cells, tissues, or organs. Similarly, the invention further embraces nGPCR-x polypeptides that have been covalently modified to include

5 one or more water-soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in providing cellular, tissue and animal models of

10 diseases/conditions characterized by aberrant nGPCR-x activity.

In a related embodiment, the present invention provides compositions comprising purified polypeptides of the invention. Preferred compositions comprise, in addition to the polypeptide of the invention, a pharmaceutically acceptable (*i.e.*, sterile and non-toxic) liquid, semisolid, or solid diluent that serves as a pharmaceutical vehicle, excipient, or medium. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, water, saline solutions, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, glycerol, calcium phosphate, mineral oil, and cocoa butter.

20 Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in assays of the invention and in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.

25 The G protein-coupled receptor functions through a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) coupled to the intracellular portion of the G protein-coupled receptor molecule. Accordingly, the G protein-coupled receptor has a specific affinity to G protein. G proteins specifically bind to guanine nucleotides. Isolation of G proteins provides a means to isolate guanine nucleotides. G

30 Proteins may be isolated using commercially available anti-G protein antibodies or

isolated G protein-coupled receptors. Similarly, G proteins may be detected in a sample isolated using commercially available detectable anti-G protein antibodies or isolated G protein-coupled receptors.

According to the present invention, the isolated n-GPCR-x proteins of the present invention are useful to isolate and purify G proteins from samples such as cell lysates. Example 15 below sets forth an example of isolation of G proteins using isolated n-GPCR-x proteins. Such methodolgy may be used in place of the use of commercially available anti-G protein antibodies which are used to isolate G proteins. Moreover, G proteins may be detected using n-GPCR-x proteins in place of commercially available detectable anti-G protein antibodies. Since n-GPCR-x proteins specifically bind to G proteins, they can be employed in any specific use where G protein specific affinity is required such as those uses where commercially available anti-G protein antibodies are employed.

#### Antibodies

Also comprehended by the present invention are antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention) specific for nGPCR-x or fragments thereof. Preferred antibodies of the invention are human antibodies that are produced and identified according to methods described in WO93/11236, published June 20, 1993, which is incorporated herein by reference in its entirety. Antibody fragments, including Fab, Fab', F(ab')<sub>2</sub>, and F<sub>v</sub>, are also provided by the invention. The term "specific for," when used to describe antibodies of the invention, indicates that the variable regions of the antibodies of the invention recognize and bind nGPCR-x polypeptides exclusively (i.e., are able to distinguish nGPCR-x polypeptides from other known GPCR polypeptides by virtue of measurable differences in binding affinity, despite the possible existence of localized sequence identity, homology, or similarity between nGPCR-x and such polypeptides). It will be understood that specific antibodies may also interact with other proteins (for example, S.

*aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and, in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive 5 discussion of such assays, see Harlow *et al.* (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the nGPCR-x polypeptides of the invention are also contemplated, provided that the antibodies are specific for nGPCR-x polypeptides. Antibodies of the invention can be produced using any method well known and routinely 10 practiced in the art.

The invention provides an antibody that is specific for the nGPCR-x of the invention. Antibody specificity is described in greater detail below. However, it should be emphasized that antibodies that can be generated from polypeptides that have previously been described in the literature and that are capable of fortuitously cross-reacting with nGPCR-x (e.g., due to the fortuitous existence of a similar epitope in both 15 polypeptides) are considered "cross-reactive" antibodies. Such cross-reactive antibodies are not antibodies that are "specific" for nGPCR-x. The determination of whether an antibody is specific for nGPCR-x or is cross-reactive with another known receptor is made using any of several assays, such as Western blotting assays, that are well known in 20 the art. For identifying cells that express nGPCR-x and also for modulating nGPCR-x-ligand binding activity, antibodies that specifically bind to an extracellular epitope of the nGPCR-x are preferred.

In one preferred variation, the invention provides monoclonal antibodies. Hybridomas that produce such antibodies also are intended as aspects of the invention. In 25 yet another variation, the invention provides a humanized antibody. Humanized antibodies are useful for *in vivo* therapeutic indications.

In another variation, the invention provides a cell-free composition comprising polyclonal antibodies, wherein at least one of the antibodies is an antibody of the invention specific for nGPCR-x. Antisera isolated from an animal is an exemplary

composition, as is a composition comprising an antibody fraction of an antisera that has been resuspended in water or in another diluent, excipient, or carrier.

In still another related embodiment, the invention provides an anti-idiotypic antibody specific for an antibody that is specific for nGPCR-x.

5 It is well known that antibodies contain relatively small antigen binding domains that can be isolated chemically or by recombinant techniques. Such domains are useful nGPCR-x binding molecules themselves, and also may be reintroduced into human antibodies, or fused to toxins or other polypeptides. Thus, in still another embodiment, the invention provides a polypeptide comprising a fragment of a nGPCR-x-specific 10 antibody, wherein the fragment and the polypeptide bind to the nGPCR-x. By way of non-limiting example, the invention provides polypeptides that are single chain antibodies and CDR-grafted antibodies.

15 Non-human antibodies may be humanized by any of the methods known in the art. In one method, the non-human CDRs are inserted into a human antibody or consensus antibody framework sequence. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

20 Antibodies of the invention are useful for, e.g., therapeutic purposes (by modulating activity of nGPCR-x), diagnostic purposes to detect or quantitate nGPCR-x, and purification of nGPCR-x. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for which the antibody is immunospecific.

### Compositions

25 Mutations in the nGPCR-x gene that result in loss of normal function of the nGPCR-x gene product underlie nGPCR-x-related human disease states. The invention comprehends gene therapy to restore nGPCR-x activity to treat those disease states. Delivery of a functional nGPCR-x gene to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, *Nature*, 30 supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene

therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*, 357: 455-460 (1992). Alternatively, it is contemplated that in other human disease states, preventing the expression of, or inhibiting the activity of, nGPCR-x will be useful in treating disease states. It is 5 contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of nGPCR-x.

Another aspect of the present invention is directed to compositions, including pharmaceutical compositions, comprising any of the nucleic acid molecules or recombinant expression vectors described above and an acceptable carrier or diluent. 10 Preferably, the carrier or diluent is pharmaceutically acceptable. Suitable carriers are described in the most recent edition of *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field, which is incorporated herein by reference in its entirety. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. 15 Liposomes and nonaqueous vehicles such as fixed oils may also be used. The formulations are sterilized by commonly used techniques.

Also within the scope of the invention are compositions comprising polypeptides, polynucleotides, or antibodies of the invention that have been formulated with, e.g., a pharmaceutically acceptable carrier.

20 The invention also provides methods of using antibodies of the invention. For example, the invention provides a method for modulating ligand binding of a nGPCR-x comprising the step of contacting the nGPCR-x with an antibody specific for the nGPCR-x, under conditions wherein the antibody binds the receptor.

25 GPCRs that may be expressed in the brain, such as nGPCR-x, provide an indication that aberrant nGPCR-x signaling activity may correlate with one or more neurological or psychological disorders. The invention also provides a method for treating a neurological or psychiatric disorder comprising the step of administering to a mammal in need of such treatment an amount of an antibody-like polypeptide of the invention that is sufficient to modulate ligand binding to a nGPCR-x in neurons of the 30 mammal. nGPCR-x may also be expressed in other tissues, including but not limited to,

5 peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, thyroid gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues. Within the brain, nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where specific nGPCRs of the present invention are expressed are identified in the Examples below.

**Kits**

The present invention is also directed to kits, including pharmaceutical kits. The kits can comprise any of the nucleic acid molecules described above, any of the polypeptides described above, or any antibody which binds to a polypeptide of the 5 invention as described above, as well as a negative control. The kit preferably comprises additional components, such as, for example, instructions, solid support, reagents helpful for quantification, and the like.

In another aspect, the invention features methods for detection of a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the 10 steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a polypeptide having sequences selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the 15 sequences and fragments; and (b) detecting the presence or amount of the probe:target region hybrid as an indication of the disease.

In preferred embodiments of the invention, the disease is selected from the group consisting of thyroid disorders (e.g. thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (e.g., Crohn's disease); diseases related to cell differentiation 20 and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's 25 Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc.); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial 30 infarction, cardiomyopathies, atherosclerosis, etc.); proliferative diseases and cancers

(e.g., different cancers such as breast, colon, lung, etc., and hyperproliferative disorders such as psoriasis, prostate hyperplasia, etc.); hormonal disorders (e.g., male/female hormonal replacement, polycystic ovarian syndrome, alopecia, etc.); and sexual dysfunction, among others.

- 5 As described above and in Example 5 below, the genes encoding nGPCR-1002 (nucleic acid sequence SEQ ID NO:2, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, amino acid sequence SEQ ID NO:15, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46), and nGPCR-1007 (nucleic acid sequence SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:12, amino acid sequence SEQ ID NO:20, SEQ ID NO:25) have been detected in brain tissue
- 10 indicating that these n-GPCR-x proteins are neuroreceptors. Kits may be designed to detect either expression of polynucleotides encoding these proteins or the proteins themselves in order to identify tissue as being neurological. For example, oligonucleotide hybridization kits can be provided which include a container having an oligonucleotide probe specific for the n-GPCR-x-specific DNA and optionally, containers
- 15 with positive and negative controls and/or instructions. Similarly, PCR kits can be provided which include a container having primers specific for the n-GPCR-x-specific sequences, DNA and optionally, containers with size markers, positive and negative controls and/or instructions.

Hybridization conditions should be such that hybridization occurs only with the genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined *supra*.

- 20 The diseases for which detection of genes in a sample could be diagnostic include diseases in which nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By "amplification" is meant increased numbers of DNA or RNA in a cell compared with normal cells.

The diseases that could be diagnosed by detection of nucleic acid in a sample preferably include central nervous system and metabolic diseases. The test samples

- 30 suitable for nucleic acid probing methods of the present invention include, for example,

cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a 5 sample that is compatible with the method utilized.

Alternatively, immunoassay kits can be provided which have containers container having antibodies specific for the n-GPCR-x-protein and optionally, containers with positive and negative controls and/or instructions.

Kits may also be provided useful in the identification of GPCR binding partners 10 such as natural ligands or modulators (agonists or antagonists). Substances useful for treatment of disorders or diseases preferably show positive results in one or more *in vitro* assays for an activity corresponding to treatment of the disease or disorder in question. Substances that modulate the activity of the polypeptides preferably include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and inhibitors of protein 15 kinases.

#### **Methods of inducing immune response**

Another aspect of the present invention is directed to methods of inducing an immune response in a mammal against a polypeptide of the invention by administering to the mammal an amount of the polypeptide sufficient to induce an immune response. The 20 amount will be dependent on the animal species, size of the animal, and the like but can be determined by those skilled in the art.

#### **Methods of identifying ligands**

The invention also provides assays to identify compounds that bind nGPCR-x. One such assay comprises the steps of: (a) contacting a composition comprising a 25 nGPCR-x with a compound suspected of binding nGPCR-x; and (b) measuring binding between the compound and nGPCR-x. In one variation, the composition comprises a cell expressing nGPCR-x on its surface. In another variation, isolated nGPCR-x or cell membranes comprising nGPCR-x are employed. The binding may be measured directly, e.g., by using a labeled compound, or may be measured indirectly by several techniques,

including measuring intracellular signaling of nGPCR-x induced by the compound (or measuring changes in the level of nGPCR-x signaling).

Specific binding molecules, including natural ligands and synthetic compounds, can be identified or developed using isolated or recombinant nGPCR-x products,

5 nGPCR-x variants, or preferably, cells expressing such products. Binding partners are useful for purifying nGPCR-x products and detection or quantification of nGPCR-x products in fluid and tissue samples using known immunological procedures. Binding molecules are also manifestly useful in modulating (*i.e.*, blocking, inhibiting or stimulating) biological activities of nGPCR-x, especially those activities involved in

10 signal transduction.

The DNA and amino acid sequence information provided by the present invention also makes possible identification of binding partner compounds with which a nGPCR-x polypeptide or polynucleotide will interact. Methods to identify binding partner compounds include solution assays, *in vitro* assays wherein nGPCR-x polypeptides are

15 immobilized, and cell-based assays. Identification of binding partner compounds of nGPCR-x polypeptides provides candidates for therapeutic or prophylactic intervention in pathologies associated with nGPCR-x normal and aberrant biological activity.

The invention includes several assay systems for identifying nGPCR-x binding partners. In solution assays, methods of the invention comprise the steps of (a)

20 contacting a nGPCR-x polypeptide with one or more candidate binding partner compounds and (b) identifying the compounds that bind to the nGPCR-x polypeptide. Identification of the compounds that bind the nGPCR-x polypeptide can be achieved by isolating the nGPCR-x polypeptide/binding partner complex, and separating the binding partner compound from the nGPCR-x polypeptide. An additional step of characterizing

25 the physical, biological, and/or biochemical properties of the binding partner compound is also comprehended in another embodiment of the invention. In one aspect, the nGPCR-x polypeptide/binding partner complex is isolated using an antibody immunospecific for either the nGPCR-x polypeptide or the candidate binding partner compound.

In still other embodiments, either the nGPCR-x polypeptide or the candidate binding partner compound comprises a label or tag that facilitates its isolation, and methods of the invention to identify binding partner compounds include a step of isolating the nGPCR-x polypeptide/binding partner complex through interaction with the 5 label or tag. An exemplary tag of this type is a poly-histidine sequence, generally around six histidine residues, that permits isolation of a compound so labeled using nickel chelation. Other labels and tags, such as the FLAG® tag (Eastman Kodak, Rochester, NY), well known and routinely used in the art, are embraced by the invention.

In one variation of an *in vitro* assay, the invention provides a method comprising 10 the steps of (a) contacting an immobilized nGPCR-x polypeptide with a candidate binding partner compound and (b) detecting binding of the candidate compound to the nGPCR-x polypeptide. In an alternative embodiment, the candidate binding partner compound is immobilized and binding of nGPCR-x is detected. Immobilization is accomplished using any of the methods well known in the art, including covalent bonding 15 to a support, a bead, or a chromatographic resin, as well as non-covalent, high affinity interactions such as antibody binding, or use of streptavidin/biotin binding wherein the immobilized compound includes a biotin moiety. Detection of binding can be accomplished (i) using a radioactive label on the compound that is not immobilized, (ii) using of a fluorescent label on the non-immobilized compound, (iii) using an antibody 20 immunospecific for the non-immobilized compound, (iv) using a label on the non-immobilized compound that excites a fluorescent support to which the immobilized compound is attached, as well as other techniques well known and routinely practiced in the art.

The invention also provides cell-based assays to identify binding partner 25 compounds of a nGPCR-x polypeptide. In one embodiment, the invention provides a method comprising the steps of contacting a nGPCR-x polypeptide expressed on the surface of a cell with a candidate binding partner compound and detecting binding of the candidate binding partner compound to the nGPCR-x polypeptide. In a preferred embodiment, the detection comprises detecting a calcium flux or other physiological 30 event in the cell caused by the binding of the molecule.

Another aspect of the present invention is directed to methods of identifying compounds that bind to either nGPCR-x or nucleic acid molecules encoding nGPCR-x, comprising contacting nGPCR-x, or a nucleic acid molecule encoding the same, with a compound, and determining whether the compound binds nGPCR-x or a nucleic acid

5 molecule encoding the same. Binding can be determined by binding assays which are well known to the skilled artisan, including, but not limited to, gel-shift assays, Western blots, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, ELISA, and the like, which are described in, for example, *Current*

10 *Protocols in Molecular Biology*, 1999, John Wiley & Sons, NY, which is incorporated herein by reference in its entirety. The compounds to be screened include (which may include compounds which are suspected to bind nGPCR-x, or a nucleic acid molecule encoding the same), but are not limited to, extracellular, intracellular, biologic or chemical origin. The methods of the invention also embrace ligands, especially

15 neuropeptides, that are attached to a label, such as a radiolabel (e.g.,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^3\text{H}$ ), a fluorescence label, a chemiluminescent label, an enzymic label and an immunogenic label. Modulators falling within the scope of the invention include, but are not limited to, non-peptide molecules such as non-peptide mimetics, non-peptide allosteric effectors, and peptides. The nGPCR-x polypeptide or polynucleotide employed in such a test may

20 either be free in solution, attached to a solid support, borne on a cell surface or located intracellularly or associated with a portion of a cell. One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

25 In another embodiment of the invention, high throughput screening for compounds having suitable binding affinity to nGPCR-x is employed. Briefly, large numbers of different small peptide test compounds are synthesized on a solid substrate. The peptide test compounds are contacted with nGPCR-x and washed. Bound nGPCR-x is then detected by methods well known in the art. Purified polypeptides of the invention

30 can also be coated directly onto plates for use in the aforementioned drug screening

techniques. In addition, non-neutralizing antibodies can be used to capture the protein and immobilize it on the solid support.

Generally, an expressed nGPCR-x can be used for HTS binding assays in conjunction with its defined ligand, in this case the corresponding neuropeptide that activates it. The identified peptide is labeled with a suitable radioisotope, including, but not limited to, <sup>125</sup>I, <sup>3</sup>H, <sup>35</sup>S or <sup>32</sup>P, by methods that are well known to those skilled in the art. Alternatively, the peptides may be labeled by well-known methods with a suitable fluorescent derivative (Baindur *et al.*, *Drug Dev. Res.*, 1994, 33, 373-398; Rogers, *Drug Discovery Today*, 1997, 2, 156-160). Radioactive ligand specifically bound to the receptor in membrane preparations made from the cell line expressing the recombinant protein can be detected in HTS assays in one of several standard ways, including filtration of the receptor-ligand complex to separate bound ligand from unbound ligand (Williams, *Med. Res. Rev.*, 1991, 11, 147-184; Sweetnam *et al.*, *J. Natural Products*, 1993, 56, 441-455). Alternative methods include a scintillation proximity assay (SPA) or a FlashPlate format in which such separation is unnecessary (Nakayama, *Cur. Opinion Drug Disc. Dev.*, 1998, 1, 85-91 Bossé *et al.*, *J. Biomolecular Screening*, 1998, 3, 285-292.). Binding of fluorescent ligands can be detected in various ways, including fluorescence energy transfer (FRET), direct spectrophotofluorometric analysis of bound ligand, or fluorescence polarization (Rogers, *Drug Discovery Today*, 1997, 2, 156-160; Hill, *Cur. Opinion Drug Disc. Dev.*, 1998, 1, 92-97).

Other assays may be used to identify specific ligands of a nGPCR-x receptor, including assays that identify ligands of the target protein through measuring direct binding of test ligands to the target protein, as well as assays that identify ligands of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Alternatively, such binding interactions are evaluated indirectly using the yeast two-hybrid system described in Fields *et al.*, *Nature*, 340:245-246 (1989), and Fields *et al.*, *Trends in Genetics*, 10:286-292 (1994), both of which are incorporated herein by reference. The two-hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest, or to delineate domains

or residues critical for an interaction. Variations on this methodology have been developed to clone genes that encode DNA binding proteins, to identify peptides that bind to a protein, and to screen for drugs. The two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity

5 with a DNA binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast. The assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a second protein. The DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack

10 an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot by itself activate expression of the reporter gene because it does not bind the UAS. However, when both hybrid proteins are present, the noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of

15 the reporter gene. For example, when the first protein is a GPCR gene product, or fragment thereof, that is known to interact with another protein or nucleic acid, this assay can be used to detect agents that interfere with the binding interaction. Expression of the reporter gene is monitored as different test agents are added to the system. The presence of an inhibitory agent results in lack of a reporter signal.

20 The function of nGPCR-x gene products is unclear and no ligands have yet been found which bind the gene product. The yeast two-hybrid assay can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to a nGPCR-x receptor, or fragment thereof, a fusion polynucleotide encoding both a nGPCR-x receptor (or fragment) and a UAS binding domain (*i.e.*, a first protein) may be

25 used. In addition, a large number of hybrid genes each encoding a different second protein fused to an activation domain are produced and screened in the assay. Typically, the second protein is encoded by one or more members of a total cDNA or genomic DNA fusion library, with each second protein-coding region being fused to the activation domain. This system is applicable to a wide variety of proteins, and it is not even

30 necessary to know the identity or function of the second binding protein. The system is

highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.

Other assays may be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in U.S. Patent No. 5,585,277, incorporated herein by reference. This method relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two states. When a test ligand binds to the folded form of a target protein (*i.e.*, when the test ligand is a ligand of the target protein), the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method that distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

Another method for identifying ligands of a target protein is described in Wieboldt *et al.*, *Anal. Chem.*, 69:1683-1691 (1997), incorporated herein by reference. This technique screens combinatorial libraries of 20-30 agents at a time in solution phase for binding to the target protein. Agents that bind to the target protein are separated from other library components by simple membrane washing. The specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analyzed by HPLC and pneumatically assisted electrospray (ion spray) ionization mass spectroscopy. This procedure selects library components with the greatest affinity for the target protein, and is particularly useful for small molecule libraries.

Other embodiments of the invention comprise using competitive screening assays in which neutralizing antibodies capable of binding a polypeptide of the invention specifically compete with a test compound for binding to the polypeptide. In this manner, the antibodies can be used to detect the presence of any peptide that shares one

or more antigenic determinants with nGPCR-x. Radiolabeled competitive binding studies are described in A.H. Lin *et al. Antimicrobial Agents and Chemotherapy*, 1997, vol. 41, no. 10. pp. 2127-2131, the disclosure of which is incorporated herein by reference in its entirety.

5 As described above and in Example 5 below, the genes encoding nGPCR-1002 (nucleic acid sequence SEQ ID NO:2, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, amino acid sequence SEQ ID NO:15, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46), and nGPCR-1007 (nucleic acid sequence SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:12, amino acid sequence SEQ ID NO:20, SEQ ID NO:25) have been detected in brain tissue  
10 indicating that these n-GPCR-x proteins are neuroreceptors. Accordingly, natural binding partners of these molecules include neurotransmitters.

**Identification of modulating agents**

The invention also provides methods for identifying a modulator of binding between a nGPCR-x and a nGPCR-x binding partner, comprising the steps of: (a) 15 contacting a nGPCR-x binding partner and a composition comprising a nGPCR-x in the presence and in the absence of a putative modulator compound; (b) detecting binding between the binding partner and the nGPCR-x; and (c) identifying a putative modulator compound or a modulator compound in view of decreased or increased binding between the binding partner and the nGPCR-x in the presence of the putative modulator, as 20 compared to binding in the absence of the putative modulator.

nGPCR-x binding partners that stimulate nGPCR-x activity are useful as agonists in disease states or conditions characterized by insufficient nGPCR-x signaling (e.g., as a result of insufficient activity of a nGPCR-x ligand). nGPCR-x binding partners that block ligand-mediated nGPCR-x signaling are useful as nGPCR-x antagonists to treat 25 disease states or conditions characterized by excessive nGPCR-x signaling. In addition nGPCR-x modulators in general, as well as nGPCR-x polynucleotides and polypeptides, are useful in diagnostic assays for such diseases or conditions.

In another aspect, the invention provides methods for treating a disease or abnormal condition by administering to a patient in need of such treatment a substance 30 that modulates the activity or expression of a polypeptide having sequences selected from

the group consisting of SEQ ID NO:14 to SEQ ID NO:27, SEQ ID NO:42, SEQ ID NO:44, and SEQ ID NO:46.

Agents that modulate (*i.e.*, increase, decrease, or block) nGPCR-x activity or expression may be identified by incubating a putative modulator with a cell containing a

5 nGPCR-x polypeptide or polynucleotide and determining the effect of the putative modulator on nGPCR-x activity or expression. The selectivity of a compound that modulates the activity of nGPCR-x can be evaluated by comparing its effects on nGPCR-x to its effect on other GPCR compounds. Selective modulators may include, for example, antibodies and other proteins, peptides, or organic molecules that specifically

10 bind to a nGPCR-x polypeptide or a nGPCR-x-encoding nucleic acid. Modulators of nGPCR-x activity will be therapeutically useful in treatment of diseases and physiological conditions in which normal or aberrant nGPCR-x activity is involved.

nGPCR-x polynucleotides, polypeptides, and modulators may be used in the treatment of such diseases and conditions as infections, such as viral infections caused by HIV-1 or

15 HIV-2; pain; cancers; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); Parkinson's disease; hypotension; hypertension; and psychotic and neurological disorders, including anxiety, mental disorder, manic depression, delirium, dementia,

20 severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome, among others. nGPCR-x polynucleotides and polypeptides, as well as nGPCR-x modulators, may also be used in diagnostic assays for such diseases or conditions.

Methods of the invention to identify modulators include variations on any of the

25 methods described above to identify binding partner compounds, the variations including techniques wherein a binding partner compound has been identified and the binding assay is carried out in the presence and absence of a candidate modulator. A modulator is identified in those instances where binding between the nGPCR-x polypeptide and the binding partner compound changes in the presence of the candidate modulator compared

30 to binding in the absence of the candidate modulator compound. A modulator that

increases binding between the nGPCR-x polypeptide and the binding partner compound is described as an enhancer or activator, and a modulator that decreases binding between the nGPCR-x polypeptide and the binding partner compound is described as an inhibitor.

The invention also comprehends high-throughput screening (HTS) assays to

- 5 identify compounds that interact with or inhibit biological activity (*i.e.*, affect enzymatic activity, binding activity, *etc.*) of a nGPCR-x polypeptide. HTS assays permit screening of large numbers of compounds in an efficient manner. Cell-based HTS systems are contemplated to investigate nGPCR-x receptor-ligand interaction. HTS assays are designed to identify "hits" or "lead compounds" having the desired property, from which
- 10 modifications can be designed to improve the desired property. Chemical modification of the "hit" or "lead compound" is often based on an identifiable structure/activity relationship between the "hit" and the nGPCR-x polypeptide.

Another aspect of the present invention is directed to methods of identifying compounds which modulate (*i.e.*, increase or decrease) activity of nGPCR-x comprising

- 15 contacting nGPCR-x with a compound, and determining whether the compound modifies activity of nGPCR-x. The activity in the presence of the test compared is measured to the activity in the absence of the test compound. Where the activity of the sample containing the test compound is higher than the activity in the sample lacking the test compound, the compound will have increased activity. Similarly, where the activity of the sample
- 20 containing the test compound is lower than the activity in the sample lacking the test compound, the compound will have inhibited activity.

The present invention is particularly useful for screening compounds by using nGPCR-x in any of a variety of drug screening techniques. The compounds to be screened include (which may include compounds which are suspected to modulate nGPCR-x activity), but are not limited to, extracellular, intracellular, biologic or chemical origin. The nGPCR-x polypeptide employed in such a test may be in any form, preferably, free in solution, attached to a solid support, borne on a cell surface or located intracellularly. One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled

in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

The activity of nGPCR-x polypeptides of the invention can be determined by, for example, examining the ability to bind or be activated by chemically synthesized peptide 5 ligands. Alternatively, the activity of nGPCR-x polypeptides can be assayed by examining their ability to bind calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and photons. Alternatively, the activity of the nGPCR-x polypeptides can be determined by examining the activity of effector molecules including, but not limited to, adenylate cyclase, phospholipases and ion 10 channels. Thus, modulators of nGPCR-x polypeptide activity may alter a GPCR receptor function, such as a binding property of a receptor or an activity such as G protein-mediated signal transduction or membrane localization. In various embodiments of the method, the assay may take the form of an ion flux assay, a yeast growth assay, a non-hydrolyzable GTP assay such as a [<sup>35</sup>S]-GTP S assay, a cAMP assay, an inositol 15 triphosphate assay, a diacylglycerol assay, an Aequorin assay, a Luciferase assay, a FLIPR assay for intracellular Ca<sup>2+</sup> concentration, a mitogenesis assay, a MAP Kinase activity assay, an arachidonic acid release assay (e.g., using [<sup>3</sup>H]-arachidonic acid), and an assay for extracellular acidification rates, as well as other binding or function-based assays of nGPCR-x activity that are generally known in the art. In several of these 20 embodiments, the invention comprehends the inclusion of any of the G proteins known in the art, such as G<sub>16</sub>, G<sub>15</sub>, or chimeric G<sub>qds</sub>, G<sub>qss</sub>, G<sub>qos</sub>, G<sub>q2s</sub>, and the like. nGPCR-x activity can be determined by methodologies that are used to assay for FcRP activity, which is well known to those skilled in the art. Biological activities of nGPCR-x 25 receptors according to the invention include, but are not limited to, the binding of a natural or an unnatural ligand, as well as any one of the functional activities of GPCRs known in the art. Non-limiting examples of GPCR activities include transmembrane signaling of various forms, which may involve G protein association and/or the exertion of an influence over G protein binding of various guanidylate nucleotides; another exemplary activity of GPCRs is the binding of accessory proteins or polypeptides that 30 differ from known G proteins.

The modulators of the invention exhibit a variety of chemical structures, which can be generally grouped into non-peptide mimetics of natural GPCR receptor ligands, peptide and non-peptide allosteric effectors of GPCR receptors, and peptides that may function as activators or inhibitors (competitive, uncompetitive and non-competitive)

5 (e.g., antibody products) of GPCR receptors. The invention does not restrict the sources for suitable modulators, which may be obtained from natural sources such as plant, animal or mineral extracts, or non-natural sources such as small molecule libraries, including the products of combinatorial chemical approaches to library construction, and peptide libraries. Examples of peptide modulators of GPCR receptors exhibit the

10 following primary structures: GLGPRPLRFamide, GNSFLRFamide, GGPQGPLRFamide, GPSGPLRFamide, PDVDHVFLRFamide, and pyro-EDVDHVFLRFamide.

Other assays can be used to examine enzymatic activity including, but not limited to, photometric, radiometric, HPLC, electrochemical, and the like, which are described in, 15 for example, *Enzyme Assays: A Practical Approach*, eds. R. Eisenthal and M. J. Danson, 1992, Oxford University Press, which is incorporated herein by reference in its entirety.

The use of cDNAs encoding GPCRs in drug discovery programs is well-known; assays capable of testing thousands of unknown compounds per day in high-throughput screens (HTSs) are thoroughly documented. The literature is replete with examples of the 20 use of radiolabelled ligands in HTS binding assays for drug discovery (see Williams, *Medicinal Research Reviews*, 1991, 11, 147-184.; Sweetnam, *et al.*, *J. Natural Products*, 1993, 56, 441-455 for review). Recombinant receptors are preferred for binding assay HTS because they allow for better specificity (higher relative purity), provide the ability to generate large amounts of receptor material, and can be used in a broad variety of 25 formats (see Hodgson, *Bio/Technology*, 1992, 10, 973-980; each of which is incorporated herein by reference in its entirety).

A variety of heterologous systems is available for functional expression of recombinant receptors that are well known to those skilled in the art. Such systems include bacteria (Strosberg, *et al.*, *Trends in Pharmacological Sciences*, 1992, 13, 95-98), 30 yeast (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494), several kinds of insect cells

(Vanden Broeck, *Int. Rev. Cytology*, 1996, 164, 189-268), amphibian cells (Jayawickreme *et al.*, *Current Opinion in Biotechnology*, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK293, COS, etc.; see Gerhardt, *et al.*, *Eur. J. Pharmacology*, 1997, 334, 1-23). These examples do not preclude the use of other 5 possible cell expression systems, including cell lines obtained from nematodes (PCT application WO 98/37177).

In preferred embodiments of the invention, methods of screening for compounds that modulate nGPCR-x activity comprise contacting test compounds with nGPCR-x and assaying for the presence of a complex between the compound and nGPCR-x. In such 10 assays, the ligand is typically labeled. After suitable incubation, free ligand is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular compound to bind to nGPCR-x.

It is well known that activation of heterologous receptors expressed in recombinant systems results in a variety of biological responses, which are mediated by G 15 proteins expressed in the host cells. Occupation of a GPCR by an agonist results in exchange of bound GDP for GTP at a binding site on the G<sub>α</sub> subunit; one can use a radioactive, non-hydrolyzable derivative of GTP, GTPγ[<sup>35</sup>S], to measure binding of an agonist to the receptor (Sim *et al.*, *Neuroreport*, 1996, 7, 729-733). One can also use this 20 binding to measure the ability of antagonists to bind to the receptor by decreasing binding of GTPγ[<sup>35</sup>S] in the presence of a known agonist. One could therefore construct a HTS based on GTPγ[<sup>35</sup>S] binding, though this is not the preferred method.

The G proteins required for functional expression of heterologous GPCRs can be native constituents of the host cell or can be introduced through well-known recombinant technology. The G proteins can be intact or chimeric. Often, a nearly universally 25 competent G protein (e.g., G<sub>α16</sub>) is used to couple any given receptor to a detectable response pathway. G protein activation results in the stimulation or inhibition of other native proteins, events that can be linked to a measurable response.

Examples of such biological responses include, but are not limited to, the following: the ability to survive in the absence of a limiting nutrient in specifically 30 engineered yeast cells (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494); changes in

intracellular  $\text{Ca}^{2+}$  concentration as measured by fluorescent dyes (Murphy, *et al.*, *Cur. Opinion Drug Disc. Dev.*, 1998, 1, 192-199). Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH; an automated system suitable for HTS has been described for these purposes (Schroeder, *et al.*, *J. Biomolecular Screening*, 1996, 1, 75-80). Melanophores prepared from *Xenopus laevis* show a ligand-dependent change in pigment organization in response to heterologous GPCR activation; this response is adaptable to HTS formats (Jayawickreme *et al.*, *Cur. Opinion Biotechnology*, 1997, 8, 629-634). Assays are also available for the measurement of common second messengers, including cAMP, phosphoinositides and arachidonic acid, but these are not generally preferred for HTS.

Preferred methods of HTS employing these receptors include permanently transfected CHO cells, in which agonists and antagonists can be identified by the ability to specifically alter the binding of  $\text{GTP}\gamma^{[35]\text{S}}$  in membranes prepared from these cells. In another embodiment of the invention, permanently transfected CHO cells could be used for the preparation of membranes which contain significant amounts of the recombinant receptor proteins; these membrane preparations would then be used in receptor binding assays, employing the radiolabelled ligand specific for the particular receptor. Alternatively, a functional assay, such as fluorescent monitoring of ligand-induced changes in internal  $\text{Ca}^{2+}$  concentration or membrane potential in permanently transfected CHO cells containing each of these receptors individually or in combination would be preferred for HTS. Equally preferred would be an alternative type of mammalian cell, such as HEK293 or COS cells, in similar formats. More preferred would be permanently transfected insect cell lines, such as *Drosophila* S2 cells. Even more preferred would be recombinant yeast cells expressing the *Drosophila melanogaster* receptors in HTS formats well known to those skilled in the art (e.g., Pausch, *Trends in Biotechnology*, 1997, 15, 487-494).

The invention contemplates a multitude of assays to screen and identify inhibitors of ligand binding to nGPCR-x receptors. In one example, the nGPCR-x receptor is immobilized and interaction with a binding partner is assessed in the presence and absence of a candidate modulator such as an inhibitor compound. In another example,

interaction between the nGPCR-x receptor and its binding partner is assessed in a solution assay, both in the presence and absence of a candidate inhibitor compound. In either assay, an inhibitor is identified as a compound that decreases binding between the nGPCR-x receptor and its binding partner. Another contemplated assay involves a 5 variation of the dihybrid assay wherein an inhibitor of protein/protein interactions is identified by detection of a positive signal in a transformed or transfected host cell, as described in PCT publication number WO 95/20652, published August 3, 1995.

Candidate modulators contemplated by the invention include compounds selected from libraries of either potential activators or potential inhibitors. There are a number of 10 different libraries used for the identification of small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of random chemical structures, some of which are analogs of known compounds or analogs of compounds that have been identified as "hits" or "leads" in other drug discovery 15 screens, some of which are derived from natural products, and some of which arise from non-directed synthetic organic chemistry. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries 20 include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see *Science* 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. These libraries are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are non- 25 peptide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, *Curr. Opin. Biotechnol.* 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" 30 (or "lead") to optimize the capacity of the "hit" to modulate activity.

Still other candidate inhibitors contemplated by the invention can be designed and include soluble forms of binding partners, as well as such binding partners as chimeric, or fusion, proteins. A "binding partner" as used herein broadly encompasses non-peptide modulators, as well as such peptide modulators as neuropeptides other than natural

5 ligands, antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified nGPCR-x gene.

The polypeptides of the invention are employed as a research tool for identification, characterization and purification of interacting, regulatory proteins.

10 Appropriate labels are incorporated into the polypeptides of the invention by various methods known in the art and the polypeptides are used to capture interacting molecules. For example, molecules are incubated with the labeled polypeptides, washed to remove unbound polypeptides, and the polypeptide complex is quantified. Data obtained using different concentrations of polypeptide are used to calculate values for the number,

15 affinity, and association of polypeptide with the protein complex.

Labeled polypeptides are also useful as reagents for the purification of molecules with which the polypeptide interacts including, but not limited to, inhibitors. In one embodiment of affinity purification, a polypeptide is covalently coupled to a chromatography column. Cells and their membranes are extracted, and various cellular

20 subcomponents are passed over the column. Molecules bind to the column by virtue of their affinity to the polypeptide. The polypeptide-complex is recovered from the column, dissociated and the recovered molecule is subjected to protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotides for cloning the corresponding gene from an appropriate cDNA library.

25 Alternatively, compounds may be identified which exhibit similar properties to the ligand for the nGPCR-x of the invention, but which are smaller and exhibit a longer half time than the endogenous ligand in a human or animal body. When an organic compound is designed, a molecule according to the invention is used as a "lead" compound. The design of mimetics to known pharmaceutically active compounds is a

30 well-known approach in the development of pharmaceuticals based on such "lead"

compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number of molecules for a target property. Furthermore, structural data deriving from the analysis of the deduced amino acid sequences encoded by the DNAs of the present invention are useful to design new drugs, more specific and therefore with a 5 higher pharmacological potency.

Comparison of the protein sequence of the present invention with the sequences present in all the available databases showed a significant homology with the transmembrane portion of G protein coupled receptors. Accordingly, computer modeling can be used to develop a putative tertiary structure of the proteins of the invention based 10 on the available information of the transmembrane domain of other proteins. Thus, novel ligands based on the predicted structure of nGPCR-x can be designed.

In a particular embodiment, the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a composition or pharmaceutical composition can be prepared thereof for oral 15 intake, such as in tablets. The compositions, or pharmaceutical compositions, comprising the nucleic acid molecules, vectors, polypeptides, antibodies and compounds identified by the screening methods described herein, can be prepared for any route of administration including, but not limited to, oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients will 20 depend on the specific route of administration and particular embodiment of the invention to be administered. Examples of techniques and protocols that are useful in this context are, *inter alia*, found in Remington's Pharmaceutical Sciences, 16<sup>th</sup> edition, Osol, A (ed.), 1980, which is incorporated herein by reference in its entirety.

The dosage of these low molecular weight compounds will depend on the disease 25 state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating human or animals, between approximately 0.5 mg/kg of body weight to 500 mg/kg of body weight of the compound can be administered. Therapy is typically administered at lower dosages and is continued until the desired therapeutic outcome is observed.

The present compounds and methods, including nucleic acid molecules, polypeptides, antibodies, compounds identified by the screening methods described herein, have a variety of pharmaceutical applications and may be used, for example, to treat or prevent unregulated cellular growth, such as cancer cell and tumor growth. In a 5 particular embodiment, the present molecules are used in gene therapy. For a review of gene therapy procedures, see e.g. Anderson, *Science*, 1992, 256, 808-813, which is incorporated herein by reference in its entirety.

The present invention also encompasses a method of agonizing (stimulating) or antagonizing a nGPCR-x natural binding partner associated activity in a mammal 10 comprising administering to said mammal an agonist or antagonist to one of the above disclosed polypeptides in an amount sufficient to effect said agonism or antagonism. One embodiment of the present invention, then, is a method of treating diseases in a mammal with an agonist or antagonist of the protein of the present invention comprises administering the agonist or antagonist to a mammal in an amount sufficient to agonize or 15 antagonize nGPCR-x-associated functions.

In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein polypeptides. Some small organic molecules form a class of compounds that modulate the function of protein polypeptides. Examples of molecules that have been 20 reported to inhibit the function of protein kinases include, but are not limited to, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published November 26, 1992 by Maguire *et al.*), vinylene-azaindole derivatives (PCT WO 94/14808, published July 7, 1994 by Ballinari *et al.*), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992), styryl compounds (U.S. Patent No. 5,217,999), styryl- 25 substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published February 17, 1994 by Denny *et al.*), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published December 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published October 17, 1991 by 30 Dow *et al.*), all of which are incorporated by reference herein, including any drawings.

Exemplary diseases and conditions amenable to treatment based on the present invention include, but are not limited to, thyroid disorders (e.g. thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (e.g., Chron's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (e.g., different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (e.g., male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); sexual dysfunction, among others.

Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein inhibitors only weakly inhibit function. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side effects as therapeutics for diseases.

Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976 (published August 1, 1996 by Ballinari *et al.*) describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindole ring. These bicyclic substituents are in turn substituted with polar groups including hydroxylated alkyl, phosphate, and ether substituents. U.S. Patent Application Serial Nos. 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and

Methods for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 221/187) and 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298) and International Patent Publication WO 96/22976, published August 1, 1996

5 by Ballinari *et al.*, all of which are incorporated herein by reference in their entirety, including any drawings, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. Applications 08/702,232, filed August 23, 1996, entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease" by Tang *et al.*

10 (Lyon & Lyon Docket No. 221/187), 08/485,323, filed June 7, 1995, entitled "Benzylidene-Z-Indoline Compounds for the Treatment of Disease" by Tang *et al.* (Lyon & Lyon Docket No. 223/298), and WO 96/22976, published August 1, 1996 by Ballinari *et al.* teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives, both of

15 which are incorporated by reference herein, including any drawings.

Other examples of substances capable of modulating kinase activity include, but are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well-known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker *et al.*, EPO Publication No. 0 520 722 A1; Jones *et al.*, U.S. Patent No. 4,447,608; Kabbe *et al.*, U.S. Patent No. 4,757,072; Kaul and Vougioukas, U.S. Patent No. 5, 316,553; Kreighbaum and Comer, U.S. Patent No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker *et al.*, Proc. of Am. Assoc. for Cancer Research 32:327 (1991); Bertino, J.R., Cancer Research 20 3:293-304 (1979); Bertino, J.R., Cancer Research 9(2 part 1):293-304 (1979); Curtin *et al.*, Br. J. Cancer 53:361-368 (1986); Fernandes *et al.*, Cancer Research 43:1117-1123 (1983); Ferris *et al.* J. Org. Chem. 44(2):173-178; Fry *et al.*, Science 265:1093-1095 (1994); Jackman *et al.*, Cancer Research 51:5579-5586 (1981); Jones *et al.* J. Med. Chem. 29(6):1114-1118; Lee and Skibo, Biochemistry 26(23):7355-7362 (1987); Lemus 25 *et al.*, J. Org. Chem. 54:3511-3518 (1989); Ley and Seng, Synthesis 1975:415-522

(1975); Maxwell *et al.*, Magnetic Resonance in Medicine 17:189-196 (1991); Mini *et al.*, Cancer Research 45:325-330 (1985); Phillips and Castle, J. Heterocyclic Chem. 17(19):1489-1596 (1980); Reece *et al.*, Cancer Research 47(11):2996-2999 (1977); Sculier *et al.*, Cancer Immunol. and Immunother. 23:A65 (1986); Sikora *et al.*, Cancer Letters 23:289-295 (1984); and Sikora *et al.*, Analytical Biochem. 172:344-355 (1988), all of which are incorporated herein by reference in their entirety, including any drawings.

Quinoxaline is described in Kaul and Vougioukas, U.S. Patent No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

Quinolines are described in Dolle *et al.*, J. Med. Chem. 37:2627-2629 (1994); 10 MaGuire, J. Med. Chem. 37:2129-2131 (1994); Burke *et al.*, J. Med. Chem. 36:425-432 (1993); and Burke *et al.* BioOrganic Med. Chem. Letters 2:1771-1774 (1992), all of which are incorporated by reference in their entirety, including any drawings.

Tyrphostins are described in Allen *et al.*, Clin. Exp. Immunol. 91:141-156 (1993); Anafi *et al.*, Blood 82:12:3524-3529 (1993); Baker *et al.*, J. Cell Sci. 102:543-555 (1992); Bilder *et al.*, Amer. Physiol. Soc. pp. 6363-6143:C721-C730 (1991); Brunton *et al.*, Proceedings of Amer. Assoc. Cancer Rsch. 33:558 (1992); Bryckaert *et al.*, Experimental Cell Research 199:255-261 (1992); Dong *et al.*, J. Leukocyte Biology 53:53-60 (1993); Dong *et al.*, J. Immunol. 151(5):2717-2724 (1993); Gazit *et al.*, J. Med. Chem. 32:2344-2352 (1989); Gazit *et al.*, J. Med. Chem. 36:3556-3564 (1993); Kaur *et al.*, Anti-Cancer Drugs 5:213-222 (1994); King *et al.*, Biochem. J. 275:413-418 (1991); 20 Kuo *et al.*, Cancer Letters 74:197-202 (1993); Levitzki, A., The FASEB J. 6:3275-3282 (1992); Lyall *et al.*, J. Biol. Chem. 264:14503-14509 (1989); Peterson *et al.*, The Prostate 22:335-345 (1993); Pillemer *et al.*, Int. J. Cancer 50:80-85 (1992); Posner *et al.*, Molecular Pharmacology 45:673-683 (1993); Rendu *et al.*, Biol. Pharmacology 25 44(5):881-888 (1992); Sauro and Thomas, Life Sciences 53:371-376 (1993); Sauro and Thomas, J. Pharm. and Experimental Therapeutics 267(3):119-1125 (1993); Wolbring *et al.*, J. Biol. Chem. 269(36):22470-22472 (1994); and Yoneda *et al.*, Cancer Research 51:4430-4435 (1991); all of which are incorporated herein by reference in their entirety, including any drawings.

Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Serial No. 08/702,232 filed August 23, 1996, incorporated herein by reference in its entirety, including any drawings.

Methods of determining the dosages of compounds to be administered to a patient 5 and modes of administering compounds to an organism are disclosed in U.S. Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number WO 96/22976, published August 1 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can 10 be easily adapted to it.

The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used and the size and physiological condition of the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be 15 formulated in animal models to achieve a circulating concentration range that initially takes into account the  $IC_{50}$  as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most 20 appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharm-acokinetic characteristics, can be optimized by 25 altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 30 2) blood samples are periodically obtained via the tail vein from one mouse in each

treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

5        At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 202:229-249, 1993). Representative animals from each treatment group can then be examined by gross

10      10 necropsy for immediate evidence of metastasis, unusual illness or toxicity. Gross abnormalities in tissue are noted and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

15      15 For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness. Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the

20      20 lower the plasma levels necessary to achieve efficacy.

nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, brain, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues. Within the brain, nGPCR-x mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where specific nGPCR mRNA transcripts are expressed are identified in the Examples, below.

Sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, 30      30 SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45 will, as detailed above, enable

screening the endogenous neurotransmitters/hormones/ligands which activate, agonize, or antagonize nGPCR-x and for compounds with potential utility in treating disorders including, but not limited to, thyroid disorders (e.g. thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (e.g., Chron's disease); diseases related to cell

5 differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease

10 or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc.); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (e.g., type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension,

15 thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, etc.); proliferative diseases and cancers (e.g., different cancers such as breast, colon, lung, etc., and hyperproliferative disorders such as psoriasis, prostate hyperplasia, etc.); hormonal disorders (e.g., male/female hormonal replacement, polycystic ovarian syndrome, alopecia, etc.); sexual dysfunction, among others.

20 For example, nGPCR-x may be useful in the treatment of respiratory ailments such as asthma, where T cells are implicated by the disease. Contraction of airway smooth muscle is stimulated by thrombin. Cicala *et al* (1999) Br J Pharmacol 126:478-484. Additionally, in bronchiolitis obliterans, it has been noted that activation of thrombin receptors may be deleterious. Hauck *et al.* (1999) Am J Physiol 277:L22-L29.

25 Furthermore, mast cells have also been shown to have thrombin receptors. Cirino *et al* (1996) J Exp Med 183:821-827. nGPCR-x may also be useful in remodeling of airway structures in chronic pulmonary inflammation via stimulation of fibroblast procollagen synthesis. See, e.g., Chambers *et al.* (1998) Biochem J 333:121-127; Trejo *et al.* (1996) J Biol Chem 271:21536-21541.

In another example, increased release of sCD40L and expression of CD40L by T cells after activation of thrombin receptors suggests that nGPCR-x may be useful in the treatment of unstable angina due to the role of T cells and inflammation. See Aukrust *et al.* (1999) *Circulation* 100:614-620.

5 A further example is the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and thyroiditis. Due to the tissue expression profile of nGPCR-x, inhibition of thrombin receptors may be beneficial for these diseases. See, e.g., Morris *et al.* (1996) *Ann Rheum Dis* 55:841-843. In addition to T cells, NK cells and monocytes are also critical cell types which contribute 10 to the pathogenesis of these diseases. See, e.g., Naldini & Carney (1996) *Cell Immunol* 172:35-42; Hoffman & Cooper (1995) *Blood Cells Mol Dis* 21:156-167; Colotta *et al.* (1994) *Am J Pathol* 144:975-985.

15 Expression of nGPCR-x in bone marrow and spleen may suggest that it may play a role in the proliferation of hematopoietic progenitor cells. See DiCuccio *et al.* (1996) *Exp Hematol* 24:914-918.

As another example, nGPCR-x may be useful in the treatment of acute and/or traumatic brain injury. Astrocytes have been demonstrated to express thrombin receptors. Activation of thrombin receptors may be involved in astrogliosis following brain injury. Therefore, inhibition of receptor activity may be beneficial for limiting 20 neuroinflammation. Scar formation mediated by astrocytes may also be limited by inhibiting thrombin receptors. See, e.g., Pindon *et al.* (1998) *Eur J Biochem* 255:766-774; Ubl & Reiser. (1997) *Glia* 21:361-369; Grabham & Cunningham (1995) *J Neurochem* 64:583-591.

nGPCR-x receptor activation may mediate neuronal and astrocyte apoptosis and 25 prevention of neurite outgrowth. Inhibition would be beneficial in both chronic and acute brain injury. See, e.g., Donovan *et al.* (1997) *J Neurosci* 17:5316-5326; Turgeon *et al* (1998) *J Neurosci* 18:6882-6891; Smith-Swintosky *et al.* (1997) *J Neurochem* 69:1890-1896; Gill *et al.* (1998) *Brain Res* 797:321-327; Suidan *et al.* (1996) *Semin Thromb Hemost* 22:125-133.

The attached Sequence Listing contains the sequences of the polynucleotides and polypeptides of the invention and is incorporated herein by reference in its entirety.

As described above and in Example 5 below, the genes encoding nGPCR-1002 (nucleic acid sequence SEQ ID NO:2, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, 5 amino acid sequence SEQ ID NO:15, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46), and nGPCR-1007 (nucleic acid sequence SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:12, amino acid sequence SEQ ID NO:20, SEQ ID NO:25) have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. The identification of 10 modulators such as agonists and antagonists is therefore useful for the identification of compounds useful to treat neurological diseases and disorders. Such neurological diseases and disorders, including but are not limited to, mental disorder, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia as well as depression, anxiety, bipolar disease, epilepsy, 15 neuritis, neurasthenia, neuropathy, neuroses, and the like.

#### Methods of Screening Human Subjects

Thus in yet another embodiment, the invention provides genetic screening procedures that entail analyzing a person's genome -- in particular their alleles for GPCRs of the invention -- to determine whether the individual possesses a genetic 20 characteristic found in other individuals that are considered to be afflicted with, or at risk for, developing a mental disorder or disease of the brain that is suspected of having a hereditary component. For example, in one embodiment, the invention provides a method for determining a potential for developing a disorder affecting the brain in a human subject comprising the steps of analyzing the coding sequence of one or more 25 GPCR genes from the human subject; and determining development potential for the disorder in said human subject from the analyzing step.

More particularly, the invention provides a method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of: (a) assaying nucleic acid of a human subject to determine a presence or an 30 absence of a mutation altering the amino acid sequence, expression, or biological activity

of at least one seven transmembrane receptor that is expressed in the brain, wherein the seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, and SEQ ID NO:46, or an allelic variant thereof, and wherein the nucleic acid corresponds to the gene encoding the seven transmembrane receptor; and (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of allele in the nucleic acid correlates with an increased risk of developing the disorder. In preferred variations, the seven transmembrane receptor is nGPCR-1002 or nGPCR-1007 comprising amino acid sequences set forth in SEQ ID NO:46 for nGPCR-1002 and SEQ ID NO:25 for nGPCR-1007, or an allelic variant thereof, and the disease is mental disorder.

By "human subject" is meant any human being, human embryo, or human fetus. It will be apparent that methods of the present invention will be of particular interest to individuals that have themselves been diagnosed with a disorder affecting the brain or have relatives that have been diagnosed with a disorder affecting the brain.

By "screening for an increased risk" is meant determination of whether a genetic variation exists in the human subject that correlates with a greater likelihood of developing a disorder affecting the brain than exists for the human population as a whole, or for a relevant racial or ethnic human sub-population to which the individual belongs.

Both positive and negative determinations (i.e., determinations that a genetic predisposition marker is present or is absent) are intended to fall within the scope of screening methods of the invention. In preferred embodiments, the presence of a mutation altering the sequence or expression of at least one nGPCR-1002 or nGPCR-1007 seven transmembrane receptor allele in the nucleic acid is correlated with an increased risk of developing mental disorder, whereas the absence of such a mutation is reported as a negative determination.

The "assaying" step of the invention may involve any techniques available for analyzing nucleic acid to determine its characteristics, including but not limited to well-known techniques such as single-strand conformation polymorphism analysis (SSCP) [Orita *et al.*, *Proc Natl. Acad. Sci. USA*, 86: 2766-2770 (1989)]; heteroduplex analysis

[White *et al.*, *Genomics*, 12: 301-306 (1992)]; denaturing gradient gel electrophoresis analysis [Fischer *et al.*, *Proc. Natl. Acad. Sci. USA*, 80: 1579-1583 (1983); and Riesner *et al.*, *Electrophoresis*, 10: 377-389 (1989)]; DNA sequencing; RNase cleavage [Myers *et al.*, *Science*, 230: 1242-1246 (1985)]; chemical cleavage of mismatch techniques [Rowley *et al.*, *Genomics*, 30: 574-582 (1995); and Roberts *et al.*, *Nucl. Acids Res.*, 25: 3377-3378 (1997)]; restriction fragment length polymorphism analysis; single nucleotide primer extension analysis [Shumaker *et al.*, *Hum. Mutat.*, 7: 346-354 (1996); and Pastinen *et al.*, *Genome Res.*, 7: 606-614 (1997)]; 5' nuclease assays [Pease *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:5022-5026 (1994)]; DNA Microchip analysis [Ramsay, G., *Nature Biotechnology*, 16: 40-48 (1999); and Chee *et al.*, U.S. Patent No. 5,837,832]; and ligase chain reaction [Whiteley *et al.*, U.S. Patent No. 5,521,065]. [See generally, Schafer and Hawkins, *Nature Biotechnology*, 16: 33-39 (1998).] All of the foregoing documents are hereby incorporated by reference in their entirety.

Thus, in one preferred embodiment involving screening nGPCR-1002 or nGPCR-1007 sequences, for example, the assaying step comprises at least one procedure selected from the group consisting of: (a) determining a nucleotide sequence of at least one codon of at least one nGPCR-1002 or nGPCR-1007 allele of the human subject; (b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; (c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and (d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

In a highly preferred embodiment, the assaying involves sequencing of nucleic acid to determine nucleotide sequence thereof, using any available sequencing technique. [See, e.g., Sanger *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 74: 5463-5467 (1977) (dideoxy chain termination method); Mirzabekov, *TIBTECH*, 12: 27-32 (1994) (sequencing by hybridization); Drmanac *et al.*, *Nature Biotechnology*, 16: 54-58 (1998); U.S. Patent No. 5,202,231; and *Science*, 260: 1649-1652 (1993) (sequencing by hybridization);

Kieleczawa *et al.*, *Science*, 258: 1787-1791 (1992) (sequencing by primer walking); (Douglas *et al.*, *Biotechniques*, 14: 824-828 (1993) (Direct sequencing of PCR products); and Akane *et al.*, *Biotechniques* 16: 238-241 (1994); Maxam and Gilbert, *Meth. Enzymol.*, 65: 499-560 (1977) (chemical termination sequencing), all incorporated herein 5 by reference.] The analysis may entail sequencing of the entire nGPCR gene genomic DNA sequence, or portions thereof; or sequencing of the entire seven transmembrane receptor coding sequence or portions thereof. In some circumstances, the analysis may involve a determination of whether an individual possesses a particular allelic variant, in which case sequencing of only a small portion of nucleic acid -- enough to determine the 10 sequence of a particular codon characterizing the allelic variant -- is sufficient. This approach is appropriate, for example, when assaying to determine whether one family member inherited the same allelic variant that has been previously characterized for another family member, or, more generally, whether a person's genome contains an allelic variant that has been previously characterized and correlated with a mental disorder 15 having a heritable component.

In another highly preferred embodiment, the assaying step comprises performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences. In a preferred embodiment, the hybridization involves a determination of whether nucleic acid 20 derived from the human subject will hybridize with one or more oligonucleotides, wherein the oligonucleotides have nucleotide sequences that correspond identically to a portion of the GPCR gene sequence taught herein, such as the nGPCR-1002 or nGPCR-1007 coding sequence set forth in SEQ ID NOS:45 for nGPCR-1002 or 12 for nGPCR-1007, or that correspond identically except for one mismatch. The hybridization 25 conditions are selected to differentiate between perfect sequence complementarity and imperfect matches differing by one or more bases. Such hybridization experiments thereby can provide single nucleotide polymorphism sequence information about the nucleic acid from the human subject, by virtue of knowing the sequences of the oligonucleotides used in the experiments.

Several of the techniques outlined above involve an analysis wherein one performs a polynucleotide migration assay, e.g., on a polyacrylamide electrophoresis gel (or in a capillary electrophoresis system), under denaturing or non-denaturing conditions. Nucleic acid derived from the human subject is subjected to gel electrophoresis, usually 5 adjacent to (or co-loaded with) one or more reference nucleic acids, such as reference GPCR-encoding sequences having a coding sequence identical to all or a portion of SEQ ID NOS: 45 or 12 (or identical except for one known polymorphism). The nucleic acid from the human subject and the reference sequence(s) are subjected to similar chemical or enzymatic treatments and then electrophoresed under conditions whereby the

10 polynucleotides will show a differential migration pattern, unless they contain identical sequences. [See generally Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, New York: John Wiley & Sons, Inc. (1987-1999); and Sambrook *et al.*, (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (1989), both incorporated herein by reference in their entirety.]

15 In the context of assaying, the term "nucleic acid of a human subject" is intended to include nucleic acid obtained directly from the human subject (e.g., DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample); and also nucleic acid derived from nucleic acid obtained directly from the human subject. By way of non-limiting examples, well known procedures exist for creating cDNA that is

20 complementary to RNA derived from a biological sample from a human subject, and for amplifying (e.g., via polymerase chain reaction (PCR)) DNA or RNA derived from a biological sample obtained from a human subject. Any such derived polynucleotide which retains relevant nucleotide sequence information of the human subject's own DNA/RNA is intended to fall within the definition of "nucleic acid of a human subject"

25 for the purposes of the present invention.

In the context of assaying, the term "mutation" includes addition, deletion, and/or substitution of one or more nucleotides in the GPCR gene sequence (e.g., as compared to the seven transmembrane receptor-encoding sequences set forth of SEQ ID NO:25, and SEQ ID NO:46 and other polymorphisms that occur in introns (where introns exist) and

30 that are identifiable via sequencing, restriction fragment length polymorphism, or other

techniques. The various activity examples provided herein permit determination of whether a mutation modulates activity of the relevant receptor in the presence or absence of various test substances.

In a related embodiment, the invention provides methods of screening a person's genotype with respect to GPCRs of the invention, and correlating such genotypes with diagnoses for disease or with predisposition for disease (for genetic counseling). For example, the invention provides a method of screening for an nGPCR-1002 or nGPCR-1007 hereditary mental disorder genotype in a human patient, comprising the steps of: (a) providing a biological sample comprising nucleic acid from the patient, the nucleic acid including sequences corresponding to said patient's nGPCR-1002 or nGPCR-1007 alleles; (b) analyzing the nucleic acid for the presence of a mutation or mutations; (c) determining an nGPCR-1002 or nGPCR-1007 genotype from the analyzing step; and (d) correlating the presence of a mutation in an nGPCR-1002 or nGPCR-1007 allele with a hereditary mental disorder genotype. In a preferred embodiment, the biological sample is a cell sample containing human cells that contain genomic DNA of the human subject. The analyzing can be performed analogously to the assaying described in preceding paragraphs. For example, the analyzing comprises sequencing a portion of the nucleic acid (e.g., DNA or RNA), the portion comprising at least one codon of the nGPCR-1002 or nGPCR-1007 alleles.

Although more time consuming and expensive than methods involving nucleic acid analysis, the invention also may be practiced by assaying protein of a human subject to determine the presence or absence of an amino acid sequence variation in GPCR protein from the human subject. Such protein analyses may be performed, e.g., by fragmenting GPCR protein via chemical or enzymatic methods and sequencing the resultant peptides; or by Western analyses using an antibody having specificity for a particular allelic variant of the GPCR.

The invention also provides materials that are useful for performing methods of the invention. For example, the present invention provides oligonucleotides useful as probes in the many analyzing techniques described above. In general, such oligonucleotide probes comprise 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,

22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides that have a sequence that is identical, or exactly complementary, to a portion of a human GPCR gene sequence taught herein (or allelic variant thereof), or that is identical or exactly complementary except for one nucleotide 5 substitution. In a preferred embodiment, the oligonucleotides have a sequence that corresponds in the foregoing manner to a human GPCR coding sequence taught herein, and in particular, the coding sequences set forth in SEQ ID NO: 45 and 12. In one variation, an oligonucleotide probe of the invention is purified and isolated. In another variation, the oligonucleotide probe is labeled, *e.g.*, with a radioisotope, chromophore, or 10 fluorophore. In yet another variation, the probe is covalently attached to a solid support. [See generally Ausubel *et al.* and Sambrook *et al.*, *supra*.]

In a related embodiment, the invention provides kits comprising reagents that are useful for practicing methods of the invention. For example, the invention provides a kit for screening a human subject to diagnose a mental disorder or a genetic predisposition 15 therefor, comprising, in association: (a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-1002 or nGPCR-1007 seven transmembrane receptor gene, the oligonucleotide comprising 6-50 nucleotides that have a sequence that is identical or exactly complementary to a portion of a human nGPCR- 1002 or nGPCR-1007 gene sequence or nGPCR-1002 or nGPCR-1007 coding sequence, 20 except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and (b) a media packaged with the oligonucleotide containing information identifying polymorphisms identifiable with the probe that correlate with mental disorder or a genetic predisposition therefor. Exemplary information-containing media include printed paper package inserts or 25 packaging labels; and magnetic and optical storage media that are readable by computers or machines used by practitioners who perform genetic screening and counseling services. The practitioner uses the information provided in the media to correlate the results of the analysis with the oligonucleotide with a diagnosis. In a preferred variation, the oligonucleotide is labeled.

In still another embodiment, the invention provides methods of identifying those allelic variants of GPCRs of the invention that correlate with mental disorders. For example, the invention provides a method of identifying a seven transmembrane allelic variant that correlates with a mental disorder, comprising steps of: (a) providing a

5 biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny; (b) analyzing the nucleic acid for the presence of a mutation or mutations in at least one seven transmembrane receptor that is expressed in the brain, wherein the at least one seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID

10 NO:25, and SEQ ID NO:46 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding the at least one seven transmembrane receptor; (c) determining a genotype for the patient for the at least one seven transmembrane receptor from said analyzing step; and (d) identifying an allelic variant that correlates with the mental disorder from the determining step. To expedite

15 this process, it may be desirable to perform linkage studies in the patients (and possibly their families) to correlate chromosomal markers with disease states. The chromosomal localization data provided herein facilitates identifying an involved GPCR with a chromosomal marker.

The foregoing method can be performed to correlate GPCR's of the invention to a

20 number of disorders having hereditary components that are causative or that predispose persons to the disorder. For example, in one preferred variation, the disorder is a mental disorder, and the at least one seven transmembrane receptor comprises nGPCR-1002 having an amino acid sequence set forth in SEQ ID NO:46 or an allelic variant thereof.

Also contemplated as part of the invention are polynucleotides that comprise the

25 allelic variant sequences identified by such methods, and polypeptides encoded by the allelic variant sequences, and oligonucleotide and oligopeptide fragments thereof that embody the mutations that have been identified. Such materials are useful in *in vitro* cell-free and cell-based assays for identifying lead compounds and therapeutics for treatment of the disorders. For example, the variants are used in activity assays, binding

30 assays, and assays to screen for activity modulators described herein. In one preferred

embodiment, the invention provides a purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-1002 or nGPCR-1007 receptor allelic variant identified according to the methods described above; and an oligonucleotide that comprises the sequences that differentiate the allelic variant from the nGPCR-1002 or

5 nGPCR-1007 sequences set forth in SEQ ID NOS:45 and 12. The invention also provides a vector comprising the polynucleotide (preferably an expression vector); and a host cell transformed or transfected with the polynucleotide or vector. The invention also provides an isolated cell line that is expressing the allelic variant GPCR polypeptide; purified cell membranes from such cells; purified polypeptide; and synthetic peptides that

10 embody the allelic variation amino acid sequence. In one particular embodiment, the invention provides a purified polynucleotide comprising a nucleotide sequence encoding a nGPCR-1002 seven transmembrane receptor protein of a human that is affected with a mental disorder; wherein said polynucleotide hybridizes to the complement of SEQ ID NO:45 under the following hybridization conditions: (a) hybridization for 16 hours at

15 42°C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS; and wherein the polynucleotide encodes a nGPCR-1002 amino acid sequence that differs from SEQ ID NO:46 by at least one residue.

An exemplary assay for using the allelic variants is a method for identifying a

20 modulator of nGPCR-x biological activity, comprising the steps of: (a) contacting a cell expressing the allelic variant in the presence and in the absence of a putative modulator compound; (b) measuring nGPCR-x biological activity in the cell; and (c) identifying a putative modulator compound in view of decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator.

25 Additional features of the invention will be apparent from the following Examples. Examples 1, 2, 3, 5, and 14 are actual, while the remaining Examples are prophetic. Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description, and all such features are intended as aspects of the invention. Likewise, features of the

30 invention described herein can be re-combined into additional embodiments that also are

intended as aspects of the invention, irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described 5 herein as critical are intended as aspects of the invention.

## EXAMPLES

### EXAMPLE 1: IDENTIFICATION OF nGPCR-X

#### A. Database search

10 The Celera database was searched using known GPCR receptors as query sequences to find patterns suggestive of novel G protein-coupled receptors. Positive hits were further analyzed with the GCG program BLAST to determine which ones were the most likely candidates to encode G protein-coupled receptors, using the standard (default) alignment produced by BLAST as a guide.

15 Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul *et al.*, *J. Mol. Biol.*, 1990, 215, 403-410, which is incorporated herein by reference in its entirety). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first 20 identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing 25 them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of 30 either sequence is reached. The Blast algorithm parameters W, T and X determine the

sensitivity and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

5 The BLAST algorithm (Karlin et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5877, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide  
10 or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a GPCR gene or cDNA if the smallest sum probability in comparison of the test nucleic acid to a GPCR nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

15 Homology searches are performed with the program BLAST version 2.08. A collection of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with  
20 proteins that are not related to GPCRs.

Multiple query sequences may have a significant alignment to the same genomic region, although each alignment may not cover exactly the same DNA region. A procedure is used to determine the region of maximum common overlap between the alignments from several query sequences. This region is called the consensus DNA  
25 region. The procedure for determining this consensus involves the automatic parsing of the BLAST output files using the program MSPcrunch to produce a tabular report. From this tabular report the start and end of each alignment in the genomic DNA is extracted. This information is used by a PERL script to derive the maximum common overlap. These regions are reported in the form of a unique sequence identifier, a start and the end

position in the sequence. The sequences defined by these regions were extracted from the original genomic sequence file using the program fetchdb.

The consensus regions are assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as 5 candidate DNA regions coding for nGPCRs. These sequences were then submitted for further sequence analysis.

Further sequence analysis involves the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCR's.

#### **nGPCR-1003**

10 For nGPCR-1003, the transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" [Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)]. Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. One of these sequences (Celera GA\_6691258) consisted of a fragment of the above SEQ ID NO:11 with a significant 15 homology to the rat putative GPCR RTA (SwissProt Acc P23749).

For nGPCR-1007, the transmembrane regions for remaining sequences were determined using a computer program TMHMM1.0 [Sonnhammer EL, von Heijne G, Krogh A, Ismb 1998; 6:175-82; available at the website, "www.cbs.dtu.dk/services/TMHMM-1.0/". Only sequences that contained 20 transmembrane regions in a pattern found in GPCRs were retained. One high scoring sequence pair was obtained with the human putative G protein-coupled receptor *Lymnaea stagnalis* conopressin receptor 2 (GenBank Accession AAC46987; locus LSU40491). The amino acid sequence of conopressin receptor 2 was used as query sequence to probe the public human genomic nucleotide database in GenBank (available at 25 www.ncbi.nlm.nih.gov/Genbank/index.html) using TBLASTN. A high scoring sequence pair was discovered in *Homo sapiens* genomic contig NT\_000380 (chromosome 7p14-p15). This sequence was used as query sequence together with the amino acid sequence of conopressin receptor 2 using the computer software GeneWise (part of the Wise2.1.20c package; available at www.sanger.ac.uk/Software/Wise2/ , c.f., Birney E, 30 Thompson JD, Gibson TJ. *Nucleic Acids Res.* 1996 Jul 15;24(14):2730-9.). The result

revealed the major part of an encoded protein sequence homologous to conopressin receptor 2 the gene of which was divided into several exons in the region of 591,648 through 661,842 in the above human genomic sequence contig.

For nGPCR-1006, the transmembrane regions for the sequences that remained 5 were determined using a computer program TMHMM1.0. Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. A high scoring sequence pair was obtained with the human putative G protein-coupled receptor to the mouse GPR73 gene (GenBank Acc # AAF43706). The amino acid sequence of GPR73 gene was used as query sequence to probe the public human genomic nucleotide database 10 in GenBank using TBLASTN. A high scoring sequence pair was discovered in Homo sapiens genomic sequence Z69648. This sequence was used as query sequence together with the amino acid sequence of GPR73 gene using the computer software GeneWise (part of the Wise2.1.20c package; available at [www.sanger.ac.uk/Software/Wise2/](http://www.sanger.ac.uk/Software/Wise2/), c.f., Birney E, Thompson JD, Gibson TJ. Nucleic Acids Res. 1996 Jul 5;24(14):2730-9.). The 15 result revealed part of an encoded protein sequence homologous to the amino terminus of GPR73 in the above human genomic sequence between nucleotides 33449 through 33934. This was further extended by repeated BLASTN runs against the Celera human genomic database to build a contiguous sequence covering also the C-terminal half in a separate exon as revealed by using GeneWise and translation of the nucleotide sequence. 20 The Celera human genomic contigs used for assembly were GA\_21679130; GA\_65467205; GA\_36816495; GA\_53193385. This provided the nucleotide and amino acid sequences of nGPCR-1006 (SEQ ID NO:13 and 26-27, respectively).

nGPRCR-x cDNAs were sequenced directly using an ABI377 fluorescence-based sequencer (Perkin-Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and 25 the ABI PRISM™ Ready Dye-Deoxy Terminator kit with Taq FS™ polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98 °C for 1 minute, followed by 50 cycles using the following parameters: 98 °C for 30 seconds, annealing at 50 °C for 30 seconds, and extension at 60 °C for 4 minutes. Temperature cycles and times 30 were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified

using Centriflex™ gel filtration cartridges (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples 5 were dried under vacuum for about 40 minutes and then dissolved in 5 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90 °C for three minutes and loaded into the gel sample wells for sequence analysis using the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann 10 Arbor, MI). Generally, sequence reads of 700 bp were obtained. Potential sequencing errors were minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers annealing at different locations until all sequencing ambiguities were removed.

The following Table 5 contains the sequences of the polynucleotides and 15 polypeptides of the invention. Start and stop codons within the polynucleotide sequence are identified by boldface type. The transmembrane domains within the polypeptide sequence are identified by underlining.

20 **Table 5**

	The following DNA sequence nGPCR-seq1001 <SEQ ID NO. 1> was identified in <i>H. sapiens</i> :
25	CACTCTCCCTGGGGCCACTCTCAGGCCATCCTCACCATCGTCTGACTCCTCGTCGTTGCCATGAGGGCCA TGCACCTCTCCCGGACAGCTTGAGGTCAAGCCGGTAGCGGTGCGCAGGCCAGAGGAACACAGGCAGCAGC AGGGCCTGGGGCACGGAGCACCACAGCACGCAGAGTGCCATCCAGGGCGTGAGGCGTCGGCCCGCAGGCT GCTGAAGCTCACCAACCTGTGGGCA
30	The following amino acid sequence <SEQ ID NO. 14> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 1:
	CPQVVSFSSLRADASAPWMALCVLWCSVAQALLLPVFLWACDRYRADLKAVREKCMALMANDEESDDGEDG LRVAPGRV
35	The following DNA sequence nGPCR-seq1002<SEQ ID NO. 2> was identified in <i>H. sapiens</i> :
40	ACACATGGTGCAACACAGCAGAGGCCAGCAGCACCGCTGCCACCCAGGCCACAGCGTCCGGCACAAGTGGCGGC TGGGCTCCCCGAAGAACTGGGTGCAGGGCGCCGCTGAGCAGCAGGTGCAGCAGCAGGCAAGAGGGCCAGGTG AGGGCGCACACACAGGTGGTCAGGTGGCGTGGGCGGGCAGCAGTACCAAGGCTGGGAAGAGGGCGGCCAG GCACTGCTCCACGCTGACGGCCGCCAGGAGACTCAGGCCACGATGTAGCAGAAGAAGCGCAGCGTTGCCA

GGCTGGTCTGCACGAAGCCGGGAAGTCCAGCCGGCTTGCAGCAAGTCGGGACGATGGCCACCATGTGG  
CAGCCAAGGAAGATGAGATCCGCGCAGGCCACGTCAGGGAGGTAGATGGCGAAGGGGTTCTGTAGACATT  
GGAGCTGAGCAGCCAGAGGACTGCCCCATTCCCCAGCAGCCCACCGAGGGCGAGCCCCCTCGGTGAGGGACA  
GGATGATGAGGTTGAAGGCCACATCCTCCTGGCGCCGTTGGCGGCCCCACGTGCTGTCC

5

The following amino acid sequence <SEQ ID NO. 15> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 2:

10 GQHVGAAANGAQEDVAFNLLILSLEGLGLGLLGNGAVLWLSSNVYRNPFAIYLLDVACADLIFLGCHMV  
AIVPDLLQGRILDPGFVQTSLATLRFFCYIVGLSLLAASVEQCLAAFLFPAWYSCRPRHLTTVCALTW  
LCLLHLLLSGACTQFFGEPSRHLCTRLWLVAAVLALLCCTMC

15

The following DNA sequence nGPCR-seq1003<SEQ ID NO. 3> was identified in *H. sapiens*:

15

TAAGAAGCCACAGAACCTTCCCTTCCAAGATGCTCAGCAGTAGGGACAGGGCCAGAGCAGGACACACACGA  
CCGCTGACAGGTGTCTGGGCGGCCAGCGATACCAGATGGCCACAGGACGGACAGGCAGCGCTCGGTG  
CTGACGGTGCTCAGCATGCTCAGGCCTGCAAGGTAGGCACAGGTATCAGTGGTGAAGAAGCTAGGGAA  
ATTGATGGAGATGGAACAGAACAGAAGTTACTGAGGTACACCAGGCAATTATAATCTGGAAGCAGAGGAAGA  
GGAAGTCGGCCCCGGCCAGGCTGAGGACGTAGACAGAGAACGGCTCTGCGCATGCGGAAGCCCAGGAGC  
CAGAGCACAAACCCGTTCTACCAGCCGACCAGGGCAATGAAAAGGATCAGGAAGACCGGGAT

20

The following amino acid sequence <SEQ ID NO. 16> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 3:

25

IPVFLILFIALVGLVGNGFVLWLLGFRMRRNAFSVYVLSLAGADFLFLCFQIINCLVYLSNFFCSISINFP  
SFTTVMTCAYLAGLSMLSTVSTERCLSVLWPIWYRCRRPRHLSAVVCVLLWALSLLSILEGKPCGFL

	The following DNA sequence nGPCR-seq1004<SEQ ID NO. 4> was identified in <i>H. sapiens</i> :
5	GTCCCTGCCGGGGCGAGGGCCGCCCTTCTCTGTCTTCACGGTCCCTGGTGGTGACGCTGCTAGTGCTGCTGATCGCTGCCACTTCCCTGTGGAACCTGCTGGTCCGGTCACCATCCCGGGGTCCTGCGCTTCCACCGCGTGC
10	CGCATAACTTGGTGGCCTCGACGGCCGCTCGAACGAACTAGTGGCAGCCTGGCGATGCCACCGAGCCTGCGAGTGAGCTGTCGACCGGGCGACGTCGGCTGCTGGCCGGAGCCTGTGCCACGTGTGGATCTCCTTCGACGCCGGAGCCTGT
15	The following amino acid sequence <SEQ ID NO. 17> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 4: VLPGRGPPFSVFTVLVVTLLVLLIAATFLWNLLVPVTIPRVRAFHRVPHNLVASTAVSDELVAALAMPPSLASELSTGRRRLLGRSLCHVWISFDAGAC
20	The following DNA sequence nGPCR-seq1005<SEQ ID NO. 5> was identified in <i>H. sapiens</i> :
25	CTGTGCTGCCCGCCGGCCCTGGGAACGTGGCGGCCATGCCCTGGGCCGACGGGCATCACACGGCACCTGCAGCACACGCTGCGCACCCGAGCCGCGCTCGTTGCTCATGATCGCGCTGCCCGGGTGCCTGCGTCCAGCTCGTCGGCGCTCATGCCCTCGGCCGCTGCTCTTGGCCGGGCGAGGTGTGCGACGCTCGGCCAGGTGAGCCGGAAACCCCTCATGCCCTTCCACCGCGCCCTTCCACCTGCCGTTGGCGTGGTGCCGTTTGCTACCGGAAGATCTACGAGGCGCCAAGTTGCTTCGGCCGCCGCCGGAGAGCTGTGCTGCCGTGCGCCGACCATGAGGTGAGGGGGTGGGCTGAGGAACGTTGCTATGGGAAGCGGTTGCTAGAGAAGGAGGCAGCTTCGCGAATGGGAGAGTGGGCGGAAGCTTGTACTAATGGAGCGCGCCAGAGATCACCTGGGCGCACGAGGAGACAAGTTGCCATCAGTTCTCTGAAGCGGGCACCGAGGGGCTGTCACCGGCTCACCTGGCA
30	CGCAAGTGAGGGGTTGCCAGCTGCGTACTTGGTGCAGCAGAGAAAGGGTTCAAAATCTGCACGTLCPPAGLGNVAIALGRDGAITRHLQHTLRTRSRASLILMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAKFRFGRRRRAVLPLPATMQRGGLRNVAMGKRLLEKEAASRMGEWAEACTNGARAQRSPGAHEDKFAISSSEAGTEGLVTGSPGTQVRGSPAAYLVRAEERVSQSAR
35	The following DNA sequence nGPCR-seq1006<SEQ ID NO. 6> was identified in <i>H. sapiens</i> :
40	The following amino acid sequence <SEQ ID NO. 18> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 5: LCCPAGLGNVAIALGRDGAITRHLQHTLRTRSRASLILMIALARVPSALIALAPLLFGRGEVCDARLQRCQVSREPSYAAFSTRGAFHLPLGVVPFVYRKIYEAKFRFGRRRRAVLPLPATMQRGGLRNVAMGKRLLEKEAASRMGEWAEACTNGARAQRSPGAHEDKFAISSSEAGTEGLVTGSPGTQVRGSPAAYLVRAEERVSQSAR
45	ATGGATGACAATGCCACCAACACTTCACCAAGCTTCCCTTCTGTGCTAACCTCATGGAGCCCAGCTGCCACTTCC
50	The following amino acid sequence <SEQ ID NO. 19> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 6: MDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSDYDMPLDEDEDVNTNSRTFFAAKIVIGMALVGIMLVCGIGNFIFIAALVRYKKLRNLTNLLIANLAIISDFLVAIVCCPFEMDYYVVRQLSWEHGVLCNSVNYLRTVSLYVSTNALLAIADRVQQQWQQRSGRKGHWNCPPLLVCSCRLMRGVSIIPRCGCMGDSKACPLTDSEKSSPFPALE
55	The following DNA sequence nGPCR-seq1007<SEQ ID NO. 7> was identified in <i>H. sapiens</i> :
	GCCTTCATCTGCTGTTGGAGTCCATACTTCCCTGTTGACATTGGACAATTCAACCTCCTCCAGACACCCAGGAGCGTTCTATGCCCTGTGATCATTGAGAACCTGCCAGCATTGAATAGTGCCTCAACCCCCCTCATCTACTGTGCTTCAGCAGCTCCATCTCTTCCCCCTGC
	The following amino acid sequence <SEQ ID NO. 20> is the predicted

amino acid sequence derived from the DNA sequence of SEQ ID NO. 7:

AFICCWSPYFLFDILDNFNLLPDTQERFYASVIIQNLPALNSAINPLIYCVFSSSISFPC

5 The following DNA sequence nGPCR-seq1008<SEQ ID NO. 8> was identified in *H. sapiens*:

GAAAAGCAAGGCCAGGGCTCTATTGTGATCGCCTGGAGGCCGTCTTCTGTTCTCCATTCCCACCCGTGAT  
CATATTGGAAAGAGGACACTGTCCAACGGTGAAGTGCAGTGCCTGGGCCGTGGCCGTGACGACTCCTACT  
10 GGACCCCATACATGACCATCGTGGCCCTGGTACTTCATCCCTGTACAATCATC

15 The following amino acid sequence <SEQ ID NO. 21> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 8:

15 EKQARVLIVIAWSLSFLFSIPTLIIFGKRTLSNGEVQCWALWPDDSYWTPYMTIVAFLVYFIPLTII

20 The following DNA sequence nGPCR-seq1009<SEQ ID NO. 9> was identified in *H. sapiens*:

20 CACCAGCACAGGGAAAGCCATGAGGCAGTCGTAGATGAAGACTATGGTGGTCACGAGGCCGTGGTCTGCAGAGAGC

25 The following amino acid sequence <SEQ ID NO. 22> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 9:

25 SQYRMLGRGTCDNVHSISYARNKALPHWLCHDYDILGVWGAVVRIPYRSPEAWGGPVGDARSLCSTLPHARLSNAKKQAVHTVMGIWMSFILSALPAVGWHDTSERFYTHGCRFIVAEIGLGFVCFLLLVGGSVAMGVI  
CTAIALFQTLAVQVGRQADRRRAFTVPTIVVEDAQGKRRSSIDGSEPAKTSLQTTGLVTTIVFIYDCLMGFP  
VLV

30 The following DNA sequence nGPCR-seq1010<SEQ ID NO. 10> was identified in *H. sapiens*:

30 CCGGTAGTTGACAGGCCAGCAGACCATCCACATCGGGTGGTAGGAGAGGGAGGTGACAGAGAAACAGGTGG  
CCAGGGTGAGGGTGTAGAAGGTGGACACGAAGACCTTGCAAGAGACCCCTCATTCCACTCGAAGTCGGGGCGC  
35 TGCCGCCGCACTGCACCAACGGAGTAGGTGGCGATGGCACGGCCACATTAGCATGTGGTGGCCGAG  
TGTACACAGCAGGAACCTCAAGGGCTTCCACTTCTGCTGGGCCAACGCTGAGGATGCCAGGCAT  
TGGCCAGCAGGGAGAGGCCACATACCAGCCAGCCACTGCAGTGCAGGCCGCTCATCACTC  
AT

40 The following amino acid sequence <SEQ ID NO. 23> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 10:  
MSDERRLPGSAVGWLVCGLSLLANAWGILSVGAKQKKWPFLCTLAATHMLNVAVPIATYSVQQLRR  
QRPDFEWNEGCKVFVSTFYTLATCFSVTSLSYHRMWMVCWPVNYR

45 The following DNA sequence nGPCR-seq1003<SEQ ID NO. 11> was identified in *H. sapiens*:

45 CCTGTAAACAGGGCGGTAAATTACACATAACAGGCTGGTCATGAAAATCAGTGAACATGCAGCAGGTGCT  
CAAGTCCTGTTTGTGTTCCAGGGCACCAGTGGAGGTTCTGAGCATGGATCCAACCACCCGGCTGGGGAAAC  
50 CACAGTGTGGTGTCCCTCTGGCCCTTGGCATTAGTGGTCTTAATATTATGGATCTGGA  
AGGATTCTGATGTCTTATTTGTATTCATCCAGTTAGTGTCTGTCACTCTTAACAGCAGTGCC  
AACCCCATCTTACTTCGTGGCTCTTAGGAAGCAGTGGCGGTGCGAGGCCATCTCAAGCT  
GGCTCTCCAGAGGGCTCTGCAGGACATTGCTGAGGTGGATCACAGTGAAGGATGCTCCGTAGGGCACCC  
CGGAGATGTCGAGAAGCAGTCTGGTGTAGAGATGGACAGCCTCTACTTCCATCAGATATGTGGCTTGA

GAGGCAACTT

The following amino acid sequence <SEQ ID NO. 24> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 11:

MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPFLFIALVGLVGNGFVLWLGFMRMRRNAFSSVYVLSL  
AGADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAVLAGLSMLSTVSTERCLSVLWPIWYRCRRP  
RHLSAVVCVLLWALSLLSILEGKFCGFLFSDGDSGWCQTFDFITAAWLFLFVLCGSSLALLVRILCGS  
RGLPLTRLYLTILLTVLVEFLCGLPFGIQWFLILWIKSDVLFCHIHPVSVLSSLNSSANPILYFFVGS  
FRKQWRLQQPILKLALQRALQDIAEVDHSEGCFRQGTPEMSRSSLV

The following DNA sequence nGPCR-seq1007<SEQ ID NO.12> was identified in *H. sapiens*:

GTGATGGATATCTGCAGAATTGCCCTTAAGCAGTGGTAAACAAACGAGACTACGCCGGAGGAGGCAAGCT  
CAATCATCAGCATCATGTATGGCATGGAACTATTTGGATTAAAAG  
CAAAACCTACGAAACAGTGTATTCCAACGCTCAGATGGAAACTGTGAGCAGCTATAACCGAGGACTCA  
TCTCAAAGGAAAAATCAAGGCTATCAAGTATAGCATTATCATCATTCTGCCATCTGCTGTTGGAGT  
CCATACCTCCTGTTGACATTTGGACAATTCAACCTCCCTCCAGACACCCAGGAGCGTTCTATGCCCTC  
TGTGATCATTAGAAGACCTGCCAGGATTGAATAGTGCCATCAACCCCCCATCTACTGTGCTTCAGCAGCT  
CCATCTCTTCCCTGCAAGGGAGCAAAGATCACAGGATTCCAGAATGACGCTCCGGGAGAGAACTGAGAGG  
CATGAGATGCAGATTCTGTCCAAGGCCAGAATTCACTAGACCCCTAGGGCAGTGCCAGTGCTAGGCTGAGCA  
CCATCAGCTCTCCAGGCTCTGTACCTGCTGGCACGTGCACTGGAAACCCGAGCCAATTCAACCCACC  
CTCGTCATTACCTGGGAGATGCAAAAGACAAATGTTCTAATGACTGCATGCACTGCTTAAGTATTGGCAA  
CACGAACCTCCCAGTTATTCACTGCCAGGCCAGGAAGGAAACGCCCTCCCTCCCCACCATCCAGCCCTCCT  
TCCCACTGGCCAGCACCTGAACCCAGTGAACACAGGCATTAGTGGTCCAGGGTCTGGCTGGAGCCAGTG  
AGTAGAGACAGGCAAGCAGAGGGACAAAGGTAGCTGGTTACATGAATATTCTCATTACAATAGAAGAAA  
ATAAAAGACTTAATTAAGCCAAAAA

The following amino acid sequence <SEQ ID NO. 25> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 12:

MPANFTEGSFDSSGTGQTLDSSPVACTETVTFTEVVEGKEWGSFYYSFKTEQLITLWLFVFTIVGNSVVL  
FSTWRRKKKSRTMFFVTQLAITDSFTGLVNILTDIIWRFTGDFTAPDLVCRVVRYLQVVLLYASTYVLVSL  
SIDRYHAIVYPMKFLQGEKQARYLIVIAWSLFLSFIPTLIIIFGKRTLSNGEVQCWALWPGDSYWTPYMTI  
VAFLVYFIPLTIIISIMYGVIRTIWIKSKTYETVISNCSDGKLCSSYNRGLISKAKIKAIKYSSIIILAFI  
CCWSPYFLFDILDNFNLLPDTQERFYASVIIQNLPALNSAINPPIYCVFSSSISFPCREQRSDSRMTFRE  
RTERHEMQILSKPEFI

The following DNA sequence nGPCR-seq1006<SEQ ID NO.13> was identified in *H. sapiens*:

CAAAGATGCTGGCAGAGACATTCTGACTCATTAAGGGAGAGCTGGCTGATAGCAGAGAGGGTGACATCA  
GCCTTGAGACATTGCCCTGGGAAATTCTGAGCAGTGTGCTCACAGCACCCACCTGCCAGATGGAGACC  
ACCATGGGGTTCATGGATGACAATGCCACCAACACTCCACCAGCTTCCCTTCTGTGCTCAACCTCATG  
GAGCCCATGCCACTTCCCACTCAACCTCAGCTACAGCAGACTATGATATGCCCTTGGATGAAGATGA  
GGATGTGACCAATTCCAGGACGTTCTGCTGCCAAGATTGTCTTGGATGGCCCTGGTGGCATCATG  
CTGGTCTGCCGATTGGAAACTTCATCTTATCGCTGCCCTGGCTACAAGAAACTGCGCAACCTCA  
CCAACCTGCTCATGCCAACCTGCCATCTGACTTCCTGGCCATTGTCTGCTGCCCTTGGAGAT  
GGACTACTATGTGGTGCGCCAGCTCCCTGGGAGCACGGCCACGGCCAGTGCACCTCTGTCAACTACCTG  
CGCACTGTCTCTCATGTCTCCACCAATGCCCTGCTGCCCATCGCATTGACAGGTATCTGGCTATTG  
TCCATCCGCTGAGACCACGGATGAAGTGCACAGCCACTGCCCTGATTGCCCTGGTGTGGACGGTGTGTC  
CATCCCTGATGCCCATCCCTCCGCCACTTCACCAACGGAGACGGCTCGTCAAGAGCCAGGAA

5           AAGATCTTCTGCGGCCAGATCTGGCTGTGGACCAAGCAGCTCTACTACAAGTCTACTTCTCTTATCT  
 TTGGCATAGAATTCTGGCCCCGTGGTACCATGACCCGTGCTATGCCAGGATCTCCGGAGCTCTG  
 GTTCAAGGCGTCCCTGGATTCCAGACAGAGCAGATCCGCAAGAGGCTGGCTGCCAGGAAGACGGTC  
 CTGGTGCTCATGTGATCCTCACCGCTACGTGCTATGCTGGCGCCCTCTACGGCTTACCATCGTC  
 GCGACTTCTTCCCCACCGTGTGAAAGGAGAACGACTACCTCACTGCCCTCTACATCGTCAGTGCAT  
 CGCCATGAGAACAGCATGATCAACACTCTGTGCTCGTACCGTCAAGAACGACACCGTCAAGTACTTC  
 AAAAGATCATGTTGCTCCACTGGAAGGCTCTACAATGGCGTAAGTCCAGTGCAGACCTGGACCTCA  
 AGACAATTGGATGCGTGCACCGAAGAGGTTGACTGCATCAGACTAAAATAACCCCTGGACTTGC  
 AGTTAACACAAAGCAGGGCTGTGGACACTGACTAGTGTGTTGGATGCACATC

10

The following amino acid sequence <SEQ ID NO. 26> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 13:

15

METTMGFMDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSYDMPLEDEDEDVTNSRTFFAAKIVIGMALV  
IMLVCIGNFIFIALVRYKKLRNLTNLIANLAISDFIVAIVCCPFEMDYVVRQLSWEHGHLCTSVN  
LRTVSLVSTNALAIDRYLAIVHPLRPRMKQTATGLIALVWTVSILIAIPSAYFTTETVLVKSQE  
KIFCGQIWPVDQQLYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRCRKTV  
VLMCILTAYVLCWAPFYGFTIVRDFFPTVFKEHYLTAFYIECIAMSNSMINTLCFVTVKNDTVKYFK  
IMLHWKASYNGKSSADLLKTIGMPATEEVDCIRLK

20

The following amino acid sequence <SEQ ID NO. 27> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 13:

25

MGFMDDNATNTSTSFLSVLNPHGAHATSFPFNFSYSYDMPLEDEDEDVTNSRTFFAAKIVIGMALV  
CGIGNFIFIALVRYKKLRNLTNLIANLAISDFIVAIVCCPFEMDYVVRQLSWEHGHLCTSVN  
SLVSTNALAIDRYLAIVHPLRPRMKQTATGLIALVWTVSILIAIPSAYFTTETVLVKSQE  
KQIWPVDQQLYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRCRKTV  
VLMCILTAYVLCWAPFYGFTIVRDFFPTVFKEHYLTAFYIECIAMSNSMINTLCFVTVKNDTVKYFK  
HWKASYNGKSSADLLKTIGMPATEEVDCIRLK

30

The following DNA sequence Seq-63 <SEQ ID NO. 41> was identified in *H. sapiens*:

35

CAGTGAGCCGAGATGGTGCCATTGCACTCTAGCCTGGGGCAACAGAGCCAGACTCCATCTCCAAAAAAA  
 AGGCCATTCTGAGGATCAAGGCAACACTAGCAACAGGGAGCCCCATGGGTCTCAGACCCCTCTCCCCACATC  
 TCCTGGTCCCTGCCACCTGGCGTACAGGGACAGCCCCACGGAAAGGCTTGGAGGCCAGGTAAACCATG  
 GGGAGGGAGGAATGGGACACCTCTCTGGAGGTCTTGGGAAGAGAAGCTTAGGGTCAGGTGGCTGAG  
 GGTGGAAATGAGAGAGGGTCTCTCTGGAGGTCTCACCATTCCCTGGTCACCCACCCAACTCTCATC  
 TCCCCTGATGTGGGGAGGAGCAGGGGGCATGGATTCTGAGCCCCAGACTCAACTGTTGGTTAACAGGG  
 GCATCAGGAGAGAGCGAGCAACACACTCCCTGAGCATCCCCCTGGCCCCGGCATGATGGAGGCCAGAGA/  
 CCTCCCTTCCCTTCTGGGGCTGGCATCTACTGGCTGTCCCCGAACCTGCTCTGGTACATCC  
 CCCACTACTCTTCTACCACTTCAGCTCTCATGGCCGGCGTGCAGTCGCGGCCAAGCCCGTCGTACTTC  
 TGCCTGGGAGTGGCCAGGGCCGAGGGCTGGCTCTCCGGCTGGTGGACATAGCAGCCCTGGGGCCCC  
 TGAGCTGGGGCCGTAGGGAGACCTCCGCCGGGCTGGTGGACATAGCAGCCCTGGGGAGAGCGAGGC  
 CGACCCCCAGCTGCAGCCCCGTAGGGCAAGAGGGTGACGTGGGAAAGGTGGTGGGTCAAGGGCTGGGG  
 AGCCGGACCTGGAGGAGGGCTTGGTGGGTGACCCGGTATGTGCTGTCAAAGTTGTGACCCCTGGCTGG  
 GCATGAGGCTCCCTGGAGGAGCAGCTGGAAAGG

50

The following amino acid sequence <SEQ ID NO. 42> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 41:

55

VSRDGAIALPGATEPDSISKKRPFGRHQQGAPWVSDPLPTS PGPCPHLAYRDQPHGRLLRPGNHGEGR  
 NGDTFLLSVLGKRSLGQVAEGGNERGVSSWRVSPFPWSPTQLSSPLMWGGAGGMDSAPDSTVVVYRGIRRE

5

SEQNTLLQHPLAPRPMMEPREAGQHVGAAANGAQEDVAFNLIIILSLTEGLGLGGLLGNGAVLWLSSNVYRN  
PFAIYLLDVACADLIFL GCHMVAIVPDLLQGRLDPGFVQTSLATLRF<sup>CYIVGL</sup> SLLAASVEQCLAALFP  
 AWYSCRPRH<sup>LTTCV</sup> CALTWALCLLLHLLSGACTOFFGEPSRHL<sup>CRTLWLVAAVLL</sup> ALLCCTMC GASLML  
 LLRVERGPQRPPP<sup>RGFPGL</sup> LILLTVLLFLFCGLP<sup>FGIY</sup> WLSRNLLWYI<sup>PHYFYHFS</sup> F<sup>LM</sup> MAAVHCAAKPVVYF  
CLGSAQGRRLPLRLV LQRALGDEAEELGAVRETSRRGLVDIAAALGPPTPAAAPVRQEGDVGVVVGSEAGAS  
 RTWRRPWWVTRSCAVKVVTGLEHEAPLGGSWK

10 The following DNA sequence nGPCR-63 <SEQ ID NO. 43> was identified in *H. sapiens*:

15 CAGTGAGCCGAGATGGTGCCATTGCAC<sup>T</sup>CTAGCCTGGGCAACAGAGCCAGACTCCATCTCCAAAAAAA  
 AGGCCATTCTGAGGATCAAGGACC<sup>A</sup>CTAGCAACAGGGAGCCCCATGGGTC<sup>T</sup>CTGAGACCC<sup>C</sup>CTCCCCACATC  
 TCCTGGTCCCTGCC<sup>C</sup>CCACCTGGCGTACAGGGACAGGCCACGG<sup>A</sup>GGCTT<sup>C</sup>GGCTGAGG<sup>C</sup>CCAGGTAA<sup>C</sup>CCATG  
 GGGAGGGAGGA<sup>A</sup>ATGGGACACCTTCTCTGAGTGTCTTAGGGAAAGAGAAGCTTAGGTCAGGTGGCTGAG  
 GGTGGA<sup>A</sup>ATGAGAGAGGGGTCTCTCTGGAGGGTCTCACCATTCC<sup>T</sup>GGTCACCCACCCAA<sup>C</sup>CTCATC  
 TCCCTGATGTGGGAGGAGCAGGGGCATGGATTCCTGAGCCCCAGACTCAACTGTGTGGTTAACAGGG  
 GCATCAGGAGAGAGAGCGAGCAGAACACACTCCTGCAGCATCCCC<sup>T</sup>GGCCCCCGCC<sup>C</sup>CATGATGGAGCCCAGAGA  
 CCTCCTCTTCTCTTCTGCGGC<sup>T</sup>CTGCC<sup>C</sup>TCGGCATCTACTGGCTGT<sup>C</sup>CCGGAAC<sup>T</sup>GTCTGGTACATCC  
 CCCACTACTCTACC<sup>A</sup>CTTCAGCTTC<sup>C</sup>TCATGGCC<sup>C</sup>CGTGC<sup>A</sup>CTGCGCCGCAAGGCC<sup>G</sup>CTCGT<sup>C</sup>ACTTC  
 TGCTGGGCAGTG<sup>C</sup>CCAGGGCGCAGG<sup>C</sup>CTGCC<sup>C</sup>CGTGCAGCGAGCGTGGAGACGAGGC  
 TGAGCTGGGGGCC<sup>G</sup>GTCA<sup>G</sup>GGAGACCTCCGCC<sup>G</sup>GGGCTGGTGGACATAGCAGC<sup>T</sup>GTGAGCC<sup>C</sup>CTGGGGCCCC  
 CGACCC<sup>C</sup>AGCTG<sup>C</sup>AGCCCC<sup>C</sup>GTGAGGCAAGAGGGTGACGTGGGAAGGTGGTGGGGT<sup>C</sup>AGAGGCTGGGGCC  
 AGCCGGACCTGGAGGAGGCC<sup>T</sup>GGTGGACCCGGTAC<sup>T</sup>GTGCTGTCAAAGTTGTGACCC<sup>T</sup>GGTCTGGGA  
 GCATGAGGCTCCC<sup>C</sup>CTGGAGGCAGCTGGAAAGG

20 The following amino acid sequence <SEQ ID NO. 44> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 43:

25 MMEPREAGQHVGAAANGAQEDVAFNLIIILSLTEGLGLGGLLGNGAVLWLSSNVYRN<sup>PFAIYLLDVACADL</sup>  
IFLGCHMVAIVPDLLQGRLDPGFVQTSLATLRF<sup>CYIVGL</sup> SLLAASVEQCLAALFP<sup>AWYSCRPRH</sup>LTTCV  
CALTWALCLLLHLLSGACTOFFGEPSRHL<sup>CRTLWLVAAVLL</sup> ALLCCTMC GASLML<sup>LLRVERGPQRPPP</sup>  
RGFPGL LILLTVLLFLFCGLP<sup>FGIY</sup> WLSRNLLWYI<sup>PHYFYHFS</sup> F<sup>LM</sup> MAAVHCAAKPVVYF<sup>CLGSAQGRRLPLRLV</sup>  
 LQRALGDEAEELGAVRETSRRGLVDIAA

30 The following DNA sequence nGPCR-63 <SEQ ID NO. 45> was identified in *H. sapiens*:

35 ATGATGAGCC<sup>C</sup>CAGAGAAC<sup>G</sup>TGGACAGCACGTGGGGCCGCCAACAGCGCC<sup>C</sup>AGGAGGATGTGGC<sup>T</sup>TCACCTCAT<sup>C</sup>  
 CTGGTACATCCCC<sup>C</sup>ACTACTCTACC<sup>A</sup>CTTCAGCTTC<sup>C</sup>TCATGGCC<sup>C</sup>CGTGC<sup>A</sup>CTGCGCC<sup>C</sup>CAAGCCCG  
 TCGTCTACTCTGCCTGGCAGTG<sup>C</sup>CCAGGGCC<sup>C</sup>CAGG<sup>C</sup>CTGGC<sup>C</sup>CTCCGGCTGGTCC<sup>C</sup>CAGCGAGCGCTG  
 GGAGACGAGG<sup>C</sup>GTGAGCTGGGGCC<sup>C</sup>GTCA<sup>G</sup>GGAGACCTCCC<sup>C</sup>CCGGGCTGGTGGACATAGCAGC<sup>C</sup>CTGA

40 The following amino acid sequence <SEQ ID NO. 46> is a predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 45:

45 MMEPREAGQHVGAA<sup>A</sup>NSAQEDVAFNLIIILSLTEGLGLGGLLGNGAVLWLSSNVYRN<sup>PFAIYLLDVACADL</sup>  
IFLGCHMVAIVPDLLQGRLDPGFVQTSLATLRF<sup>CYIVGL</sup> SLLAASVEQCLAALFP<sup>AWYSCRPRH</sup>LTTCV  
CALTWALCLLLHLLSGACTOFFGEPSRHL<sup>CRTLWLVAAVLL</sup> ALLCCTMC GASLML<sup>LLRVERGPQRPPP</sup>  
RGFPGL LILLTVLLFLFCGLP<sup>FGIY</sup> WLSRNLLWYI<sup>PHYFYHFS</sup> F<sup>LM</sup> MAAVHCAAKPVVYF<sup>CLGSAQGRRLPLRLV</sup>  
 LQRALGDEAEELGAVRETSRRGLVDIAA

55

**EXAMPLE 2: CLONING OF nGPCR-x**

cDNAs may be sequenced directly using an AB1377 or ABI373A fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISM Ready Dye-Deoxy Terminator kit with Taq FS polymerase. Each 5 ABI cycle sequencing reaction contains about 0.5 µg of plasmid DNA. Cycle-sequencing is performed using an initial denaturation at 98 C for 1 min, followed by 50 cycles: 98 C for 30 sec, annealing at 50 C for 30 sec, and extension at 60 C for 4 min. Temperature cycles and times are controlled by a Perkin-Elmer 9600 thermocycler. Extension products are purified using Centriflex gel filtration (Advanced Genetic Technologies 10 Corp., Gaithersburg, MD). Each reaction product is loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B table top centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples are dried under vacuum for about 40 min and then dissolved in 5 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The 15 samples are then heated to 90 C for three min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis is done by importing ABI373A files into the Sequencher program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp are obtained. Potential sequencing errors are minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult 20 areas using primers at different locations until all sequencing ambiguities are removed.

To isolate a cDNA clone encoding full length nGPCR, a DNA fragment corresponding to a nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, or a portion thereof, can be used as a probe for hybridization screening of a phage cDNA library. The DNA fragment is amplified by the 25 polymerase chain reaction (PCR) method. The PCR reaction mixture of 50 ml contains polymerase mixture (0.2 mM dNTPs, 1x PCR Buffer and 0.75 ml Expand High Fidelity Polymerase (Roche Biochemicals)), 1 µg of 3206491 plasmid, and 50 pmoles of forward primer and 50 pmoles of reverse primer. The primers are preferably 10 to 25 nucleotides in length and are determined by procedures well known to those skilled in the art. 30 Amplification is performed in an Applied Biosystems PE2400 thermocycler, using the

following program: 95 C for 15 seconds, 52 C for 30 seconds and 72 C for 90 seconds; repeated for 25 cycles. The amplified product is separated from the plasmid by agarose gel electrophoresis, and purified by Qiaquick gel extraction kit (Qiagen).

A lambda phage library containing cDNAs cloned into lambda ZAPII phage-  
5 vector is plated with *E. coli* XL-1 blue host, on 15 cm LB-agar plates at a density of 50,000 pfu per plate, and grown overnight at 37 C; (plated as described by Sambrook et al., *supra*). Phage plaques are transferred to nylon membranes (Amersham Hybond NJ), denatured for 2 minutes in denaturation solution (0.5 M NaOH, 1.5 M NaCl), renatured for 5 minutes in renaturation solution (1 M Tris pH 7.5, 1.5 M NaCl), and washed briefly  
10 in 2xSSC (20x SSC: 3 M NaCl, 0.3 M Na-citrate). Filter membranes are dried and incubated at 80 C for 120 minutes to cross link the phage DNA to the membranes.

The membranes are hybridized with a DNA probe prepared as described above. A DNA fragment (25 ng) is labeled with  $\alpha$ -32P-dCTP (NEN) using Rediprime random priming (Amersham Pharmacia Biotech), according to manufacturers instructions.  
15 Labeled DNA is separated from unincorporated nucleotides by S200 spin columns (Amersham Pharmacia Biotech), denatured at 95 C for 5 minutes and kept on ice. The DNA-containing membranes (above) are pre-hybridised in 50 ml ExpressHyb (Clontech) solution at 68 C for 90 minutes. Subsequently, the labeled DNA probe is added to the hybridization solution, and the probe is left to hybridise to the membranes at 68 C for 70  
20 minutes. The membranes are washed five times in 2x SSC, 0.1% SDS at 42 C for 5 minutes each, and finally washed 30 minutes in 0.1x SSC, 0.2% SDS. Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with an intensifying screen at -80 C for 16 hours. One positive colony is isolated from the plates, and replated with about 1000 pfu on a 15 cm LB plate. Plating, plaque lift to filters and  
25 hybridization are performed as described above. About four positive phage plaques are isolated form this secondary screening.

cDNA containing plasmids (pBluescript SK-) are rescued from the isolated phages by *in vivo* excision by culturing XL-1 blue cells co-infected with the isolated phages and with the Excision helper phage, as described by manufacturer (Stratagene).  
30 *XL-blue* cells containing the plasmids are plated on LB plates and grown at 37 C for 16

hours. Colonies (18) from each plate are replated on LB plates and grown. One colony from each plate is stricken onto a nylon filter in an ordered array, and the filter is placed on a LB plate to raise the colonies. The filter is then hybridized with a labeled probe as described above. About three positive colonies are selected and grown up in LB medium.

5 Plasmid DNA is isolated from the three clones by Qiagen Midi Kit (Qiagen) according to the manufacturer's instructions. The size of the insert is determined by digesting the plasmid with the restriction enzymes NotI and SalI, which establishes an insert size. The sequence of the entire insert is determined by automated sequencing on both strands of the plasmids.

10 **nGPCR-1003**

The deduced nucleotide sequence for Seq-1003 was used to design gene specific PCR primers. The following primers were designed and synthesized:

S1003 sense primer: 5' CTGAGCATGGATCCAACCACCC 3' (SEQ ID NO:47)

S1003 antisense primer: 5'CTCTACACCAGACTGCTTCGACATCTC 3' (SEQ ID NO:48)

15 Since the gene encoding Seq-1003 is intronless, genomic DNA was used as the template to clone the full-length nGPCR-1003. The 50µl PCR-reaction was prepared using 1µg genomic DNA, 10 µM S1003 sense primer (SEQ ID NO:47), and 10µM S1003 antisense primer (SEQ ID NO:48). The PCR reaction was performed using Advantage2

20 Polymerase Mix, Clontech (cat # 8430-2). The PE GeneAmp System 9700 was used with the program: 94°C 5 min; 30 cycles of 94°C 30 sec, 66°C 2 min, and finally 68°C 10 min and cooling to 4°C. The PCR reaction was analyzed on a 1.2% agarose gel (E-gel, Invitrogen), and a band of about 1000bp was seen. The band was excised from the gel and purified through Spin-X column (Costar, cat # 8163). Four µl of the purified

25 fragment was cloned into 1 µl plasmid pCR2.1-TOPO using the TOPO TA Cloning Kit (Invitrogen, cat # K4500-01). Five µl of the ligation mix was transformed into One Shot chemically competent TOP10 *E. coli* cells (Invitrogen, cat # C4040-03). Plasmid DNA from two clones (5 ml overnight culture), were obtained by using the QIAprep Spin Miniprep Kit (QIAGEN,cat # 27104) and the subsequent sequencing was performed by

the dideoxy chain-termination method using Applied Biosystems Model AB1377 DNA sequencing system.

#### **nGPCR-1006**

The deduced nucleotide sequence for nGPCR-1006 was used to design the 5 following gene specific PCR primers in order to clone full-length nGPCR-1006.

S1006 sense primer: 5' AGATGGAGACCACCATGGGTTCAT 3' (SEQ ID NO:49)

S1006 antisense primer: 5' GGGTTATTTAGTCTGATGCAGTCCACCTC 3' (SEQ ID NO:50)

5'SMART RACE-Ready-cDNA from human Testis was used as template 10 to pick up the full-length nGPCR-1006. The 5'SMART RACE Ready cDNA reactions were performed as recommended in the SMART RACE manual (PT3269-1) and we used human testis mRNA (Clontech, cat. # 6535-1). The 50µl PCR-reactions were made with 2µl human testis cDNA, 10 µM S1006 sense primer (SEQ ID NO:49), and 10µM S1006 antisense primer (SEQ ID NO:50). The PCR reaction was performed using Advantage2 15 Polymerase Mix, Clontech (cat # 8430-2). The PE GeneAmp System 9700 was used with the program: 94°C 1 min; 30 cycles of 94°C 30 sec, 68°C 2 min, and finally 68°C 7 min and cooling to 4°C. The PCR reaction was analyzed on a 1.2% agarose gel (E-gel, Invitrogen), and a band corresponding to the expected product size of nGPCR-1006 (1185bp) was seen. The band was excised from the gel and purified through Spin-X 20 column (Costar, cat # 8163). Four µl of the purified fragment was cloned into 1 µl plasmid pCR2.1-TOPO using the TOPO TA Cloning Kit (Invitrogen, cat # K4500-01). Five µl of the ligation mix was transformed into One Shot chemically competent TOP10 *E.coli* cells (Invitrogen, cat # C4040-03). Plasmid DNA from three clones (5 ml overnight culture), were obtained by using the QIAprep Spin Miniprep Kit (QIAGEN,cat 25 # 27104) and the subsequent confirmatory sequencing was performed by the dideoxy chain-termination method using Applied Biosystems Model AB1377 DNA sequencing system.

#### **nGPCR-1007**

To isolate a cDNA clone encoding full length nGPCR-1007, the DNA sequence 30 obtained from the procedures outlined in Example 1 above was used to design PCR

primers for 5'- and 3' RACE cDNA amplification using the SMART™ RACE cDNA Amplification Kit from Clontech (catalog # K1811-1).

The following PCR primers were designed as recommended in the SMART RACE manual (PT3269-1), with the help of Oligo® 5 primer analysis software

5 (Medprobe):

S1007frwd: 5'-GCCTGGAGCCTGTCTTCTGTT CTC-3' (SEQ ID NO: 33)

S1007rew: 5'-GTAGATGAGGGGGTTGATGGCACTATTC-3' (SEQ ID NO:34)

S1007nestfrwd: 5'-CCTGATC ATATTGGGAAGAGGGACACTG-3' (SEQ ID NO:35)

10 S1007 nestrew: 5'-GATAGCCTTGATTGATTGAGATG-3' (SEQ ID NO:36)

As a template for cloning, a 5'-RACE-Ready cDNA and a 3'-RACE-Ready cDNA preparation was made from human fetal brain mRNA (Clontech cat. # 6525-1) according to the manual. One  $\mu$ g of mRNA was used for each reaction and Superscript™

15 II reverse transcriptase from LifeTechnologies (cat # 18064-22) was used for the reverse transcription. The 5'-RACE and the 3'-RACE 50  $\mu$ l PCR-reactions were made according to the manual by using 5  $\mu$ l universal primer mix (UPM), and with 1  $\mu$ l S1007 frwd primer (SEQ ID NO: 33) for the 3'-RACE reaction, and 1  $\mu$ l S1007 rew primer (SEQ ID NO: 34) for the 5'-RACE reaction. The PCR reactions were performed using

20 Advantage®2 polymerase mix from Clontech (cat # 8430-2). The PE GeneAmp System 9700 was used with the program: 94 C° 20 sec; 5 cycles of 94 C° 5 sec, 72 C° 3 min; 5 cycles of 94 C° 5 sec, 70 C° 10 sec, 72 C° 3 min; 25 cycles of 94 C° 5 sec, 68 C° 10 sec, 72 C° 3 min and finally 72 C° 7 min. The 5'-nested PCR reaction was made with 1  $\mu$ l 5'-

25 RACE product, 1  $\mu$ l S1007 nestfrwd primer (SEQ ID NO: 35) and 1  $\mu$ l nested universal primer (NUP) in a 50  $\mu$ l reaction. The 3'-nested PCR reaction was made as above, but with 5  $\mu$ l diluted 3'-RACE product (57x diluted in Trizine-EDTA buffer) and 1  $\mu$ l S1007

nestrew primer (SEQ ID NO: 36). The PE GeneAmp System 9700 was used with the program 94 C° 15 sec; 25 cycles of 94 C° 5 sec, 68 C° 10 sec, 72 C° 3 min and finally 72 C° 7 min. The products were loaded on a 1.2% agarose gel (E-gel, Invitrogen) and a

30 band of about 1000 bp was seen in both the 5 and 3'-nest race reaction. Product material

was excised from the gel and purified through SPIN-X column from Costar (cat # 8163). Four  $\mu$ l of each purified fragment was cloned into 1  $\mu$ l plasmid pCR®2.1-TOPO using the TOPO TA Cloning® Kit from Invitrogen (cat # K4500-01). Two  $\mu$ l of each ligation mix was transformed into One Shot® chemically competent TOP10 *E. coli* cells from 5 Invitrogen (cat # C4040-03). Plasmid DNA from two clones each (2.5 ml overnight culture), were obtained by using the QIAprep® Spin Miniprep Kit (QIAGEN, cat # 27104) and the subsequent sequencing was performed by the dideoxy chain-termination method using the Applied Biosystems Model AB1377 DNA sequencing system.

The complete 1,668 base nucleotide sequence encoding nGPCR-1007 is given in 10 SEQ ID NO:12. Translation of this sequence revealed an open reading frame encoding 371 amino acids (SEQ ID NO:25). Using a computer program TMHMM1.0 [Sonhammer EL, von Heijne G, Krogh A, Ismb 1998;6:175-82; also available at <http://www.cbs.dtu.dk/services/TMHMM-1.0/> ], nGPCR-1007 was shown to contain 7 transmembrane-spanning domains corresponding to the underlined residues in SEQ ID 15 NO:25.

#### Cloning of full-length cDNA encoding nGPCR-1007

The 5'RACE clone 1 (pMB1610) and 3'RACE clone 2 (pMB1611) described above were used to assemble a nGPCR-1007 full length clone. This was possible since 20 the 5'- and the 3'-RACE had overlapping sequences. The 5'RACE fragment was cut with the restriction enzymes ApaI and XbaI to isolate the 5' part of the nGPCR-1007 gene. To isolate the 3' part, the 3'RACE fragment was cut with the restriction enzymes ApaI and XhoI. The cloning vector pCR2.1-TOPO (Invitrogen) was cut with the enzymes SpeI and XhoI for accommodation of the above fragments. All the restriction enzyme reaction 25 products were separated on a 1.2% agarose gel (E-gel, Invitrogen) and the desired fragments were excised from the gel and purified with QIAEXII Agarose Gel Extraction Kit (Qiagen, cat. # 20021). This was followed by a three fragment ligation performed as recommended in Rapid DNA Ligation manual (Roche, cat. # 1635379). Five  $\mu$ l of the ligation mix was transformed into One Shot chemically competent TOP10 *E. coli* cells 30 (Invitrogen, cat # C4040-03). Plasmid DNA from one clone (5 ml overnight culture), was isolated by using the QIAprep Spin Miniprep Kit (QIAGEN, cat # 27104) and the

subsequent confirmatory sequencing was performed by the dideoxy chain-termination method using Applied Biosystems Model AB1377 DNA sequencing system.

**EXAMPLE 3: SUBCLONING OF THE CODING REGION OF NGPCR-X VIA  
5 PCR**

Additional experiments may be conducted to subclone the coding region of nGPCR and place the isolated coding region into a useful vector. Two additional PCR primers are designed based on the coding region of nGPCR, corresponding to either end. To protect against exonucleolytic attack during subsequent exposure to enzymes, *e.g.*,

10 Taq polymerase, primers are routinely synthesized with a protective run of nucleotides at the 5' end that were not necessarily complementary to the desired target.

PCR is performed in a 50  $\mu$ l reaction containing 34  $\mu$ l H<sub>2</sub>O, 5  $\mu$ l 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5  $\mu$ l 15 mM MgSO<sub>4</sub>, 2  $\mu$ l dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 10 mM), 3  $\mu$ l 15 genomic phage DNA (0.25  $\mu$ g/ $\mu$ l), 0.3  $\mu$ l Primer 1 (1  $\mu$ g/ $\mu$ l), 0.3  $\mu$ l Primer 2 (1  $\mu$ g/ $\mu$ l), 0.4  $\mu$ l High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94 °C for 2 minutes; followed by 25 cycles at 94 °C for 30 seconds, 55 °C for 30 seconds, and 72 °C for 1.3 minutes.

20 The contents from the PCR reaction are loaded onto a 2% agarose gel and fractionated. The DNA band of expected size is excised from the gel, placed in a GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microfuge. The eluted DNA is precipitated with ethanol and resuspended in 6  $\mu$ l H<sub>2</sub>O for ligation.

25 The PCR-amplified DNA fragment containing the coding region is cloned into pCR2.1 using a protocol standard in the art. In particular, the ligation reaction consists of 6  $\mu$ l of GPCR DNA, 1  $\mu$ l 10X ligation buffer, 2  $\mu$ l pCR2.1 (25 ng/ $\mu$ l, Invitrogen), and 1  $\mu$ l T4 DNA ligase (Invitrogen). The reaction mixture is incubated overnight at 14 °C and the reaction is then stopped by heating at 65 °C for 10 minutes. Two microliters of the ligation reaction are transformed into One Shot cells (Invitrogen) and plated onto 30 ampicillin plates. A single colony containing a recombinant pCR2.1 bearing an insert is

used to inoculate a 5 ml culture of LB medium. Plasmid DNA is purified using the Concert Rapid Plasmid Miniprep System (GibcoBRL) and sequenced. Following confirmation of the sequence, a 50 ml culture of LB medium is inoculated with the transformed One Shot cells, cultured, and processed using a Qiagen Plasmid Midi Kit to 5 yield purified pCR-GPCR.

#### **nGPCR-1002 (nGPCR-63)**

Isolation of a clone for nGPCR-1002 (nGPCR-63) from genomic DNA was performed by PCR in a 50  $\mu$ l reaction containing Herculase DNA Polymerase blend (Stratagene), with buffer recommendations as supplied by the manufacturer, 200 ng each 10 primers PSK16 and 17 (SEQ ID NOS: 51 and 52, respectively), 150 ng of human genomic DNA (Clontech) and 4% DMSO. The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94°C for 2 min followed by 35 cycles of 94°C for 30 sec, 65°C for 30 sec, 72°C for 2 min. The PCR reaction was purified by the QiaQuick PCR Purification Kit (Qiagen) and eluted in TE. The PCR 15 primer sequences were:

PSK16: 5'GATCGAATTCATGATGGAGCCCAGAGAAGCTGGAC (SEQ ID NO:51) and:

PSK17: 5'GATCCTCGAGTCAGGCTGCTATGTCCACCAGGCC (SEQ ID NO:52).

20 Translation initiation and termination codons are shown above in bold.

The PCR product was ligated into the pCR-BluntII-TOPO vector (Invitrogen) using the Zero Blunt Topo PCR TA cloning kit as follows. Three  $\mu$ l PCR product DNA, 1  $\mu$ l pCRII-TOPO vector, and 1  $\mu$ l TOPOII salt solution (1.2M NaCl, 0.06M MgCl<sub>2</sub>) was 25 incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42°C, placed on ice for two minutes, 250  $\mu$ l of SOC was added, then incubated at 37°C with shaking for one hour and then plated onto ampicillin plates supplemented 30 with Xgal and IPTG. Single colonies were screened by restriction digestion for the presence of the insert, and a plasmid DNA from colony 63-4-23 was purified using a Qiagen Endo-Free plasmid purification kit.

The clone containing nGPCR-1002 was sequenced directly using an ABI377 35 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDyeTM Terminator Cycle Sequencing Ready Reaction kit with Taq FSTM polymerase. Each ABI cycle sequencing reaction contained about 0.5  $\mu$ g of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98°C for 1 min, followed by 50 cycles: 96°C for 30 sec, annealing at 50°C for 30 sec, and extension at 60°C for 4 min. Temperature cycles and times were controlled by a Perkin-

Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 min at room temperature. Column-purified samples were dried under vacuum for about 40 min and then dissolved in 3  $\mu$ l of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90°C for 3.5 min and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI).

#### nGPCR-1006

To isolate a cDNA clone encoding the 5' portion of nGPCR-1006, the DNA sequence obtained from the procedures outlined in Example 1 above was used to design PCR primers for 5'-RACE cDNA amplification using the SMART™ RACE cDNA Amplification Kit from Clontech (catalog # K1811-1). The following PCR primers were designed as recommended in the SMART RACE manual (PT3269-1), with the help of Oligo® 5 primer analysis software (Medprobe):

S1006rev: 5'-GCAGCAGACAATGGCCACCAAGGAAGTCAGA-3' (SEQ ID NO: 37)  
20 S1006nestrev: 5'-TGAGCAGGTTGGTGAGGTTGCGCAGTTCT-3' (SEQ ID NO:38)

As a template for cloning, a 5'-RACE-Ready cDNA preparation was made from human testis mRNA (Clontech cat. # 6535) according to the manual. 1  $\mu$ g of mRNA was used for the reaction and Superscript™ II reverse transcriptase from LifeTechnologies (cat # 18064-22) was used for the reverse transcription. The 5'-RACE 50 $\mu$ l PCR-reaction was made according to the manual by using 5 $\mu$ l universal primer mix (UPM), and with 1  $\mu$ l S1006rev primer for the 5'-RACE reaction. The PCR reactions were performed using Advantage®2 polymerase mix from Clontech (cat # 8430-2). The PE GeneAmp System 9700 was used with the program: 94°C 20 sec; 5 cycles of 94°C 5 sec, 72°C 3 min; 5 cycles of 94°C 5 sec, 70°C 10 sec, 72°C 3 min ; 25 cycles of 94°C 5 sec, 68°C 10 sec,

72°C 3 min and finally 72°C 7 min. The 5'-nested PCR reaction was made with 1 µl 5'-RACE product, 1 µl S1006nestrev primer and 1 µl nested universal primer (NUP) in a 50 µl reaction. The PE GeneAmp System 9700 was used with the program 94°C 20 sec; 25 cycles of 94°C 5 sec, 72°C 3 min and finally 72°C 7 min and cooling to 4°C. The 5 material were loaded on a 1.2% agarose gel (E-gel, Invitrogen) and a band of about 1.7kbp was seen in the 5'-nest PCR reaction. The fragment was excised from the gel and purified through a SPIN-X column, Costar (cat # 8163). Four µl of each purified fragment was cloned into 1 µl plasmid pCR2.1-TOPO using the TOPO TA Cloning Kit, Invitrogen (cat # K4500-01). Two µl of the ligation mix was transformed into One Shot 10 chemically competent TOP10 E. coli cells, Invitrogen (cat # C4040-03). Plasmid DNA from one clone (2.5 ml overnight culture), were obtained by using the QIAprep Spin Miniprep Kit, Qiagen (cat # 27104) and the subsequent sequencing was performed by the dideoxy chain-termination method using Applied Biosystems Model AB1377 DNA sequencing system.

15

**EXAMPLE 4: HYBRIDIZATION ANALYSIS TO DEMONSTRATE nGPCR-X EXPRESSION IN BRAIN**

The expression of nGPCR-x in mammals, such as the rat, may be investigated by *in situ* hybridization histochemistry. To investigate expression in the brain, for example, 20 coronal and sagittal rat brain cryosections (20 µm thick) are prepared using a Reichert-Jung cryostat. Individual sections are thaw-mounted onto silanized, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at -80°C. Sections are processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold phosphate-buffered saline (PBS), acetylated using acetic anhydride in triethanolamine 25 buffer, and dehydrated through a series of alcohol washes in 70%, 95%, and 100% alcohol at room temperature. Subsequently, sections are delipidated in chloroform, followed by rehydration through successive exposure to 100% and 95% alcohol at room temperature. Microscope slides containing processed cryosections are allowed to air dry prior to hybridization. Other tissues may be assayed in a similar fashion.

30

A nGPCR-x-specific probe is generated using PCR. Following PCR amplification, the fragment is digested with restriction enzymes and cloned into

pBluescript II cleaved with the same enzymes. For production of a probe specific for the sense strand of nGPCR-x, the nGPCR-x clone in pBluescript II is linearized with a suitable restriction enzyme, which provides a substrate for labeled run-off transcripts (*i.e.*, cRNA riboprobes) using the vector-borne T7 promoter and commercially available T7

5 RNA polymerase. A probe specific for the antisense strand of nGPCR-x is also readily prepared using the nGPCR-x clone in pBluescript II by cleaving the recombinant plasmid with a suitable restriction enzyme to generate a linearized substrate for the production of labeled run-off cRNA transcripts using the T3 promoter and cognate polymerase. The riboprobes are labeled with [<sup>35</sup>S]-UTP to yield a specific activity of about  $0.40 \times 10^6$

10 cpm/pmol for antisense riboprobes and about  $0.65 \times 10^6$  cpm/pmol for sense-strand riboprobes. Each riboprobe is subsequently denatured and added (2 pmol/ml) to hybridization buffer which contained 50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, 1X Denhardt's Solution, and 10 mM dithiothreitol.

15 Microscope slides containing sequential brain cryosections are independently exposed to 45  $\mu$ l of hybridization solution per slide and silanized cover slips are placed over the sections being exposed to hybridization solution. Sections are incubated overnight (15-18 hours) at 52 °C to allow hybridization to occur. Equivalent series of cryosections are exposed to sense or antisense nGPCR-x-specific cRNA riboprobes.

Following the hybridization period, coverslips are washed off the slides in 1X

20 SSC, followed by RNase A treatment involving the exposure of slides to 20  $\mu$ g/ml RNase A in a buffer containing 10 mM Tris-HCl (pH 7.4), 0.5 M EDTA, and 0.5 M NaCl for 45 minutes at 37 °C. The cryosections are then subjected to three high-stringency washes in 0.1 X SSC at 52 °C for 20 minutes each. Following the series of washes, cryosections are dehydrated by consecutive exposure to 70%, 95%, and 100% ammonium acetate in

25 alcohol, followed by air drying and exposure to Kodak BioMax™ MR-1 film. After 13 days of exposure, the film is developed. Based on these results, slides containing tissue that hybridized, as shown by film autoradiograms, are coated with Kodak NTB-2 nuclear track emulsion and the slides are stored in the dark for 32 days. The slides are then developed and counterstained with hematoxylin. Emulsion-coated sections are analyzed

30 microscopically to determine the specificity of labeling. The signal is determined to be

specific if autoradiographic grains (generated by antisense probe hybridization) are clearly associated with cresyl violate-stained cell bodies. Autoradiographic grains found between cell bodies indicates non-specific binding of the probe.

Expression of nGPCR-x in the brain provides an indication that modulators of nGPCR-x activity have utility for treating neurological disorders, including but not limited to, mental disorder, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-x may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-x modulators, including nGPCR-x ligands and anti-nGPCR-x antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

#### EXAMPLE 5: TISSUE EXPRESSION PROFILING

A PCR-based system (RapidScan™ Gene Expression Panel, OriGene Technologies, Rockville, MD) may be used to generate a comprehensive expression profile of the putative nGPCR-x in human tissue, and in human brain regions. The RapidScan Expression Panel is comprised of first-strand cDNAs from various human tissues and brain regions that are serially diluted over a 4-log range and arrayed into a multi-well PCR plate. Human tissues in the array may include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, and fetal liver.

Expression of nGPCR-x in various tissues is detected using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a predetermined size fragment in the presence of the appropriate cDNA.

PCR is performed in a 50 µl reaction containing 34 µl H<sub>2</sub>O, 5 µl 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5 µl 15 mM MgSO<sub>4</sub>, 2 µl dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 10 mM), 0.3 µl forward primer (1 µg/µl), 0.3 µl reverse primer (1 µg/µl), 0.4 µl High Fidelity Taq

polymerase (Boehringer Mannheim). The PCR reaction mixture is added to each well of the PCR plate. The plate is placed in a MJ Research PTC100 thermocycler, and is then exposed to the following cycling parameters: Pre-soak 94°C for 3 min; denaturation at 94°C for 30 seconds; annealing at primer 57 C for 45 seconds; extension 72°C for 2 minutes; for 35 cycles. PCR productions are then separated and analyzed by electrophoresis on a 1.2% agarose gel stained with ethidium bromide.

The 4-log dilution range of cDNA deposited on the plate ensures that the amplification reaction is within the linear range and, hence, facilitates semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

#### **nGPCR-1002 (nGPCR-63)**

Tissue specific expression of the nGPCR-1002 (nGPCR-63) was detected using a PCR-based RapidScan™ Gene Expression Panel (OriGene Technologies, Rockville, MD). The RapidScan Expression Panel is comprised of first-strand cDNAs from 12 human tissues that are serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed included: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. PCR primers were designed based on the available sequence of the Celera sequence HUM\_IDS|Contig|11000258115466. The forward primer used was:

5'ACAGCCCCAAAGCCAAACAC3', (SEQ ID NO:53). The reverse primer was:

5'CCGCAGGAGCAATGAAAATCAG3', (SEQ ID NO:54). This primer set primed the synthesis of a 220 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain RapidScan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus,

hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN).

Twenty-five microliters of the PCR reaction mixture was added to each well of the

5     RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94° for 3min.) followed by 35 cycles of [(94° for 45 sec.) (54°C for 2 min.) (72° for 45 sec.)]. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide.

10     nGPCR-1002 (nGPCR-63) was expressed in the brain, heart, kidney, liver, muscle, ovary, prostate, small intestine, spleen, testis, peripheral blood leukocytes, and lung. Within the brain, nGPCR-1002 (nGPCR-63) was expressed in regions including but not limited to, cerebellum, amygdala, hypothalamus, medulla, temporal lobe, pons, hippocampus, substantia nigra, thalamus, frontal lobe, caudate nucleus, and spinal cord.

15     Expression of the nGPCR-1002 (nGPCR-63) in the brain provides an indication that modulators of nGPCR-1002 (nGPCR-63) activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-1002 (nGPCR-63) modulators, including nGPCR-1002 (nGPCR-63) ligands and anti-nGPCR-1002

20     (nGPCR-63) antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

### **nGPCR-1003**

#### **First-Strand cDNA Synthesis**

The 5'SMART RACE Ready cDNA reactions were performed as recommended 25 in the SMART RACE manual (PT3269-1). 5'-RACE-Ready cDNA preparation were made of human normal adipose total RNA (Invitrogen, cat. # D6005-01), human fetal brain mRNA (Clontech, cat. # 6525-1), human heart mRNA (Invitrogen, cat. # D6064-15), human liver mRNA (Clontech, cat. # 6510-1), human pancreas mRNA (Clontech, cat. # 6539-1), human placenta total RNA (Clontech, cat. #64024-1), human skeletal 30 muscle mRNA (Clontech, cat. #6541-1), human testis mRNA (Clontech, cat. # 6535-1),

and human uterus mRNA (Clontech, cat. # 6537-1). One  $\mu$ g of mRNA or total RNA was used for each reaction and Superscript II reverse transcriptase (Gibco BRL, cat # 18064-22) was used for the reverse transcription.

#### nGPCR-1003 Transcript Profiling

5 Transcript profiling was performed by PCR on the different 5'-RACE-Ready cDNA described above with gene specific primers designed from the deduced nGPCR-1003 nucleotide sequence.

S1003 sense primer: 5'-CTGAGCATGGATCCAACCACCC-3' (SEQ ID NO:55)

10 S1003 antisense primer: 5'-CTCTACACCAGACTGCTTCTGACATCTC-3' (SEQ ID NO:56).

A 50 $\mu$ l PCR-reaction was made with 2 $\mu$ l cDNA template, 10 $\mu$ M S1003 sense primer (SEQ ID NO:55), and 10 $\mu$ M antisense primer (SEQ ID NO:56). The PCR reactions were performed using Taq DNA Polymerase (Boehringer Mannheim, cat #1435094). The PE GeneAmp System 9700 was used with the program: 94°C 5 min; 30/40/50 cycles 15 of 94°C 30 sec, 66°C 2 min, and finally 68°C 10 min and cooling to 4°C. The PCR products were analyzed on a 1.2% agarose gel (E-gel, Invitrogen). After 40 cycles a band corresponding to the size of expected product size (989 bp) was seen in the PCR reaction with normal human adipose cDNA as template. A "weak" band was also seen in the PCR reaction with human liver cDNA as template.

20 Expression of nGPCR-1003 in these tissues provides an indication that modulators of nGPCR-1003 activity have utility for treating diseases and disorders including but not limited to metabolic disorders (including obesity and diabetes), as well as inflammatory disorders and cancers. Use of nGPCR-1003 modulators, including nGPCR-1003 ligands and anti-nGPCR-1003 antibodies, to treat individuals having such 25 disease states is intended as an aspect of the invention.

#### nGPCR-1006

Tissue specific expression of the cDNA encoding nGPCR-1006 was detected using a PCR-based RapidScan™ Gene Expression Panel (OriGene Technologies, Rockville, MD). The RapidScan Expression Panel is comprised of first-strand cDNAs 30 from 24 human tissues that are serially diluted over a 3-log range and arrayed into a

multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed included: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone 5 marrow, fetal brain, fetal liver. PCR primers were designed based on the available sequence of the Celera human genomic sequence GA\_6839570. The forward primer used was:

5' TTTCCCTGGCTCTGACAATGAC3', (SEQ ID NO:39), corresponding to base pairs 438 through 459 of GA\_6839570. The reverse primer was:

10 5'TCCACTTGTGTTCTGCC3', (SEQ ID NO:40), corresponding to base pairs 596 through 614 of GA\_6839570. This primer set primed the synthesis of a 177 base pair fragment in the presence of the appropriate cDNA. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System<sup>TM</sup> (Roche Molecular Biochemicals, 15 Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture were added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of [(94° for 45 sec.)(53°C for 2 min.)(72°C for 45 sec.)]. PCR reaction products were then separated and analyzed 20 by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide.

nGPCR-1006 was found to be expressed in pancreas, salivary gland, adrenal gland, ovary, prostate, skin, peripheral blood leukocytes, bone marrow, testis, and placenta. Expression of nGPCR-1006 in these tissues provides an indication that modulators of nGPCR activity have utility for treating metabolic and cardiovascular 25 diseases and disorders (e.g., type 2 diabetes, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, etc.); proliferative diseases and cancers (e.g., different cancers such as breast, colon, lung, etc., and hyperproliferative disorders such as psoriasis, prostate hyperplasia, etc.); hormonal disorders (e.g., male/female hormonal replacement, polycystic ovarian syndrome, 30 alopecia, etc.); sexual dysfunction, inflammatory conditions (e.g., Chron's disease);

diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; infections, such as viral infections caused by HIV-1 or HIV-2; among others.

#### **nGPCR-1007**

5 To determine the relative expression levels of nGPCR-1007 in different tissues, a Multiple Tissue Expression Array, (CLONTECH #775-1) was used in a hybridization experiment with a 572bp gene specific probe. The nGPCR-1007 3'RACE clone 1 from the Example 2 above was digested with the restriction enzyme EcoRI and separated on a 1,2% agarose gel (E-gel, Invitrogen). A 572bp fragment was excised from the gel and  
10 purified with QIAEXII Agarose Gel Extraction Kit (QIAGEN # 20021). Twenty-five ng of the purified fragment was used in a  $^{32}\text{P}$  labeling reaction and performed with reagents as recommended in the Strip-EZ DNA probe synthesis instruction manual (Ambion #1470). [ $\alpha$ - $^{32}\text{P}$ ]dATP used in the reaction was purchased from Amersham Pharmacia Biotech cat no AA0004. Prehybridization, hybridization and washing conditions were  
15 performed as recommended by CLONTECH manual PT3307-1. The MTE Array was exposed in a STORM860 Phosphor Screen for 25 hours. ImageQuant software was used to analyze the hybridization signal. Result from transcript profiling of nGPCR-1007 on the MTE Array showed significant expression in the central nervous system, with the highest expression in thalamus followed by amygdala, cerebellum, medulla oblongata,  
20 substantia nigra, hippocampus, and the temporal lobe. Significant expression was also observed in lymph node, thyroid gland, and testis.

Expression of nGPCR-1007 in these tissues provides an indication that modulators of nGPCR activity have utility for treating metabolic diseases and disorders (e.g., type 2 diabetes, obesity, anorexia, hypertension, atherosclerosis, etc.); and thyroid  
25 disorders (e.g. thyrotoxicosis, myxoedema); inflammatory conditions (e.g., Chron's disease); rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (e.g., pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia,  
30 severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders

such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, etc.); among others.

#### EXAMPLE 6: NORTHERN BLOT ANALYSIS

5        Northern blots are performed to examine the expression of nGPCR-x mRNA. The sense orientation oligonucleotide and the antisense-orientation oligonucleotide, described above, are used as primers to amplify a portion of the GPCR-x cDNA sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45.

10      Multiple human tissue northern blots from Clontech (Human II # 7767-1) are hybridized with the probe. Pre-hybridization is carried out at 42 C for 4 hours in 5xSSC, 1X Denhardt's reagent, 0.1% SDS, 50% formamide, 250 mg/ml salmon sperm DNA. Hybridization is performed overnight at 42°C in the same mixture with the addition of about  $1.5 \times 10^6$  cpm/ml of labeled probe.

15      The probe is labeled with  $\alpha$ -<sup>32</sup>P-dCTP by Rediprime™ DNA labeling system (Amersham Pharmacia), purified on Nick Column™ (Amersham Pharmacia) and added to the hybridization solution. The filters are washed several times at 42°C in 0.2x SSC, 0.1% SDS. Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with intensifying screen at -80°C.

20

#### EXAMPLE 7: RECOMBINANT EXPRESSION OF nGPCR-X IN EUKARYOTIC HOST CELLS

A. Expression of nGPCR-x in Mammalian Cells

To produce nGPCR-x protein, a nGPCR-x-encoding polynucleotide is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques. For example, the nGPCR-x-encoding sequence described in Example 1 is subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected into Chinese Hamster Ovary (CHO) cells using the transfection reagent FuGENE6™ (Boehringer-Mannheim) and the transfection protocol provided in the product insert. Other eukaryotic cell lines, including human embryonic kidney (HEK

293) and COS cells, are suitable as well. Cells stably expressing nGPCR-x are selected by growth in the presence of 100 µg/ml zeocin (Stratagene, LaJolla, CA). Optionally, nGPCR-x may be purified from the cells using standard chromatographic techniques. To facilitate purification, antisera is raised against one or more synthetic peptide sequences

5 that correspond to portions of the nGPCR-x amino acid sequence, and the antisera is used to affinity purify nGPCR-x. The nGPCR-x also may be expressed in-frame with a tag sequence (e.g., polyhistidine, hemagglutinin, FLAG) to facilitate purification. Moreover, it will be appreciated that many of the uses for nGPCR-x polypeptides, such as assays described below, do not require purification of nGPCR-x from the host cell.

10 B. Expression of nGPCR-x in 293 cells

For expression of nGPCR-x in mammalian cells 293 (transformed human, primary embryonic kidney cells), a plasmid bearing the relevant nGPCR-x coding sequence is prepared, using vector pSecTag2A (Invitrogen). Vector pSecTag2A contains the murine IgK chain leader sequence for secretion, the c-myc epitope for detection of the

15 recombinant protein with the anti-myc antibody, a C-terminal polyhistidine for purification with nickel chelate chromatography, and a Zeocin resistant gene for selection of stable transfectants. The forward primer for amplification of this GPCR cDNA is determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce the *HindIII* cloning site and nucleotides matching the GPCR sequence. The

20 reverse primer is also determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce an *XhoI* restriction site for cloning and nucleotides corresponding to the reverse complement of the nGPCR-x sequence. The PCR conditions are 55 °C as the annealing temperature. The PCR product is gel purified and cloned into the *HindIII-XhoI* sites of the vector.

25 The DNA is purified using Qiagen chromatography columns and transfected into 293 cells using DOTAP™ transfection media (Boehringer Mannheim, Indianapolis, IN). Transiently transfected cells are tested for expression after 24 hours of transfection, using western blots probed with anti-His and anti-nGPCR-x peptide antibodies. Permanently transfected cells are selected with Zeocin and propagated. Production of the recombinant

protein is detected from both cells and media by western blots probed with anti-His, anti-Myc or anti-GPCR peptide antibodies.

C. Expression of nGPCR-x in COS cells

For expression of the nGPCR-x in COS7 cells, a polynucleotide molecule having

5 a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45 can be cloned into vector p3-Cl. This vector is a pUC18-derived plasmid that contains the HCMV (human cytomegalovirus) promoter-intron located upstream from the bGH (bovine growth hormone) polyadenylation sequence and a multiple cloning site. In addition, the plasmid contains

10 the dhfr (dihydrofolate reductase) gene which provides selection in the presence of the drug methotrexane (MTX) for selection of stable transformants.

The forward primer is determined by routine procedures and preferably contains a 5' extension which introduces an *Xba*I restriction site for cloning, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:1 to

15 SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45. The reverse primer is also determined by routine procedures and preferably contains 5'- extension of nucleotides which introduces a *Sal*I cloning site followed by nucleotides which correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45.

20 The PCR consists of an initial denaturation step of 5 min at 95 °C 30 cycles of 30 sec denaturation at 95 °C, 30 sec annealing at 58 °C and 30 sec extension at 72 °C, followed by 5 min extension at 72 °C. The PCR product is gel purified and ligated into the *Xba*I and *Sal*I sites of vector p3-Cl. This construct is transformed into *E. coli* cells for amplification and DNA purification. The DNA is purified with Qiagen chromatography

25 columns and transfected into COS 7 cells using Lipofectamine™ reagent from BRL, following the manufacturer's protocols. Forty-eight and 72 hours after transfection, the media and the cells are tested for recombinant protein expression.

nGPCR-x expressed from a COS cell culture can be purified by concentrating the cell-growth media to about 10 mg of protein/ml, and purifying the protein by, for

example, chromatography. Purified nGPCR-x is concentrated to 0.5 mg/ml in an Amicon concentrator fitted with a YM-10 membrane and stored at -80°C.

D. Expression of nGPCR-x in Insect Cells

For expression of nGPCR-x in a baculovirus system, a polynucleotide molecule

5 having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45 can be amplified by PCR. The forward primer is determined by routine procedures and preferably contains a 5' extension which adds the *NdeI* cloning site, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ 10 ID NO:41, SEQ ID NO:43, and SEQ ID NO:45. The reverse primer is also determined by routine procedures and preferably contains a 5' extension which introduces the *KpnI* cloning site, followed by nucleotides which correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45.

15 The PCR product is gel purified, digested with *NdeI* and *KpnI*, and cloned into the corresponding sites of vector pACHTL-A (Pharmingen, San Diego, CA). The pAcHTL expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV), and a 6XHis tag upstream from the multiple cloning site. A protein kinase site for phosphorylation and a thrombin site for excision of 20 the recombinant protein precede the multiple cloning site is also present. Of course, many other baculovirus vectors could be used in place of pAcHTL-A, such as pAc373, pVL941 and pAcIM1. Other suitable vectors for the expression of GPCR polypeptides can be used, provided that the vector construct includes appropriately located signals for transcription, translation, and trafficking, such as an in-frame AUG and a signal peptide, 25 as required. Such vectors are described in Luckow *et al.*, Virology 170:31-39, among others.

The virus is grown and isolated using standard baculovirus expression methods, such as those described in Summers *et al.* (A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 30 1555 (1987)).

In a preferred embodiment, pAcHLT-A containing nGPCR-x gene is introduced into baculovirus using the "BaculoGold™" transfection kit (Pharmingen, San Diego, CA) using methods established by the manufacturer. Individual virus isolates are analyzed for protein production by radiolabeling infected cells with  $^{35}\text{S}$ -methionine at 24 hours post 5 infection. Infected cells are harvested at 48 hours post infection, and the labeled proteins are visualized by SDS-PAGE. Viruses exhibiting high expression levels can be isolated and used for scaled up expression.

For expression of a nGPCR-x polypeptide in a Sf9 cells, a polynucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ 10 ID NO:13, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45 can be amplified by PCR using the primers and methods described above for baculovirus expression. The nGPCR-x cDNA is cloned into vector pAcHLT-A (Pharmingen) for expression in Sf9 insect. The insert is cloned into the *NdeI* and *KpnI* sites, after elimination of an internal *NdeI* site (using the same primers described above for expression in baculovirus). DNA is purified 15 with Qiagen chromatography columns and expressed in Sf9 cells. Preliminary Western blot experiments from non-purified plaques are tested for the presence of the recombinant protein of the expected size which reacted with the GPCR-specific antibody. These results are confirmed after further purification and expression optimization in HiG5 cells.

20 **EXAMPLE 8: INTERACTION TRAP/TWO-HYBRID SYSTEM**

In order to assay for nGPCR-x-interacting proteins, the interaction trap/two-hybrid library screening method can be used. This assay was first described in Fields *et 25 al.*, *Nature*, 1989, 340, 245, which is incorporated herein by reference in its entirety. A protocol is published in Current Protocols in Molecular Biology 1999, John Wiley & Sons, NY, and Ausubel, F. M. *et al.* 1992, Short protocols in molecular biology, Fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety. Kits are available from Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3).

30 A fusion of the nucleotide sequences encoding all or partial nGPCR-x and the yeast transcription factor GAL4 DNA-binding domain (DNA-BD) is constructed in an

appropriate plasmid (*i.e.*, pGBKT7) using standard subcloning techniques. Similarly, a GAL4 active domain (AD) fusion library is constructed in a second plasmid (*i.e.*, pGADT7) from cDNA of potential GPCR-binding proteins (for protocols on forming cDNA libraries, see Sambrook *et al.* 1989, Molecular cloning: a laboratory manual, 5 second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY), which is incorporated herein by reference in its entirety. The DNA-BD/nGPCR-x fusion construct is verified by sequencing, and tested for autonomous reporter gene activation and cell toxicity, both of which would prevent a successful two-hybrid analysis. Similar controls are performed with the AD/library fusion construct to ensure expression in host cells and 10 lack of transcriptional activity. Yeast cells are transformed (*ca.* 105 transformants/mg DNA) with both the nGPCR-x and library fusion plasmids according to standard procedures (Ausubel *et al.*, 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, which is incorporated herein by reference in its entirety). *In vivo* binding of DNA-BD/nGPCR-x with AD/library proteins results in 15 transcription of specific yeast plasmid reporter genes (*i.e.*, lacZ, HIS3, ADE2, LEU2). Yeast cells are plated on nutrient-deficient media to screen for expression of reporter genes. Colonies are dually assayed for  $\beta$ -galactosidase activity upon growth in Xgal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside) supplemented media (filter assay for  $\beta$ -galactosidase activity is described in Breeden *et al.*, Cold Spring Harb. Symp. Quant. 20 Biol., 1985, 50, 643, which is incorporated herein by reference in its entirety). Positive AD-library plasmids are rescued from transformants and reintroduced into the original yeast strain as well as other strains containing unrelated DNA-BD fusion proteins to 25 confirm specific nGPCR-x/library protein interactions. Insert DNA is sequenced to verify the presence of an open reading frame fused to GAL4 AD and to determine the identity of the nGPCR-x-binding protein.

**EXAMPLE 9: MOBILITY SHIFT DNA-BINDING ASSAY USING GEL ELECTROPHORESIS**

A gel electrophoresis mobility shift assay can rapidly detect specific protein-DNA 30 interactions. Protocols are widely available in such manuals as Sambrook *et al.* 1989,

*Molecular cloning: a laboratory manual*, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY and Ausubel, F. M. *et al.*, 1992, *Short Protocols in Molecular Biology*, fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety.

5        Probe DNA(<300 bp) is obtained from synthetic oligonucleotides, restriction endonuclease fragments, or PCR fragments and end-labeled with  $^{32}\text{P}$ . An aliquot of purified nGPCR-x (*ca.* 15  $\mu\text{g}$ ) or crude nGPCR-x extract (*ca.* 15 ng) is incubated at constant temperature (in the range 22-37 C) for at least 30 minutes in 10-15  $\mu\text{l}$  of buffer (*i.e.* TAE or TBE, pH 8.0-8.5) containing radiolabeled probe DNA, nonspecific carrier

10      DNA (*ca.* 1  $\mu\text{g}$ ), BSA (300  $\mu\text{g}/\text{ml}$ ), and 10% (v/v) glycerol. The reaction mixture is then loaded onto a polyacrylamide gel and run at 30-35 mA until good separation of free probe DNA from protein-DNA complexes occurs. The gel is then dried and bands corresponding to free DNA and protein-DNA complexes are detected by autoradiography.

15

#### EXAMPLE 10: ANTIBODIES TO nGPCR-X

Standard techniques are employed to generate polyclonal or monoclonal antibodies to the nGPCR-x receptor, and to generate useful antigen-binding fragments thereof or variants thereof, including "humanized" variants. Such protocols can be found, 20 for example, in Sambrook *et al.* (1989) and Harlow *et al.* (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988). In one embodiment, recombinant nGPCR-x polypeptides (or cells or cell membranes containing such polypeptides) are used as antigen to generate the antibodies. In another embodiment, one or more peptides having amino acid sequences corresponding to an 25 immunogenic portion of nGPCR-x (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids) are used as antigen. Peptides corresponding to extracellular portions of nGPCR-x, especially hydrophilic extracellular portions, are preferred. The antigen may be mixed with an adjuvant or linked to a hapten to increase antibody production.

30

##### A. Polyclonal or Monoclonal antibodies

As one exemplary protocol, recombinant nGPCR-x or a synthetic fragment thereof is used to immunize a mouse for generation of monoclonal antibodies (or larger mammal, such as a rabbit, for polyclonal antibodies). To increase antigenicity, peptides are conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's 5 recommendations. For an initial injection, the antigen is emulsified with Freund's Complete Adjuvant and injected subcutaneously. At intervals of two to three weeks, additional aliquots of nGPCR-x antigen are emulsified with Freund's Incomplete Adjuvant and injected subcutaneously. Prior to the final booster injection, a serum sample is taken from the immunized mice and assayed by western blot to confirm the 10 presence of antibodies that immunoreact with nGPCR-x. Serum from the immunized animals may be used as polyclonal antisera or used to isolate polyclonal antibodies that recognize nGPCR-x. Alternatively, the mice are sacrificed and their spleen removed for generation of monoclonal antibodies.

To generate monoclonal antibodies, the spleens are placed in 10 ml serum-free 15 RPMI 1640, and single cell suspensions are formed by grinding the spleens in serum-free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml streptomycin (RPMI) (Gibco, Canada). The cell suspensions are filtered and washed by centrifugation and resuspended in serum-free 20 RPMI. Thymocytes taken from three naive Balb/c mice are prepared in a similar manner and used as a Feeder Layer. NS-1 myeloma cells, kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, are centrifuged and washed as well.

To produce hybridoma fusions, spleen cells from the immunized mice are combined with NS-1 cells and centrifuged, and the supernatant is aspirated. The cell 25 pellet is dislodged by tapping the tube, and 2 ml of 37°C PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer-Mannheim) is stirred into the pellet, followed by the addition of serum-free RPMI. Thereafter, the cells are centrifuged, resuspended in RPMI containing 15% FBS, 100 µM sodium hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and  $1.5 \times 10^6$

thymocytes/ml, and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York).

On days 2, 4, and 6 after the fusion, 100  $\mu$ l of medium is removed from the wells of the fusion plates and replaced with fresh medium. On day 8, the fusions are screened 5 by ELISA, testing for the presence of mouse IgG that binds to nGPCR-x. Selected fusion wells are further cloned by dilution until monoclonal cultures producing anti-nGPCR-x antibodies are obtained.

B. Humanization of anti-nGPCR-x monoclonal antibodies

The expression pattern of nGPCR-x as reported herein and the proven track record 10 of GPCRs as targets for therapeutic intervention suggest therapeutic indications for nGPCR-x inhibitors (antagonists). nGPCR-x-neutralizing antibodies comprise one class of therapeutics useful as nGPCR-x antagonists. Following are protocols to improve the utility of anti-nGPCR-x monoclonal antibodies as therapeutics in humans by "humanizing" the monoclonal antibodies to improve their serum half-life and render them 15 less immunogenic in human hosts (*i.e.*, to prevent human antibody response to non-human anti-nGPCR-x antibodies).

The principles of humanization have been described in the literature and are facilitated by the modular arrangement of antibody proteins. To minimize the possibility of binding complement, a humanized antibody of the IgG4 isotype is preferred.

20 For example, a level of humanization is achieved by generating chimeric antibodies comprising the variable domains of non-human antibody proteins of interest with the constant domains of human antibody molecules. (See, *e.g.*, Morrison *et al.*, *Adv. Immunol.*, 44:65-92 (1989)). The variable domains of nGPCR-x-neutralizing anti-nGPCR-x antibodies are cloned from the genomic DNA of a B-cell hybridoma or 25 from cDNA generated from mRNA isolated from the hybridoma of interest. The V region gene fragments are linked to exons encoding human antibody constant domains, and the resultant construct is expressed in suitable mammalian host cells (*e.g.*, myeloma or CHO cells).

To achieve an even greater level of humanization, only those portions of the 30 variable region gene fragments that encode antigen-binding complementarity determining

regions ("CDR") of the non-human monoclonal antibody genes are cloned into human antibody sequences. (See, e.g., Jones *et al.*, *Nature* 321:522-525 (1986); Riechmann *et al.*, *Nature* 332:323-327 (1988); Verhoeyen *et al.*, *Science* 239:1534-36 (1988); and Tempest *et al.*, *Bio/Technology* 9: 266-71 (1991)). If necessary, the  $\beta$ -sheet framework 5 of the human antibody surrounding the CDR3 regions also is modified to more closely mirror the three dimensional structure of the antigen-binding domain of the original monoclonal antibody. (See Kettleborough *et al.*, *Protein Engin.*, 4:773-783 (1991); and Foote *et al.*, *J. Mol. Biol.*, 224:487-499 (1992)).

In an alternative approach, the surface of a non-human monoclonal antibody of 10 interest is humanized by altering selected surface residues of the non-human antibody, e.g., by site-directed mutagenesis, while retaining all of the interior and contacting residues of the non-human antibody. See Padlan, *Molecular Immunol.*, 28(4/5):489-98 (1991).

The foregoing approaches are employed using nGPCR-x-neutralizing 15 anti-nGPCR-x monoclonal antibodies and the hybridomas that produce them to generate humanized nGPCR-x-neutralizing antibodies useful as therapeutics to treat or palliate conditions wherein nGPCR-x expression or ligand-mediated nGPCR-x signaling is detrimental.

C. Human nGPCR-x-Neutralizing Antibodies from Phage Display

20 Human nGPCR-x-neutralizing antibodies are generated by phage display techniques such as those described in Aujame *et al.*, *Human Antibodies* 8(4):155-168 (1997); Hoogenboom, *TIBTECH* 15:62-70 (1997); and Rader *et al.*, *Curr. Opin. Biotechnol.* 8:503-508 (1997), all of which are incorporated by reference. For example, antibody variable regions in the form of Fab fragments or linked single chain Fv 25 fragments are fused to the amino terminus of filamentous phage minor coat protein pIII. Expression of the fusion protein and incorporation thereof into the mature phage coat results in phage particles that present an antibody on their surface and contain the genetic material encoding the antibody. A phage library comprising such constructs is expressed in bacteria, and the library is screened for nGPCR-x-specific phage-antibodies using 30 labeled or immobilized nGPCR-x as antigen-probe.

D. Human nGPCR-x-neutralizing antibodies from transgenic mice

Human nGPCR-x-neutralizing antibodies are generated in transgenic mice essentially as described in Bruggemann *et al.*, *Immunol. Today* 17(8):391-97 (1996) and Bruggemann *et al.*, *Curr. Opin. Biotechnol.* 8:455-58 (1997). Transgenic mice carrying 5 human V-gene segments in germline configuration and that express these transgenes in their lymphoid tissue are immunized with a nGPCR-x composition using conventional immunization protocols. Hybridomas are generated using B cells from the immunized mice using conventional protocols and screened to identify hybridomas secreting anti-nGPCR-x human antibodies (e.g., as described above).

10

**EXAMPLE 11: ASSAYS TO IDENTIFY MODULATORS OF nGPCR-X ACTIVITY**

Set forth below are several nonlimiting assays for identifying modulators (agonists and antagonists) of nGPCR-x activity. Among the modulators that can be 15 identified by these assays are natural ligand compounds of the receptor; synthetic analogs and derivatives of natural ligands; antibodies, antibody fragments, and/or antibody-like compounds derived from natural antibodies or from antibody-like combinatorial libraries; and/or synthetic compounds identified by high-throughput screening of libraries; and the like. All modulators that bind nGPCR-x are useful for identifying nGPCR-x in tissue 20 samples (e.g., for diagnostic purposes, pathological purposes, and the like). Agonist and antagonist modulators are useful for up-regulating and down-regulating nGPCR-x activity, respectively, to treat disease states characterized by abnormal levels of nGPCR-x activity. The assays may be performed using single putative modulators, and/or may be 25 performed using a known agonist in combination with candidate antagonists (or visa versa).

A. cAMP Assays

In one type of assay, levels of cyclic adenosine monophosphate (cAMP) are measured in nGPCR-x-transfected cells that have been exposed to candidate modulator compounds. Protocols for cAMP assays have been described in the literature. (See, e.g., 30 Sutherland *et al.*, *Circulation* 37: 279 (1968); Frandsen *et al.*, *Life Sciences* 18: 529-541

(1976); Dooley *et al.*, Journal of Pharmacology and Experimental Therapeutics 283 (2): 735-41 (1997); and George *et al.*, Journal of Biomolecular Screening 2 (4): 235-40 (1997)). An exemplary protocol for such an assay, using an Adenylyl Cyclase Activation FlashPlate® Assay from NEN® Life Science Products, is set forth below.

5 Briefly, the nGPCR-x coding sequence (e.g., a cDNA or intronless genomic DNA) is subcloned into a commercial expression vector, such as pzeoSV2 (Invitrogen), and transiently transfected into Chinese Hamster Ovary (CHO) cells using known methods, such as the transfection protocol provided by Boehringer-Mannheim when supplying the FuGENE 6 transfection reagent. Transfected CHO cells are seeded into 96-  
10 well microplates from the FlashPlate® assay kit, which are coated with solid scintillant to which antisera to cAMP has been bound. For a control, some wells are seeded with wild type (untransfected) CHO cells. Other wells in the plate receive various amounts of a cAMP standard solution for use in creating a standard curve.

One or more test compounds (i.e., candidate modulators) are added to the cells in  
15 each well, with water and/or compound-free medium/diluent serving as a control or controls. After treatment, cAMP is allowed to accumulate in the cells for exactly 15 minutes at room temperature. The assay is terminated by the addition of lysis buffer containing [<sup>125</sup>I]-labeled cAMP, and the plate is counted using a Packard Topcount® 96-well microplate scintillation counter. Unlabeled cAMP from the lysed cells (or from  
20 standards) and fixed amounts of [<sup>125</sup>I]-cAMP compete for antibody bound to the plate. A standard curve is constructed, and cAMP values for the unknowns are obtained by interpolation. Changes in intracellular cAMP levels of cells in response to exposure to a test compound are indicative of nGPCR-x modulating activity. Modulators that act as agonists of receptors which couple to the G<sub>s</sub> subtype of G proteins will stimulate  
25 production of cAMP, leading to a measurable 3-10 fold increase in cAMP levels. Agonists of receptors which couple to the G<sub>10</sub> subtype of G proteins will inhibit forskolin-stimulated cAMP production, leading to a measurable decrease in cAMP levels of 50-100%. Modulators that act as inverse agonists will reverse these effects at receptors that are either constitutively active or activated by known agonists.

30           B.       Aequorin Assays

In another assay, cells (e.g., CHO cells) are transiently co-transfected with both a nGPCR-x expression construct and a construct that encodes the photoprotein apoaequorin. In the presence of the cofactor coelenterazine, apoaequorin will emit a measurable luminescence that is proportional to the amount of intracellular (cytoplasmic) free

5 calcium. (See generally, Cobbold, *et al.* "Aequorin measurements of cytoplasmic free calcium," *In: McCormack J.G. and Cobbold P.H., eds., Cellular Calcium: A Practical Approach*. Oxford:IRL Press (1991); Stables *et al.*, *Analytical Biochemistry* 252: 115-26 (1997); and Haugland, *Handbook of Fluorescent Probes and Research Chemicals*. Sixth edition. Eugene OR: Molecular Probes (1996).)

10 In one exemplary assay, nGPCR-x is subcloned into the commercial expression vector pzeoSV2 (Invitrogen) and transiently co-transfected along with a construct that encodes the photoprotein apoaequorin (Molecular Probes, Eugene, OR) into CHO cells using the transfection reagent FuGENE 6 (Boehringer-Mannheim) and the transfection protocol provided in the product insert.

15 The cells are cultured for 24 hours at 37°C in MEM (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 µg/ml streptomycin, at which time the medium is changed to serum-free MEM containing 5 µM coelenterazine (Molecular Probes, Eugene, OR). Culturing is then continued for two additional hours at 37°C. Subsequently, cells are detached from the

20 plate using VERSEN (Gibco/BRL), washed, and resuspended at 200,000 cells/ml in serum-free MEM.

Dilutions of candidate nGPCR-x modulator compounds are prepared in serum-free MEM and dispensed into wells of an opaque 96-well assay plate at 50 µl/well. Plates are then loaded onto an MLX microtiter plate luminometer (Dynex Technologies, Inc.,

25 Chantilly, VA). The instrument is programmed to dispense 50 µl cell suspensions into each well, one well at a time, and immediately read luminescence for 15 seconds. Dose-response curves for the candidate modulators are constructed using the area under the curve for each light signal peak. Data are analyzed with SlideWrite, using the equation for a one-site ligand, and EC<sub>50</sub> values are obtained. Changes in luminescence caused by

30 the compounds are considered indicative of modulatory activity. Modulators that act as

agonists at receptors which couple to the G<sub>q</sub> subtype of G proteins give an increase in luminescence of up to 100 fold. Modulators that act as inverse agonists will reverse this effect at receptors that are either constitutively active or activated by known agonists.

C. Luciferase Reporter Gene Assay

5 The photoprotein luciferase provides another useful tool for assaying for modulators of nGPCR-x activity. Cells (e.g., CHO cells or COS 7 cells) are transiently co-transfected with both a nGPCR-x expression construct (e.g., nGPCR-x in pzeoSV2) and a reporter construct which includes a gene for the luciferase protein downstream from a transcription factor binding site, such as the cAMP-response element (CRE), AP-1, or

10 10 NF-kappa B. Agonist binding to receptors coupled to the G<sub>s</sub> subtype of G proteins leads to increases in cAMP, thereby activating the CRE transcription factor and resulting in expression of the luciferase gene. Agonist binding to receptors coupled to the G<sub>q</sub> subtype of G protein leads to production of diacylglycerol that activates protein kinase C, which activates the AP-1 or NF-kappa B transcription factors, in turn resulting in expression of

15 15 the luciferase gene. Expression levels of luciferase reflect the activation status of the signaling events. (See generally, George *et al.*, Journal of Biomolecular Screening 2(4): 235-240 (1997); and Stratowa *et al.*, Current Opinion in Biotechnology 6: 574-581 (1995)). Luciferase activity may be quantitatively measured using, e.g., luciferase assay reagents that are commercially available from Promega (Madison, WI).

20 In one exemplary assay, CHO cells are plated in 24-well culture dishes at a density of 100,000 cells/well one day prior to transfection and cultured at 37°C in MEM (Gibco/BRL) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 µg/ml streptomycin. Cells are transiently co-transfected with both a nGPCR-x expression construct and a reporter construct containing the luciferase gene.

25 25 The reporter plasmids CRE-luciferase, AP-1-luciferase and NF-kappaB-luciferase may be purchased from Stratagene (LaJolla, CA). Transfections are performed using the FuGENE 6 transfection reagent (Boehringer-Mannheim) according to the supplier's instructions. Cells transfected with the reporter construct alone are used as a control. Twenty-four hours after transfection, cells are washed once with PBS pre-warmed to

30 30 37°C. Serum-free MEM is then added to the cells either alone (control) or with one or

more candidate modulators and the cells are incubated at 37°C for five hours. Thereafter, cells are washed once with ice-cold PBS and lysed by the addition of 100 µl of lysis buffer per well from the luciferase assay kit supplied by Promega. After incubation for 15 minutes at room temperature, 15 µl of the lysate is mixed with 50 µl of substrate solution (Promega) in an opaque-white, 96-well plate, and the luminescence is read immediately on a Wallace model 1450 MicroBeta scintillation and luminescence counter (Wallace Instruments, Gaithersburg, MD).

Differences in luminescence in the presence versus the absence of a candidate modulator compound are indicative of modulatory activity. Receptors that are either 10 constitutively active or activated by agonists typically give a 3 to 20-fold stimulation of luminescence compared to cells transfected with the reporter gene alone. Modulators that act as inverse agonists will reverse this effect.

D. Intracellular calcium measurement using FLIPR

Changes in intracellular calcium levels are another recognized indicator of G 15 protein-coupled receptor activity, and such assays can be employed to screen for modulators of nGPCR-x activity. For example, CHO cells stably transfected with a nGPCR-x expression vector are plated at a density of  $4 \times 10^4$  cells/well in Packard black-walled, 96-well plates specially designed to discriminate fluorescence signals emanating from the various wells on the plate. The cells are incubated for 60 minutes at 37°C in 20 modified Dulbecco's PBS (D-PBS) containing 36 mg/L pyruvate and 1 g/L glucose with the addition of 1% fetal bovine serum and one of four calcium indicator dyes (Fluo-3Ô AM, Fluo-4Ô AM, Calcium GreenÔ-1 AM, or Oregon GreenÔ 488 BAPTA-1 AM), each at a concentration of 4 µM. Plates are washed once with modified D-PBS without 1% fetal bovine serum and incubated for 10 minutes at 37°C to remove residual dye from the 25 cellular membrane. In addition, a series of washes with modified D-PBS without 1% fetal bovine serum is performed immediately prior to activation of the calcium response.

A calcium response is initiated by the addition of one or more candidate receptor agonist compounds, calcium ionophore A23187 (10 µM; positive control), or ATP (4 µM; positive control). Fluorescence is measured by Molecular Device's FLIPR with an 30 argon laser (excitation at 488 nm). (See, e.g., Kuntzweiler *et al.*, Drug Development

Research, 44(1):14-20 (1998)). The F-stop for the detector camera was set at 2.5 and the length of exposure was 0.4 milliseconds. Basal fluorescence of cells was measured for 20 seconds prior to addition of candidate agonist, ATP, or A23187, and the basal fluorescence level was subtracted from the response signal. The calcium signal is 5 measured for approximately 200 seconds, taking readings every two seconds. Calcium ionophore A23187 and ATP increase the calcium signal 200% above baseline levels. In general, activated GPCRs increase the calcium signal approximately 10-15% above baseline signal.

E. Mitogenesis Assay

10 In a mitogenesis assay, the ability of candidate modulators to induce or inhibit nGPCR-x-mediated cell division is determined. (See, e.g., Lajiness *et al.*, Journal of Pharmacology and Experimental Therapeutics 267(3): 1573-1581 (1993)). For example, CHO cells stably expressing nGPCR-x are seeded into 96-well plates at a density of 5000 cells/well and grown at 37°C in MEM with 10% fetal calf serum for 48 hours, at which 15 time the cells are rinsed twice with serum-free MEM. After rinsing, 80 µl of fresh MEM, or MEM containing a known mitogen, is added along with 20 µl MEM containing varying concentrations of one or more candidate modulators or test compounds diluted in serum-free medium. As controls, some wells on each plate receive serum-free medium alone, and some receive medium containing 10% fetal bovine serum. Untransfected cells 20 or cells transfected with vector alone also may serve as controls.

After culture for 16-18 hours, 1 µCi of [<sup>3</sup>H]-thymidine (2 Ci/mmol) is added to the wells and cells are incubated for an additional 2 hours at 37°C. The cells are trypsinized and collected on filter mats with a cell harvester (Tomtec); the filters are then counted in a Betaplate counter. The incorporation of [<sup>3</sup>H]-thymidine in serum-free test 25 wells is compared to the results achieved in cells stimulated with serum (positive control). Use of multiple concentrations of test compounds permits creation and analysis of dose-response curves using the non-linear, least squares fit equation:  $A = B \times [C / (D + C)] + G$  where A is the percent of serum stimulation; B is the maximal effect minus baseline; C is the EC<sub>50</sub>; D is the concentration of the compound; and G is the maximal 30 effect. Parameters B, C and G are determined by Simplex optimization.

Agonists that bind to the receptor are expected to increase [<sup>3</sup>H]-thymidine incorporation into cells, showing up to 80% of the response to serum. Antagonists that bind to the receptor will inhibit the stimulation seen with a known agonist by up to 100%.

5 F. [<sup>35</sup>S]GTP $\gamma$ S Binding Assay

Because G protein-coupled receptors signal through intracellular G proteins whose activity involves GTP binding and hydrolysis to yield bound GDP, measurement of binding of the non-hydrolyzable GTP analog [<sup>35</sup>S]GTP $\gamma$ S in the presence and absence of candidate modulators provides another assay for modulator activity. (See, e.g., Kowal *et al.*, *Neuropharmacology* 37:179-187 (1998).)

10 In one exemplary assay, cells stably transfected with a nGPCR-x expression vector are grown in 10 cm tissue culture dishes to subconfluence, rinsed once with 5 ml of ice-cold Ca<sup>2+</sup>/Mg<sup>2+</sup>-free phosphate-buffered saline, and scraped into 5 ml of the same buffer. Cells are pelleted by centrifugation (500 x g, 5 minutes), resuspended in TEE buffer (25 mM Tris, pH 7.5, 5 mM EDTA, 5 mM EGTA), and frozen in liquid nitrogen.

15 After thawing, the cells are homogenized using a Dounce homogenizer (one ml TEE per plate of cells), and centrifuged at 1,000 x g for 5 minutes to remove nuclei and unbroken cells.

The homogenate supernatant is centrifuged at 20,000 x g for 20 minutes to isolate the membrane fraction, and the membrane pellet is washed once with TEE and 20 resuspended in binding buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 1 mM EDTA). The resuspended membranes can be frozen in liquid nitrogen and stored at -70°C until use.

25 Aliquots of cell membranes prepared as described above and stored at -70°C are thawed, homogenized, and diluted into buffer containing 20 mM HEPES, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 120 mM NaCl, 10  $\mu$ M GDP, and 0.2 mM ascorbate, at a concentration of 10-50  $\mu$ g/ml. In a final volume of 90  $\mu$ l, homogenates are incubated with varying concentrations of candidate modulator compounds or 100  $\mu$ M GTP for 30 minutes at 30°C and then placed on ice. To each sample, 10  $\mu$ l guanosine 5'-O-(3[<sup>35</sup>S]thio) triphosphate (NEN, 1200 Ci/mmol; [<sup>35</sup>S]-GTP $\gamma$ S), was added to a final concentration of

100-200 pM. Samples are incubated at 30°C for an additional 30 minutes, 1 ml of 10mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, at 4°C is added and the reaction is stopped by filtration.

Samples are filtered over Whatman GF/B filters and the filters are washed with 20 ml ice-cold 10 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>. Filters are counted by liquid 5 scintillation spectroscopy. Nonspecific binding of [<sup>35</sup>S]-GTPγS is measured in the presence of 100 μM GTP and subtracted from the total. Compounds are selected that modulate the amount of [<sup>35</sup>S]-GTPγS binding in the cells, compared to untransfected control cells. Activation of receptors by agonists gives up to a five-fold increase in [<sup>35</sup>S]GTPγS binding. This response is blocked by antagonists.

10 G. MAP Kinase Activity Assay

Evaluation of MAP kinase activity in cells expressing a GPCR provides another assay to identify modulators of GPCR activity. (See, e.g., Lajiness *et al.*, Journal of Pharmacology and Experimental Therapeutics 267(3):1573-1581 (1993) and Boulton *et al.*, Cell 65:663-675 (1991).)

15 In one embodiment, CHO cells stably transfected with nGPCR-x are seeded into 6-well plates at a density of 70,000 cells/well 48 hours prior to the assay. During this 48-hour period, the cells are cultured at 37°C in MEM medium supplemented with 10% fetal bovine serum, 2mM glutamine, 10 U/ml penicillin and 10μg/ml streptomycin. The cells are serum-starved for 1-2 hours prior to the addition of stimulants.

20 For the assay, the cells are treated with medium alone or medium containing either a candidate agonist or 200 nM Phorbol ester- myristoyl acetate (*i.e.*, PMA, a positive control), and the cells are incubated at 37°C for varying times. To stop the reaction, the plates are placed on ice, the medium is aspirated, and the cells are rinsed with 1 ml of ice-cold PBS containing 1mM EDTA. Thereafter, 200μl of cell lysis buffer 25 (12.5 mM MOPS, pH 7.3, 12.5 mM glycerophosphate, 7.5mM MgCl<sub>2</sub>, 0.5mM EGTA, 0.5 mM sodium vanadate, 1mM benzamidine, 1mM dithiothreitol, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 2μg/ml pepstatin A, and 1μM okadaic acid) is added to the cells. The cells are scraped from the plates and homogenized by 10 passages through a 23 3/4 G needle, and the cytosol fraction is prepared by centrifugation at 20,000 x g for 15 30 minutes.

Aliquots (5-10  $\mu$ l containing 1-5  $\mu$ g protein) of cytosol are mixed with 1 mM MAPK Substrate Peptide (APRTPGGRR (SEQ ID NO: 28), Upstate Biotechnology, Inc., N.Y.) and 50 $\mu$ M [ $\gamma$ -<sup>32</sup>P]ATP (NEN, 3000 Ci/mmol), diluted to a final specific activity of ~2000 cpm/pmol, in a total volume of 25  $\mu$ l. The samples are incubated for 5 minutes at 5 30°C, and reactions are stopped by spotting 20  $\mu$ l on 2 cm<sup>2</sup> squares of Whatman P81 phosphocellulose paper. The filter squares are washed in 4 changes of 1% H<sub>3</sub>PO<sub>4</sub>, and the squares are subjected to liquid scintillation spectroscopy to quantitate bound label. Equivalent cytosolic extracts are incubated without MAPK substrate peptide, and the bound label from these samples are subtracted from the matched samples with the 10 substrate peptide. The cytosolic extract from each well is used as a separate point. Protein concentrations are determined by a dye binding protein assay (Bio-Rad Laboratories). Agonist activation of the receptor is expected to result in up to a five-fold increase in MAPK enzyme activity. This increase is blocked by antagonists.

#### H. [<sup>3</sup>H]Arachidonic Acid Release

15 The activation of GPCRs also has been observed to potentiate arachidonic acid release in cells, providing yet another useful assay for modulators of GPCR activity. (See, e.g., Kanterman *et al.*, Molecular Pharmacology 39:364-369 (1991).) For example, CHO cells that are stably transfected with a nGPCR-x expression vector are plated in 24-well plates at a density of 15,000 cells/well and grown in MEM medium supplemented 20 with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10  $\mu$ g/ml streptomycin for 48 hours at 37°C before use. Cells of each well are labeled by incubation with [<sup>3</sup>H]-arachidonic acid (Amersham Corp., 210 Ci/mmol) at 0.5  $\mu$ Ci/ml in 1 ml MEM supplemented with 10mM HEPES, pH 7.5, and 0.5% fatty-acid-free bovine serum albumin for 2 hours at 37°C. The cells are then washed twice with 1 ml of the 25 same buffer.

Candidate modulator compounds are added in 1 ml of the same buffer, either alone or with 10 $\mu$ M ATP and the cells are incubated at 37°C for 30 minutes. Buffer alone and mock-transfected cells are used as controls. Samples (0.5 ml) from each well are counted by liquid scintillation spectroscopy. Agonists which activate the receptor

will lead to potentiation of the ATP-stimulated release of [<sup>3</sup>H]-arachidonic acid. This potentiation is blocked by antagonists.

I. Extracellular Acidification Rate

In yet another assay, the effects of candidate modulators of nGPCR-x activity are assayed by monitoring extracellular changes in pH induced by the test compounds. (See, e.g., Dunlop *et al.*, Journal of Pharmacological and Toxicological Methods 40(1):47-55 (1998).) In one embodiment, CHO cells transfected with a nGPCR-x expression vector are seeded into 12 mm capsule cups (Molecular Devices Corp.) at  $4 \times 10^5$  cells/cup in MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 U/ml penicillin, and 10  $\mu$ g/ml streptomycin. The cells are incubated in this medium at 37°C in 5% CO<sub>2</sub> for 24 hours.

Extracellular acidification rates are measured using a Cytosensor microphysiometer (Molecular Devices Corp.). The capsule cups are loaded into the sensor chambers of the microphysiometer and the chambers are perfused with running buffer (bicarbonate-free MEM supplemented with 4 mM L-glutamine, 10 units/ml penicillin, 10  $\mu$ g/ml streptomycin, 26 mM NaCl) at a flow rate of 100  $\mu$ l/minute. Candidate agonists or other agents are diluted into the running buffer and perfused through a second fluid path. During each 60-second pump cycle, the pump is run for 38 seconds and is off for the remaining 22 seconds. The pH of the running buffer in the sensor chamber is recorded during the cycle from 43-58 seconds, and the pump is restarted at 60 seconds to start the next cycle. The rate of acidification of the running buffer during the recording time is calculated by the Cytosoft program. Changes in the rate of acidification are calculated by subtracting the baseline value (the average of 4 rate measurements immediately before addition of a modulator candidate) from the highest rate measurement obtained after addition of a modulator candidate. The selected instrument detects 61 mV/pH unit. Modulators that act as agonists of the receptor result in an increase in the rate of extracellular acidification compared to the rate in the absence of agonist. This response is blocked by modulators which act as antagonists of the receptor.

30

**Example 12 - Using nGPCR-x proteins to isolate neurotransmitters**

The isolated nGPCR-x proteins, particularly nGPCR-1002, and nGPCR-1007, (SEQ ID NOS: SEQ ID NO: 46, and SEQ ID NO:25, respectively) can be used to isolate novel or known neurotransmitters (Saito *et al.*, *Nature* 400: 265-269, 1999). The cDNAs that encode the isolated nGPCR-x can be cloned into mammalian expression vectors and used to stably or transiently transfet mammalian cells including CHO, Cos or HEK293 cells. Receptor expression can be determined by Northern blot analysis of transfected cells and identification of an appropriately sized mRNA band (predicted size from the cDNA). Brain regions shown by mRNA analysis to express each of the nGPCR-x proteins could be processed for peptide extraction using any of several protocols (Reinscheidk R.K. *et al.*, *Science* 270: 243-247, 1996; Sakurai, T., *et al.*, *Cell* 92; 573-585, 1998; Hinuma, S., *et al.*, *Nature* 393: 272-276, 1998). Chromotographic fractions of brain extracts could be tested for ability to activate nGPCR-x proteins by measuring second messenger production such as changes in cAMP production in the presence or absence of forskolin, changes in inositol 3-phosphate levels, changes in intracellular calcium levels or by indirect measures of receptor activation including receptor stimulated mitogenesis, receptor mediated changes in extracellular acidification or receptor mediated changes in reporter gene activation in response to cAMP or calcium (these methods should all be referenced in other sections of the patent). Receptor activation could also be monitored by co-transfeting cells with a chimeric  $\text{G}\text{I}_{\alpha/3}$  to force receptor coupling to a calcium stimulating pathway (Conklin *et al.*, *Nature* 363; 274-276, 1993). Neurotransmitter mediated activation of receptors could also be monitored by measuring changes in [ $^{35}\text{S}$ ]-GTPKS binding in membrane fractions prepared from transfected mammalian cells. This assay could also be performed using baculoviruses containing nGPCR-x proteins infected into SF9 insect cells.

The neurotransmitter which activates nGPCR-x proteins can be purified to homogeneity through successive rounds of purification using nGPCR-x proteins activation as a measurement of neurotransmitter activity. The composition of the neurotransmitter can be determined by mass spectrometry and Edman degradation if peptidergic. Neurotransmitters isolated in this manner will be bioactive materials which

will alter neurotransmission in the central nervous system and will produce behavioral and biochemical changes.

**Example 13 - Using nGPCR-x proteins to isolate and purify G proteins**

5 cDNAs encoding nGPCR-x proteins are epitope-tagged at the amino terminus end of the cDNA with the cleavable influenza-hemagglutinin signal sequence followed by the FLAG epitope (IBI, New Haven, CT). Additionally, these sequences are tagged at the carboxyl terminus with DNA encoding six histidine residues. (Amino and Carboxyl

10 Terminal Modifications to Facilitate the Production and Purification of a G Protein-Coupled Receptor, B.K. Kobilka, *Analytical Biochemistry*, Vol. 231, No. 1, Oct 1995, pp. 269-271). The resulting sequences are cloned into a baculovirus expression vector such as pVL1392 (Invitrogen). The baculovirus expression vectors are used to infect SF-9 insect cells as described (Guan, X. M., Kobilka, T. S., and Kobilka, B. K. (1992) *J.*

15 *Biol. Chem.* **267**, 21995-21998). Infected SF-9 cells could be grown in 1000-ml cultures in SF900 II medium (Life Technologies, Inc.) containing 5% fetal calf serum (Gemini, Calabasas, CA) and 0.1 mg/ml gentamicin (Life Technologies, Inc.) for 48 hours at which time the cells could be harvested. Cell membrane preparations could be separated from soluble proteins following cell lysis. nGPCR-x protein purification is carried out as

20 described for purification of the J2 receptor (Kobilka, *Anal. Biochem.*, **231** (1): 269-271, 1995) including solubilization of the membranes in 0.8-1.0 % *n*-dodecyl -D-maltoside (DM) (CalBiochem, La Jolla, CA) in buffer containing protease inhibitors followed by Ni-column chromatography using chelating Sepharose™ (Pharmacia, Uppsala, Sweden). The eluate from the Ni-column is further purified on an M1 anti-FLAG antibody column

25 (IBI). Receptor containing fractions are monitored by using receptor specific antibodies following western blot analysis or by SDS-PAGE analysis to look for an appropriate sized protein band (appropriate size would be the predicted molecular weight of the protein).

This method of purifying G protein is particularly useful to isolate G proteins that bind to the nGPCR-x proteins in the absence of an activating ligand.

**EXAMPLE 14: CLONE DEPOSIT INFORMATION**

In accordance with the Budapest Treaty, clones of the present invention have been deposited at the Agricultural Research Culture Collection (NRRL) International Depository Authority, 1815 N. University Street, Peoria, Illinois 61604, U.S.A.

- 5 Accession numbers and deposit dates are provided below in Table 6.

**Table 6: DEPOSIT INFORMATION**

Clone	Accession Number NRRL	Budapest Treaty Deposit Date
nGPCR-1002 (SEQ ID NO:43, 45)	B-30315	2000 July 6
nGPCR -1003 (SEQ ID NO: 11)	B-30289	2000 May 5

Some of the preferred embodiments of the invention described above are outlined below and include, but are not limited to, the following embodiments. As those skilled in the art will appreciate, numerous changes and modifications may be made to the preferred 10 embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the invention.

The entire disclosure of each publication cited herein is hereby incorporated by reference.

**What is claimed is:**

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes 5 a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of: SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46, and fragments thereof; said nucleic acid molecule encoding at least a portion of nGPCR-x.
2. The isolated nucleic acid molecule of claim 1 comprising a sequence that encodes 10 a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46, and fragments thereof.
3. The isolated nucleic acid molecule of claim 1 comprising a sequence homologous 15 to a sequence selected from the group consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and fragments thereof.
4. The isolated nucleic acid molecule of claim 1 comprising a sequence selected 20 from the group of sequences consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and fragments thereof.
5. The isolated nucleic acid molecule of claim 4 comprising a sequence selected 25 from the group of sequences consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45.
6. The isolated nucleic acid molecule of claim 4 wherein said nucleotide sequence is selected from the group consisting of: SEQ ID NO:12 and SEQ ID NO:45.
7. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule 30 is DNA.
8. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is RNA.

9. An expression vector comprising a nucleic acid molecule of any one of claims 1 to 5.

5 10. The expression vector of claim 9 wherein said nucleic acid molecule comprises a sequence selected from the group of sequences consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45.

10 11. The expression vector of claim 9 wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:45.

12. The expression vector of claim 9 wherein said vector is a plasmid.

15 13. The expression vector of claim 9 wherein said vector is a viral particle.

14. The expression vector of claim 13 wherein said vector is selected from the group consisting of adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses.

20

15. The expression vector of claim 9 wherein said nucleic acid molecule is operably connected to a promoter selected from the group consisting of simian virus 40, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, rous sarcoma virus, 25 human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.

16. A host cell transformed with an expression vector of claim 9.

30 17. The transformed host cell of claim 16 wherein said cell is a bacterial cell.

18. The transformed host cell of claim 17 wherein said bacterial cell is *E. coli*.
19. The transformed host cell of claim 16 wherein said cell is yeast.  
5
20. The transformed host cell of claim 19 wherein said yeast is *S. cerevisiae*.
21. The transformed host cell of claim 16 wherein said cell is an insect cell.
- 10 22. The transformed host cell of claim 21 wherein said insect cell is *S. frugiperda*.
23. The transformed host cell of claim 16 wherein said cell is a mammalian cell.
24. The transformed host cell of claim 23 wherein mammalian cell is selected from  
15 the group consisting of chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human 293 cells, and murine 3T3 fibroblasts.
25. An isolated nucleic acid molecule comprising a nucleotide sequence  
complementary to at least a portion of a sequence selected from the group of sequences  
20 consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, said portion comprising at least 10 nucleotides.
26. The nucleic acid molecule of claim 25 wherein said molecule is an antisense  
oligonucleotide directed to a region of a sequence selected from the group of sequences  
25 consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45.
27. The nucleic acid molecule of claim 26 wherein said oligonucleotide is directed to  
a regulatory region of a sequence selected from the group of sequences consisting of SEQ  
ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45.

28. The nucleic acid molecule of claim 25 wherein said molecule is an antisense oligonucleotide directed to a region of nucleotide sequence selected from the group consisting of: SEQ ID NO:12, and SEQ ID NO:45.

5 29. A composition comprising a nucleic acid molecule of any one of claims 1 to 5 or 25 and an acceptable carrier or diluent.

30. A composition comprising a recombinant expression vector of claim 9 and an acceptable carrier or diluent.

10

31. A method of producing a polypeptide that comprises a sequence selected from the group of sequences consisting SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46, and homologs and fragments thereof, said method comprising the steps of:

- 15 a) introducing a recombinant expression vector of claim 10 into a compatible host cell;
- b) growing said host cell under conditions for expression of said polypeptide; and
- c) recovering said polypeptide.

20 32. The method of claim 31 wherein said host cell is lysed and said polypeptide is recovered from the lysate of said host cell.

33. The method of claim 31 wherein said polypeptide is recovered by purifying the culture medium without lysing said host cell.

25

34. An isolated polypeptide encoded by a nucleic acid molecule of claim 1.

35. The polypeptide of claim 34 wherein said polypeptide comprises a sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and 30 SEQ ID NO:46.

36. The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46.

5

37. The polypeptide of claim 34 wherein said sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46 comprises at least one conservative amino acid substitution compared to the sequences in the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46.

10

38. The polypeptide of claim 34 wherein said polypeptide comprises a fragment of a polypeptide with a sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46.

15

39. The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:46.

40. A composition comprising a polypeptide of claim 34 and an acceptable carrier or 20 diluent.

41. An isolated antibody which binds to an epitope on a polypeptide of claim 34.

42. The antibody of claim 41 wherein said antibody is a monoclonal antibody.

25

43. A composition comprising an antibody of claim 41 and an acceptable carrier or diluent.

44. A method of inducing an immune response in a mammal against a polypeptide of 30 claim 34 comprising administering to said mammal an amount of said polypeptide

sufficient to induce said immune response.

45. A method for identifying a compound which binds nGPCR-x comprising the steps of:

5           a)     contacting nGPCR-x with a compound; and  
              b)     determining whether said compound binds nGPCR-x.

46. The method of claim 45 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:46.

10

47. The method of claim 45 wherein binding of said compound to nGPCR-x is determined by a protein binding assay.

48. The method of claim 45 wherein said protein binding assay is selected from the group consisting of a gel-shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, and ELISA.

49. A compound identified by the method of claim 45.

20

50. A method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x comprising the steps of:

25           a)     contacting said nucleic acid molecule encoding nGPCR-x with a compound; and  
              b)     determining whether said compound binds said nucleic acid molecule.

51. The method of claim 50 wherein binding is determined by a gel-shift assay.

30 52. A compound identified by the method of claim 50.

53. A method for identifying a compound which modulates the activity of nGPCR-x comprising the steps of:

- 5 a) contacting nGPCR-x with a compound; and
- b) determining whether nGPCR-x activity has been modulated.

54. The method of claim 53 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25 and SEQ ID NO:46.

10 55. The method of claim 53 wherein said activity is neuropeptide binding.

56. The method of claim 53 wherein said activity is neuropeptide signaling.

57. A compound identified by the method of claim 53.

15 58. A method of identifying an animal homolog of nGPCR-x comprising the steps:

- a) comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequence consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and portions thereof, said portions being at least 10 nucleotides; and
- 20 b) identifying nucleic acid sequences of the animal that are homologous to said sequence selected from the group sequence consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and portions thereof.

25 59. The method of claim 58 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequences consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and portions thereof, said portions being at least 10 nucleotides, is performed by DNA hybridization.

30 60. The method of claim 58 wherein comparing the nucleic acid sequences of the

animal with a sequence selected from the group of sequences consisting of SEQ ID NO:11 to SEQ ID NO:13, and SEQ ID NO:45, and portions thereof, said portions being at least 10 nucleotides, is performed by computer homology search.

5 61. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:

(a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR that is expressed in the brain, wherein the nGPCR comprises an 10 amino acid sequence selected from the group consisting of: SEQ ID NO:12, and SEQ ID NO:45, and allelic variants thereof, and wherein the nucleic acid corresponds to a gene encoding the nGPCR; and

15 (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

62. A method according to claim 61, wherein the nGPCR is nGPCR-1002 comprising an amino acid sequence set forth in SEQ ID NO:46 or an allelic variant thereof.

20

63. A method according to claim 61, wherein the nGPCR is nGPCR-1007 comprising an amino acid sequence set forth in SEQ ID NO:25 or an allelic variant thereof.

25

64. A method according to claim 61, wherein the disease is a mental disorder.

65. A method according to claim 61, wherein the assaying step comprises at least one procedure selected from the group consisting of:

a) comparing nucleotide sequences from the human subject and reference sequences and determining a difference of either

30

at least a nucleotide of at least one codon between

the nucleotide sequences from the human subject that encodes an nGPCR-1002 allele and an nGPCR-1002 reference sequence, or

at least a nucleotide of at least one codon between

the nucleotide sequences from the human subject that encodes an nGPCR-1007 allele and 5 an nGPCR-1007 reference sequence;

(b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences;

(c) performing a polynucleotide migration assay to determine whether 10 nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and

(d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

15

66. A method according to claim 65 wherein the assaying step comprises: performing a polymerase chain reaction assay to amplify nucleic acid comprising nGPCR-1002 or nGPCR-1007 coding sequence, and determining nucleotide sequence of the amplified nucleic acid.

20

67. A method of screening for an nGPCR-1002 or nGPCR-1007 hereditary mental disorder genotype in a human patient, comprising the steps of:

(a) providing a biological sample comprising nucleic acid from said patient, said nucleic acid including sequences corresponding to alleles of nGPCR-25 1002 or nGPCR-1007; and

(b) detecting the presence of one or more mutations in the nGPCR-1002 allele or the nGPCR-1007 allele;

wherein the presence of a mutation in a nGPCR-1002 allele or nGPCR-1007 allele is indicative of a hereditary mental disorder genotype.

30

68. The method according to claim 67 wherein said biological sample is a cell sample.

69. The method according to claim 67 wherein said detecting the presence of a 5 mutation comprises sequencing at least a portion of said nucleic acid, said portion comprising at least one codon of said nGPCR-1002 or nGPCR-1007 alleles.

70. The method according to claim 67 wherein said nucleic acid is DNA.

10 71. The method according to claim 67 wherein said nucleic acid is RNA.

72. A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:

15 (a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-1002 gene or a human nGPCR-1007 gene, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-1002 or nGPCR-1007 gene sequence or nGPCR-1002 or nGPCR-1007 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide 20 substitution; and

(b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

25

73. A method of identifying a nGPCR allelic variant that correlates with a mental disorder, comprising the steps of:

30 (a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;

(b) detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain, wherein the nGPCR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, and SEQ ID NO:46, and allelic variants thereof, and wherein the nucleic acid includes sequence 5 corresponding to the gene or genes encoding nGPCR;  
wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

74. A method according to claim 73, wherein the disorder is a mental disorder, and 10 wherein the at least one nGPCR is nGPCR-1002, nGPCR-1007, or an allelic variant thereof.

75. A purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-1002 or nGPCR-1007 allelic variant identified according to claim 74.

15 76. A host cell transformed or transfected with a polynucleotide according to claim 75 or with a vector comprising the polynucleotide.

77. A purified polynucleotide comprising a nucleotide sequence encoding nGPCR- 20 1002 or nGPCR-1007 of a human with a mental disorder;

wherein said polynucleotide hybridizes to the complement of SEQ ID NO:12 or of SEQ ID NO:45 under the following hybridization conditions:

(a) hybridization for 16 hours at 42°C in a hybridization solution comprising 25 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and  
(b) washing 2 times for 30 minutes at 60°C in a wash solution comprising 0.1x SSC and 1% SDS; and

wherein the polynucleotide that encodes nGPCR-1002 or nGPCR-1007 amino acid sequence of the human differs from SEQ ID NO:25 or SEQ ID NO:46 by at least one residue.

78. A vector comprising a polynucleotide according to claim 77.

79. A host cell that has been transformed or transfected with a polynucleotide according to claim 77 and that expresses the nGPCR-1002 or nGPCR-1007 protein  
5 encoded by the polynucleotide.

80. A host cell according to claim 79 that has been co-transfected with a polynucleotide encoding the nGPCR-1002 or nGPCR-1007 amino acid sequence set forth in SEQ ID NO:25 or SEQ ID NO:46 and that expresses the nGPCR-1002 or nGPCR-  
10 1007 protein having the amino acid sequence set forth in SEQ ID NO:25 or SEQ ID NO:46.

81. A method for identifying a modulator of biological activity of nGPCR-1002 or nGPCR-1007 comprising the steps of:  
15 a) contacting a cell according to claim 79 in the presence and in the absence of a putative modulator compound;  
b) measuring nGPCR-1002 or nGPCR-1007 biological activity in the cell;  
wherein decreased or increased nGPCR-1002 or nGPCR-1007 biological activity  
20 in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

82. A method to identify compounds useful for the treatment of a mental disorder, said method comprising the steps of:  
25 (a) contacting a composition comprising nGPCR-1002 with a compound suspected of binding nGPCR-1002 or contacting a composition comprising nGPCR-1007 with a compound suspected of binding nGPCR-1007;  
(b) detecting binding between nGPCR-1002 and the compound suspected of binding nGPCR-1002 or between nGPCR-1007 and the compound  
30 suspected of binding nGPCR-1007;

wherein compounds identified as binding nGPCR-1002 or nGPCR-1007 are candidate compounds useful for the treatment of a mental disorder.

83. A method for identifying a compound useful as a modulator of binding between  
5 nGPCR-1002 and a binding partner of nGPCR-1002 or between nGPCR-1007 and a binding partner of nGPCR-1007 comprising the steps of:

(a) contacting the binding partner and a composition comprising nGPCR-1002 or nGPCR-1007 in the presence and in the absence of a putative modulator compound;

10 (b) detecting binding between the binding partner and nGPCR-1002 or nGPCR-1007;

wherein decreased or increased binding between the binding partner and nGPCR-1002 or nGPCR-1007 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound  
15 useful for the treatment of a mental disorder.

84. A method according to claim 82 or 83 wherein the composition comprises a cell expressing nGPCR-1002 or nGPCR-1007 on its surface.

20 85. A method according to claim 84 wherein the composition comprises a cell transformed or transfected with a polynucleotide that encodes nGPCR-1002 or nGPCR-1007.

86. A method of purifying a G protein from a sample containing said G protein  
25 comprising the steps of:

- a) contacting said sample with a polypeptide of claim 1 for a time sufficient to allow said G protein to form a complex with said polypeptide;
- b) isolating said complex from remaining components of said sample;
- c) maintaining said complex under conditions which result in  
30 dissociation of said G protein from said polypeptide; and

d) isolating said G protein from said polypeptide.

87. The method of claim 86 wherein said sample comprises an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and  
5 SEQ ID NO:46.

88. The method of claim 86 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:24 to SEQ ID NO:27, and SEQ ID NO:46.

10

89. The method of claim 86 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:25 and SEQ ID NO:46.

## SEQUENCE LISTING

<110> **Pharmacia & Upjohn Company**

<120> **Novel G Protein Coupled Receptors**

<130> **PUJ-0298**

<150> **60/184, 305**

<151> **2000-02-23**

<150> **60/188, 880**

<151> **2000-03-13**

<150> **60/219, 492**

<151> **2000-07-20**

<150> **60/173, 339**

<151> **1999-12-28**

<150> **60/224, 321**

<151> **2000-08-11**

<150> **60/200, 534**

<151> **2000-04-27**

<150> **60/239, 062**

<151> **2000-10-09**

<160> **56**

<170> **PatentIn version 3.0**

<210> **1**

<211> **237**

<212> **DNA**

<213> **Homo sapiens**

<400> **1**

cactctccct gggccactc tcagggccatc ctcaccatcg tctgactcct cgtcgttggc 60

catgagggcc atgcacttct cccggacagc tttgaggtca gccccgttagc ggtcgccaggc 120

ccagaggaac acaggcagca gcagggcctg gcccacggag caccacagca cgcagagtgc 180

catccagggc gctgaggcgt cggcccgag gctgctgaag ctcaccacct gtgggca 237

<210> **2**

<211> **558**

<212> **DNA**

<213> **Homo sapiens**

<400> **2**

acacatggtg caacacagca gagccagcag caccgctgcc accagccaca gcgtccggca 60

caagtggcgg ctgggctccc cgaagaactg ggtgcaggcg ccgctgagca gcaggtgcag 120

cagcaggcag agggcccagg tgagggcgca cacacaggtg gtcaggtggc gtgggcccgc 180

gcacgagtac caggctggga agagggcggc caggcactgc tccacgctga cggccgcccag 240  
gagactcagg cccacgatgt agcagaagaa gcgacgcgtt gccaggctgg tctgcacgaa 300  
gcccggaaag tccagccggc cttgcagcaa gtcggggacg atggccacca tgtggcagcc 360  
aaggaagatg agatccgcgc aggccacgac caggaggtac atggcgaagg ggtttctgtac 420  
gacattggag ctgagcagcc agaggactgc cccattcccc acgagcccac cgaggcccgag 480  
cccctcggtg agggacagga tcatgaggtt gaaggccaca tcctcctggg cgccgttggc 540  
ggccccccacg tgctgtcc 558

<210> 3  
<211> 420  
<212> DNA  
<213> Homo sapiens

<400> 3  
taagaagcca cagaacttcc cttccaagat gctcagcagt agggacaggg cccagagcag 60  
gacacacacg accgctgaca ggtgtctggg gcggcggcag cgataccaga tgggccacag 120  
gacggacagg cagcgctcgg tgctgacggt gctcagcatg ctcaggcctg caaggttaggc 180  
acaggtcatc acagtggtga agaagctagg gaaattgtat gagatggaac agaagaagtt 240  
actgaggtac accaggcaat ttataatctg gaagcagagg aagaggaatg cggcccccggc 300  
caggctgagg acgttagacag agaaggcggtt cctgcgcatg cgaaagccca ggagccagag 360  
cacaaacccg tttcctacca gcccgaccag ggcaatgaaa agatcagga agaccggat 420

<210> 4  
<211> 297  
<212> DNA  
<213> Homo sapiens

<400> 4  
gtcctgcgg gcccggggcc gcccctctct gtcttcacgg tccctgggt gacgctgcta 60  
gtgctgctga tcgctgccac tttcctgtgg aacctgctgg ttccggtcac catcccgccg 120  
gtccgtgcct tccaccgcgt gcccgcataac ttggtggcct cgacggccgt ctcggacgaa 180  
ctagtggcag cgctggcgat gcccaccgac ctggcgagtg agctgtcgac cggggcgcgt 240  
cggtgtctgg gcccggccct gtgccacgtg tggatctct tccgacgcgg agcctgt 297

<210> 5  
<211> 636  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctgtgctgcc ccgccggcct cgggaacgtg gcggccatcg ccctgggccc cgacggggcc 60  
atcacacggc acctgcagca cacgctgcgc acccgagcc gcgcctcggt gctcatgatc 120  
gcgcgtcccc gggtgccgtc ggccgtcatc gcgcgtcgcc cgctgcttt tggccggggc 180  
gaggtgtgcg acgctcggt ccagcgctgc caggtgagcc gggAACCTC ctatgcggcc 240  
ttctccaccc gcggcgccctt ccacctgccc cttggcgtgg tgccgttgtt ctaccgaaag 300  
atctacgagg cgccaaagtt tcgtttcgcc cgccgcccga gagctgtgtt gccgttgcgg 360  
gccaccatgc aggtgagggg tgggctgagg aacgttgcta tggggaaagcg gttgttagag 420  
aaggaggcag ctgcgaat gggagagtgg gcggaaagctt gtactaatgg agcgcgcgccc 480  
cagagatcac ctggggcgca cgaggacaag tttccatca gttcttctga agcgggcacc 540  
gaggggcttg tcaccggctc acctggcacg caagtgaggg gttcgccagc tgcgtacttg 600  
gtgcgcgcag aggaaagggt ttccacaatct gcacgt 636

<210> 6  
<211> 654  
<212> DNA  
<213> Homo sapiens  
  
<400> 6  
atggatgaca atgccaccaa cacttccacc agttccctt ctgtgctcaa ccctcatggaa 60  
gcctcatgcca ctcccttccc attcaacttc agctacagcg actatgatat gcctttggat 120  
gaagatgagg atgtgaccaa ttccaggacg ttctttgtg ccaagattgt cattggatg 180  
gccttgggg gcatcatgct ggtctgcggc attggaaact tcataatggat cgcgtccctg 240  
gtccgcatac agaaactgacg caacccatcacc aacctgctca tcggcaaccc ggcacatct 300  
gacttccctgg tggccattgt ctgctggccc tttgagatgg actactatgt ggtgcgcac 360  
ctctccctggg agcacggcca cgtccctgtgc acctctgtca actacccatgc cactgtctct 420  
ctctatgtct ccaccaatgc cctgctggcc atcgccattg acaggtgagt gcagcagcag 480  
tggggacaac aaaggcggtc agggaggaag gggcattggaa attgccccct cctgtactgc 540  
agttgcagat tgatgagagg tgtctctatt ccccttagat gtggttgcat gggggactca 600  
aaagcttggcc cattgactga cagtgagaag agttctccctt ttccagctt gttc 654

<210> 7  
<211> 180  
<212> DNA  
<213> Homo sapiens

<400> 7

gccttcatct gctgttggag tccatacttc ctgtttgaca ttttggacaa tttcaacctc 60  
cttccagaca cccaggagcg ttcttatgcc tctgtatca ttcagaacct gccagcattg 120  
aatagtggcca tcaaaaaaaa catctactgt gtcttcagca gctccatctc tttccccctgc 180

<210> 8  
<211> 201  
<212> DNA  
<213> *Homo sapiens*

```
<400> 8
gaaaagcaag ccagggtcct cattgtgatc gcctggagcc tgcgtttct gttctccatt 60
cccaccctga tcatatttgg gaagaggaca ctgtccaaacg gtgaagtgca gtgctggcc 120
ctgtggcctg acgactccct a cttggacccca tacatgacca tcgtggcctt cctggtgtac 180
ttcatccctc tgacaatcat c 201
```

<210> 9  
<211> 648  
<212> DNA  
<213> *Homo sapiens*

<400> 9  
caccagcaca gggaaagccca tgaggcagtc gtagatgaag actatggtgg tcacgaggcc 60  
cgtggctcgc agagagggtt tggcgggctc cgagccatcg atggaggagc gcccgttgc 120  
ctgcgcgtcc tccaccacga tggtgggcac ggtgaaggcg cggcggtcgg cctggcgc 180  
cacctgcacg gccagcgtct ggaagaggc gatggctgtg cagatcacgc ccatggccac 240  
gctgccgccc accagcagca ggaagcagac gccaaagccc aggccgatct cagccacgat 300  
gaagcggcag ccatgggtgt agaagcgtc gctgggtgc tgccagccaa cggcaggcag 360  
ggccgacagg atgaaggaca ccatccagat acccatgact gtgtgcaccc cctgcttctt 420  
ggcattgctc agcctggcat gaggcaggg ggaacagagg gatctggcgt caccacagg 480  
gcctccccag gcctctgggg acctgttaggg gatccgcacc acccaggcac cccacacccc 540  
cagtatatca tagtcatggc acagccagtg tggcaggcc ttgttccttg cataggagat 600  
actgtgaaca ttgtcacacg tccctcttcc aaqcattctq tattqqct 648

<210> 10  
<211> 357  
<212> DNA  
<213> *Homo sapiens*

<400> 10  
ccggtagttg acaggccagc agaccatcca catgcggtgg taggagaggg aggtgacacaga 60

gaaacaggtg	gccagggtga	gggtgtagaa	ggtggacacg	aagaccttc	agagaccctc	120
atccactcg	aagtccgggc	gctgccgccc	cagctgcacc	acggagtagg	tggcgatggg	180
cacggccaca	tttagcatgt	gggtggccgc	gagtgtacac	agcaggaact	ccaagggctt	240
ccacttcttc	tgcttggcgc	caacgctgag	gatgccccag	gcattggcca	gcagggagag	300
gcccccacat	accagccagc	ccactgcact	gccaggcagc	cgccgctaat	cactcat	357

<210> 11  
<211> 1163  
<212> DNA  
<213> Homo sapiens

<400> 11	cctgtaaaaca	ggggcggtaa	ttaccacata	acaggctggt	catgaaaatc	agtgaacatg	60
cacgaggtgc	tcaagtcttgc	tttttggtttgc	caggggcacc	agtggaggtt	ttctgagcat	120	
ggatccaacc	accccgccct	ggggAACAGA	aagtacaaca	gtgaatggaa	atgaccaagc	180	
ccttcttctg	ctttgtggca	aggagaccct	gatccggc	ttcctgatcc	ttttcattgc	240	
cctggtcggg	ctggtaggaa	acgggtttgt	gctctggc	ctgggcttcc	gcatgcgcag	300	
gaacgccttc	tctgtctacg	tcctcagcct	ggccggggcc	gacttcctct	tcctctgctt	360	
ccagattata	aattgcctgg	tgtacccatg	taacttcttc	tgttccatct	ccatcaattt	420	
ccctagcttc	ttcaccactg	tgatgacctg	tgccctacctt	gcaggcctga	gcatgctgag	480	
caccgtcagc	accgagcgct	gcctgtccgt	cctgtggccc	atctggtatac	gctgccgcgc	540	
ccccagacac	ctgtcagcgg	tcgtgtgtgt	cctgctctgg	gccctgtccc	tactgctgag	600	
catcttggaa	gggaagttct	gtggcttctt	atttagtata	ggtgactctg	tttgggttca	660	
gacatttgat	ttcatcaactg	cagcgtggct	gatttttta	ttcatggttc	tctgtgggtc	720	
cagtctggcc	ctgctggtca	ggatcctctg	tggctccagg	ggtctgccac	tgaccaggct	780	
gtacctgacc	atcctgctca	cagtgtgggt	gttccctctc	tgccgcctgc	ccttggcat	840	
tcagtggttc	ctaataattat	ggatctggaa	ggattctgtat	gtcttatttt	gtcatattca	900	
tccagttca	tttgcctgt	catctctaa	cagcagtgcc	aacccatca	tttacttctt	960	
cgtggctct	tttaggaagc	agtggcgct	gcagcagccg	atcctcaagc	tggctctcca	1020	
gagggctctg	caggacatttgc	ctgaggttgg	tcacagtgaa	ggatgcttcc	gtcaggcag	1080	
cccgagatg	tcgagaagca	gtctgggtta	gagatggaca	gcctctactt	ccatcagata	1140	
tatgtggctt	tgagaggcaa	ctt				1163	

<210> 12

<211> 1668  
<212> DNA  
<213> Homo sapiens

<400> 12

gtgatggata tctgcagaat tcgccttaa gcagtggtaa acaacgcaga gtacgcggga	60
ggagggcaagc tggactccct cactcagctg caggagcaag gacagtgagg ctcaaccccg	120
cctgagccat gccagccaac ttcacagagg gcagcttcga ttccagtggg accgggcaga	180
cgctggattc ttccccagtg gcttgcactg aaacagtgac ttttactgaa gtgggagaag	240
gaaaggaatg gggttccttc tactactcct ttaagactga gcaattgata actctgtggg	300
tcctcttgc ttttaccatt gttggaaact ccgttgcgtc ttttccaca tggaggagaa	360
agaagaagtc aagaatgacc ttctttgtga ctcagctggc catcacagat tcttcacag	420
gactggtcaa catcttgaca gatattattt ggcgattcac tggagacttc acggcacctg	480
acctggtttgc cgagtggtc cgctatttgc aggttgcgtc gctctacgcc tctacctacg	540
tcctgggtgc cctcagcata gacagatacc atgccatcgat ctacccatg aagtcccttc	600
aaggagaaaa gcaagccagg gtcctcattt tgatgcctg gagcctgtct tttctgttct	660
ccattccac cctgatcata tttggaaaga ggacactgtc caacggtgaa gtgcagtgc	720
ggccctgtg gcctggcgac tcctactgga ccccatatacat gaccatcgat gcctccctgg	780
tgtacttcat ccctctgaca atcatcagca tcatgtatgg cattgtgcata cgaactattt	840
ggattaaaag caaaacctac gaaacagtga tttccaactg ctcagatggg aaactgtgca	900
gcagctataa ccgaggactc atctcaaagg caaaaatcaa ggctatcaag tatagcatta	960
tcatcatttc tgccttcatac tgctgttggc gtcctactt cctgtttgac attttggaca	1020
atttcaacct cttccagac acccaggagc gtttctatgc ctctgtgatc attcagaacc	1080
tgccagcatt gaatagtgcc atcaacccccc ccatctactg tgtcttcagc agctccatct	1140
ctttccccctg cagggagcaa agatcacagg attccagaat gacgttccgg gagagaactg	1200
agaggcatga gatgcagatt ctgtccaagc cagaattcat cttagaccata gggcagtgcc	1260
agtgcgttgc tgagcaccat cagctctccc aggtccttgc cacctgcttgc ggcacgtgca	1320
tggAACCCGA gccaacttca ccccacccctc gtcattaccc gggagatgca caagacaaat	1380
gttctaatga ctgcattgcac tgcttaagta ttggccaaca cgaactcccc agttattcat	1440
gccagccagg aaggaaacgc cttccccc caccattccc agccctcctt cccactggcc	1500
agcacctgaa cccagtgaac acaggcatta gtggtccagg gtcctggctt ggagccagtg	1560
agtagacagg caagcagagg ggacaaaggt agctgggtta tacatgaata ttctcattac	1620

aatagaagaa aataaaagac ttaatataac ccaaaaaaaaaa aaaaaaaaaa 1668

<210> 13  
<211> 1387  
<212> DNA  
<213> Homo sapiens

<400> 13  
caagatgct ggcagagaca ttctgactca ttaaggaga gctggctgat agcagagagg 60  
ggtgacatca gccttgcaga cattgccctg ggaaattctg agcagtgttgc 120  
ctcacagcac  
cacctggcca gatggagacc accatgggt tcatggatga caatgccacc aacacttcca 180  
ccagcttcct ttctgtgctc aaccctcatg gagccatgc cacttccttc ccattcaact 240  
tcagctacag cgactatgtat atgcctttgg atgaagatga ggtatgtgacc aattccagga 300  
cgttcttgc tgccaagatt gtcattggga tggccctgggt gggcatcatg ctggctcg 360  
gcattggaaa cttcatctt atcgctgccc tggccgcta caagaaactg cgcaacctca 420  
ccaacctgct catcgccaaac ctggccatct ctgacttcct ggtggccatt gtctgctgcc 480  
cctttgagat ggactactat gtggtgcgccc agctctcctg ggagcacggc cacgtcctgt 540  
gcacccctgt caactacctg cgcaactgtct ctctctatgt ctccaccaat gccctgctgg 600  
ccatcgccat tgacaggtat ctggctatttgc tccatccgct gagaccacgg atgaagtgc 660  
aaacagccac tggcctgatt gccttgggtt ggacggtgtc catcctgatc gccatccctt 720  
ccgcctactt caccaccgag acggtcctcg tcattgtcaa gagccagggaa aagatcttct 780  
gccccccatctg ctggcctgtg gaccagcagc tctactacaa gtcctacttc ctctttatct 840  
ttggcataga attcggtggc cccgtggta ccatgaccct gtgctatgcc aggatctccc 900  
gggagctctg gttcaaggcg gtcctggat tccagacaga gcagatccgc aagaggctgc 960  
gctgcccgag gaagacggtc ctggtgctca tgtgcatttc caccgcctac gtgctatgt 1020  
gggcgcctt ctacggcttc accatcgatgc gcgacttctt ccccacggc tttgtgaagg 1080  
agaagacta cctcaactgatc ttctacatcg tcgagtgcatttgc cccatgagc aacagcatga 1140  
tcaacactct gtgcttcgtg accgtcaaga acgacaccgt caagtacttc aaaaagatca 1200  
tggtgctcca ctggaaaggct tcttacaatg gcggtaagtc cagtgcagac ctggacctca 1260  
agacaattgg gatgcctgccc accgaagagg tggactgcatttgc cagactaaaa taacccctg 1320  
gactttgcaaa agtttaaaca caaagcaggg tcctgtggac actgactagt gtgcttggat 1380  
gcacatc 1387

<210> 14

<211> 79  
<212> PRT  
<213> Homo sapiens

<400> 14

Cys Pro Gln Val Val Ser Phe Ser Ser Leu Arg Ala Asp Ala Ser Ala  
1 5 10 15

Pro Trp Met Ala Leu Cys Val Leu Trp Cys Ser Val Ala Gln Ala Leu  
20 25 30

Leu Leu Pro Val Phe Leu Trp Ala Cys Asp Arg Tyr Arg Ala Asp Leu  
35 40 45

Lys Ala Val Arg Glu Lys Cys Met Ala Leu Met Ala Asn Asp Glu Glu  
50 55 60

Ser Asp Asp Gly Glu Asp Gly Leu Arg Val Ala Pro Gly Arg Val  
65 70 75

<210> 15

<211> 186

<212> PRT

<213> Homo sapiens

<400> 15

Gly Gln His Val Gly Ala Ala Asn Gly Ala Gln Glu Asp Val Ala Phe  
1 5 10 15

Asn Leu Ile Ile Leu Ser Leu Thr Glu Gly Leu Gly Leu Gly Gly Leu  
20 25 30

Leu Gly Asn Gly Ala Val Leu Trp Leu Leu Ser Ser Asn Val Tyr Arg  
35 40 45

Asn Pro Phe Ala Ile Tyr Leu Leu Asp Val Ala Cys Ala Asp Leu Ile  
50 55 60

Phe Leu Gly Cys His Met Val Ala Ile Val Pro Asp Leu Leu Gln Gly  
65 70 75 80

Arg Leu Asp Phe Pro Gly Phe Val Gln Thr Ser Leu Ala Thr Leu Arg  
85 90 95

Phe Phe Cys Tyr Ile Val Gly Leu Ser Leu Leu Ala Ala Val Ser Val  
100 105 110

Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala Trp Tyr Ser Cys Arg Arg  
115 120 125

Pro Arg His Leu Thr Thr Cys Val Cys Ala Leu Thr Trp Ala Leu Cys  
130 135 140

Leu Leu Leu His Leu Leu Leu Ser Gly Ala Cys Thr Gln Phe Phe Gly  
145 150 155 160

Glu Pro Ser Arg His Leu Cys Arg Thr Leu Trp Leu Val Ala Ala Val

165

170

175

Leu Leu Ala Leu Leu Cys Cys Thr Met Cys  
180 185

<210> 16  
<211> 140  
<212> PRT  
<213> Homo sapiens

<400> 16

Ile Pro Val Phe Leu Ile Leu Phe Ile Ala Leu Val Gly Leu Val Gly  
1 5 10 15

Asn Gly Phe Val Leu Trp Leu Leu Gly Phe Arg Met Arg Arg Asn Ala  
20 25 30

Phe Ser Val Tyr Val Leu Ser Leu Ala Gly Ala Asp Phe Leu Phe Leu  
35 40 45

Cys Phe Gln Ile Ile Asn Cys Leu Val Tyr Leu Ser Asn Phe Phe Cys  
50 55 60

Ser Ile Ser Ile Asn Phe Pro Ser Phe Phe Thr Thr Val Met Thr Cys  
65 70 75 80

Ala Tyr Leu Ala Gly Leu Ser Met Leu Ser Thr Val Ser Thr Glu Arg  
85 90 95

Cys Leu Ser Val Leu Trp Pro Ile Trp Tyr Arg Cys Arg Arg Pro Arg  
100 105 110

His Leu Ser Ala Val Val Cys Val Leu Leu Trp Ala Leu Ser Leu Leu  
115 120 125

Leu Ser Ile Leu Glu Gly Lys Phe Cys Gly Phe Leu  
130 135 140

<210> 17  
<211> 99  
<212> PRT  
<213> Homo sapiens

<400> 17

Val Leu Pro Gly Arg Gly Pro Pro Phe Ser Val Phe Thr Val Leu Val  
1 5 10 15

Val Thr Leu Leu Val Leu Leu Ile Ala Ala Thr Phe Leu Trp Asn Leu  
20 25 30

Leu Val Pro Val Thr Ile Pro Arg Val Arg Ala Phe His Arg Val Pro  
35 40 45

His Asn Leu Val Ala Ser Thr Ala Val Ser Asp Glu Leu Val Ala Ala  
50 55 60

Leu Ala Met Pro Pro Ser Leu Ala Ser Glu Leu Ser Thr Gly Arg Arg  
Page 9

65                   70                   75                   80  
Arg Leu Leu Gly Arg Ser Leu Cys His Val Trp Ile Ser Phe Asp Ala  
85                                   90                                   95

Gly Ala Cys

<210> 18  
<211> 212  
<212> PRT  
<213> Homo sapiens

<400> 18

Leu Cys Cys Pro Ala Gly Leu Gly Asn Val Ala Ala Ile Ala Leu Gly  
1                           5                                   10                           15

Arg Asp Gly Ala Ile Thr Arg His Leu Gln His Thr Leu Arg Thr Arg  
20                           25                                   30

Ser Arg Ala Ser Leu Leu Met Ile Ala Leu Ala Arg Val Pro Ser Ala  
35                           40                                   45

Leu Ile Ala Leu Ala Pro Leu Leu Phe Gly Arg Gly Glu Val Cys Asp  
50                           55                                   60

Ala Arg Leu Gln Arg Cys Gln Val Ser Arg Glu Pro Ser Tyr Ala Ala  
65                           70                                   75                           80

Phe Ser Thr Arg Gly Ala Phe His Leu Pro Leu Gly Val Val Pro Phe  
85                           90                                   95

Val Tyr Arg Lys Ile Tyr Glu Ala Ala Lys Phe Arg Phe Gly Arg Arg  
100                           105                                   110

Arg Arg Ala Val Leu Pro Leu Pro Ala Thr Met Gln Val Arg Gly Gly  
115                           120                                   125

Leu Arg Asn Val Ala Met Gly Lys Arg Leu Leu Glu Lys Glu Ala Ala  
130                           135                                   140

Ser Arg Met Gly Glu Trp Ala Glu Ala Cys Thr Asn Gly Ala Arg Ala  
145                           150                                   155                           160

Gln Arg Ser Pro Gly Ala His Glu Asp Lys Phe Ala Ile Ser Ser Ser  
165                           170                                   175

Glu Ala Gly Thr Glu Gly Leu Val Thr Gly Ser Pro Gly Thr Gln Val  
180                           185                                   190

Arg Gly Ser Pro Ala Ala Tyr Leu Val Arg Ala Glu Glu Arg Val Ser  
195                           200                                   205

Gln Ser Ala Arg  
210

<210> 19  
<211> 217

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

Met Asp Asp Asn Ala Thr Asn Thr Ser Thr Ser Phe Leu Ser Val Leu  
1 5 10 15

Asn Pro His Gly Ala His Ala Thr Ser Phe Pro Phe Asn Phe Ser Tyr  
20 25 30

Ser Asp Tyr Asp Met Pro Leu Asp Glu Asp Glu Asp Val Thr Asn Ser  
35 40 45

Arg Thr Phe Phe Ala Ala Lys Ile Val Ile Gly Met Ala Leu Val Gly  
50 55 60

Ile Met Leu Val Cys Gly Ile Gly Asn Phe Ile Phe Ile Ala Ala Leu  
65 70 75 80

Val Arg Tyr Lys Lys Leu Arg Asn Leu Thr Asn Leu Leu Ile Ala Asn  
85 90 95

Leu Ala Ile Ser Asp Phe Leu Val Ala Ile Val Cys Cys Pro Phe Glu  
100 105 110

Met Asp Tyr Tyr Val Val Arg Gln Leu Ser Trp Glu His Gly His Val  
115 120 125

Leu Cys Thr Ser Val Asn Tyr Leu Arg Thr Val Ser Leu Tyr Val Ser  
130 135 140

Thr Asn Ala Leu Leu Ala Ile Ala Ile Asp Arg Val Gln Gln Gln Trp  
145 150 155 160

Gly Gln Gln Arg Arg Ser Gly Arg Lys Gly His Trp Asn Cys Pro Leu  
165 170 175

Leu Tyr Cys Ser Cys Arg Leu Met Arg Gly Val Ser Ile Pro Pro Arg  
180 185 190

Cys Gly Cys Met Gly Asp Ser Lys Ala Cys Pro Leu Thr Asp Ser Glu  
195 200 205

Lys Ser Ser Pro Phe Pro Ala Leu Phe  
210 215

&lt;210&gt; 20

&lt;211&gt; 60

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

Ala Phe Ile Cys Cys Trp Ser Pro Tyr Phe Leu Phe Asp Ile Leu Asp  
1 5 10 15

Asn Phe Asn Leu Leu Pro Asp Thr Gln Glu Arg Phe Tyr Ala Ser Val  
20 25 30

Ile Ile Gln Asn Leu Pro Ala Leu Asn Ser Ala Ile Asn Pro Leu Ile  
35 40 45

Tyr Cys Val Phe Ser Ser Ser Ile Ser Phe Pro Cys  
50 55 60

<210> 21

<211> 67

<212> PRT

<213> Homo sapiens

<400> 21

Glu Lys Gln Ala Arg Val Leu Ile Val Ile Ala Trp Ser Leu Ser Phe  
1 5 10 15

Leu Phe Ser Ile Pro Thr Leu Ile Ile Phe Gly Lys Arg Thr Leu Ser  
20 25 30

Asn Gly Glu Val Gln Cys Trp Ala Leu Trp Pro Asp Asp Ser Tyr Trp  
35 40 45

Thr Pro Tyr Met Thr Ile Val Ala Phe Leu Val Tyr Phe Ile Pro Leu  
50 55 60

Thr Ile Ile  
65

<210> 22

<211> 216

<212> PRT

<213> Homo sapiens

<400> 22

Ser Gln Tyr Arg Met Leu Gly Arg Gly Thr Cys Asp Asn Val His Ser  
1 5 10 15

Ile Ser Tyr Ala Arg Asn Lys Ala Leu Pro His Trp Leu Cys His Asp  
20 25 30

Tyr Asp Ile Leu Gly Val Trp Gly Ala Trp Val Val Arg Ile Pro Tyr  
35 40 45

Arg Ser Pro Glu Ala Trp Gly Gly Pro Val Gly Asp Ala Arg Ser Leu  
50 55 60

Cys Ser Thr Leu Pro His Ala Arg Leu Ser Asn Ala Lys Lys Gln Ala  
65 70 75 80

Val His Thr Val Met Gly Ile Trp Met Val Ser Phe Ile Leu Ser Ala  
85 90 95

Leu Pro Ala Val Gly Trp His Asp Thr Ser Glu Arg Phe Tyr Thr His  
100 105 110

Gly Cys Arg Phe Ile Val Ala Glu Ile Gly Leu Gly Phe Gly Val Cys  
115 120 125

Phe Leu Leu Leu Val Gly Gly Ser Val Ala Met Gly Val Ile Cys Thr  
130 135 140

Ala Ile Ala Leu Phe Gln Thr Leu Ala Val Gln Val Gly Arg Gln Ala  
145 150 155 160

Asp Arg Arg Ala Phe Thr Val Pro Thr Ile Val Val Glu Asp Ala Gln  
165 170 175

Gly Lys Arg Arg Ser Ser Ile Asp Gly Ser Glu Pro Ala Lys Thr Ser  
180 185 190

Leu Gln Thr Thr Gly Leu Val Thr Thr Ile Val Phe Ile Tyr Asp Cys  
195 200 205

Leu Met Gly Phe Pro Val Leu Val  
210 215

<210> 23  
<211> 119  
<212> PRT  
<213> Homo sapiens

<400> 23

Met Ser Asp Glu Arg Arg Leu Pro Gly Ser Ala Val Gly Trp Leu Val  
1 5 10 15

Cys Gly Gly Leu Ser Leu Leu Ala Asn Ala Trp Gly Ile Leu Ser Val  
20 25 30

Gly Ala Lys Gln Lys Trp Lys Pro Leu Glu Phe Leu Leu Cys Thr  
35 40 45

Leu Ala Ala Thr His Met Leu Asn Val Ala Val Pro Ile Ala Thr Tyr  
50 55 60

Ser Val Val Gln Leu Arg Arg Gln Arg Pro Asp Phe Glu Trp Asn Glu  
65 70 75 80

Gly Leu Cys Lys Val Phe Val Ser Thr Phe Tyr Thr Leu Thr Leu Ala  
85 90 95

Thr Cys Phe Ser Val Thr Ser Leu Ser Tyr His Arg Met Trp Met Val  
100 105 110

Cys Trp Pro Val Asn Tyr Arg  
115

<210> 24  
<211> 330  
<212> PRT  
<213> Homo sapiens

<400> 24

Met Asp Pro Thr Thr Pro Ala Trp Gly Thr Glu Ser Thr Thr Val Asn  
1 5 10 15

Gly Asn Asp Gln Ala Leu Leu Leu Cys Gly Lys Glu Thr Leu Ile  
 20 25 30  
 Pro Val Phe Leu Ile Leu Phe Ile Ala Leu Val Gly Leu Val Gly Asn  
 35 40 45  
 Gly Phe Val Leu Trp Leu Leu Gly Phe Arg Met Arg Arg Asn Ala Phe  
 50 55 60  
 Ser Val Tyr Val Leu Ser Leu Ala Gly Ala Asp Phe Leu Phe Leu Cys  
 65 70 75 80  
 Phe Gln Ile Ile Asn Cys Leu Val Tyr Leu Ser Asn Phe Phe Cys Ser  
 85 90 95  
 Ile Ser Ile Asn Phe Pro Ser Phe Phe Thr Thr Val Met Thr Cys Ala  
 100 105 110  
 Tyr Leu Ala Gly Leu Ser Met Leu Ser Thr Val Ser Thr Glu Arg Cys  
 115 120 125  
 Leu Ser Val Leu Trp Pro Ile Trp Tyr Arg Cys Arg Arg Pro Arg His  
 130 135 140  
 Leu Ser Ala Val Val Cys Val Leu Leu Trp Ala Leu Ser Leu Leu Leu  
 145 150 155 160  
 Ser Ile Leu' Glu Gly Lys Phe Cys Gly Phe Leu Phe Ser Asp Gly Asp  
 165 170 175  
 Ser Gly Trp Cys Gln Thr Phe Asp Phe Ile Thr Ala Ala Trp Leu Ile  
 180 185 190  
 Phe Leu Phe Met Val Leu Cys Gly Ser Ser Leu Ala Leu Leu Val Arg  
 195 200 205  
 Ile Leu Cys Gly Ser Arg Gly Leu Pro Leu Thr Arg Leu Tyr Leu Thr  
 210 215 220  
 Ile Leu Leu Thr Val Leu Val Phe Leu Leu Cys Gly Leu Pro Phe Gly  
 225 230 235 240  
 Ile Gln Trp Phe Leu Ile Leu Trp Ile Trp Lys Asp Ser Asp Val Leu  
 245 250 255  
 Phe Cys His Ile His Pro Val Ser Val Val Leu Ser Ser Leu Asn Ser  
 260 265 270  
 Ser Ala Asn Pro Ile Ile Tyr Phe Phe Val Gly Ser Phe Arg Lys Gln  
 275 280 285  
 Trp Arg Leu Gln Gln Pro Ile Leu Lys Leu Ala Leu Gln Arg Ala Leu  
 290 295 300  
 Gln Asp Ile Ala Glu Val Asp His Ser Glu Gly Cys Phe Arg Gln Gly  
 305 310 315 320  
 Thr Pro Glu Met Ser Arg Ser Ser Leu Val

325

330

<210> 25  
<211> 371  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 25

Met Pro Ala Asn Phe Thr Glu Gly Ser Phe Asp Ser Ser Gly Thr Gly  
1 5 10 15

Gln Thr Leu Asp Ser Ser Pro Val Ala Cys Thr Glu Thr Val Thr Phe  
20 25 30

Thr Glu Val Val Glu Gly Lys Glu Trp Gly Ser Phe Tyr Tyr Ser Phe  
35 40 45

Lys Thr Glu Gln Leu Ile Thr Leu Trp Val Leu Phe Val Phe Thr Ile  
50 55 60

Val Gly Asn Ser Val Val Leu Phe Ser Thr Trp Arg Arg Lys Lys Lys  
65 70 75 80

Ser Arg Met Thr Phe Phe Val Thr Gln Ala Ile Thr Asp Ser Phe  
85 90 95

Thr Gly Leu Val Asn Ile Leu Thr Asp Ile Ile Trp Arg Phe Thr Gly  
100 105 110

Asp Phe Thr Ala Pro Asp Leu Val Cys Arg Val Val Arg Tyr Leu Gln  
115 120 125

Val Val Leu Leu Tyr Ala Ser Thr Tyr Val Leu Val Ser Leu Ser Ile  
130 135 140

Asp Arg Tyr His Ala Ile Val Tyr Pro Met Lys Phe Leu Gln Gly Glu  
145 150 155 160

Lys Gln Ala Arg Val Leu Ile Val Ile Ala Trp Ser Leu Ser Phe Leu  
165 170 175

Phe Ser Ile Pro Thr Leu Ile Ile Phe Gly Lys Arg Thr Leu Ser Asn  
180 185 190

Gly Glu Val Gln Cys Trp Ala Leu Trp Pro Gly Asp Ser Tyr Trp Thr  
195 200 205

Pro Tyr Met Thr Ile Val Ala Phe Leu Val Tyr Phe Ile Pro Leu Thr  
210 215 220

Ile Ile Ser Ile Met Tyr Gly Ile Val Ile Arg Thr Ile Trp Ile Lys  
225 230 235 240

Ser Lys Thr Tyr Glu Thr Val Ile Ser Asn Cys Ser Asp Gly Lys Leu  
245 250 255

Cys Ser Ser Tyr Asn Arg Gly Leu Ile Ser Lys Ala Lys Ile Lys Ala  
260 265 270

Ile Lys Tyr Ser Ile Ile Ile Leu Ala Phe Ile Cys Cys Trp Ser  
275 280 285

Pro Tyr Phe Leu Phe Asp Ile Leu Asp Asn Phe Asn Leu Leu Pro Asp  
290 295 300

Thr Gln Glu Arg Phe Tyr Ala Ser Val Ile Ile Gln Asn Leu Pro Ala  
305 310 315 320

Leu Asn Ser Ala Ile Asn Pro Pro Ile Tyr Cys Val Phe Ser Ser Ser  
325 330 335

Ile Ser Phe Pro Cys Arg Glu Gln Arg Ser Gln Asp Ser Arg Met Thr  
340 345 350

Phe Arg Glu Arg Thr Glu Arg His Glu Met Gln Ile Leu Ser Lys Pro  
355 360 365

Glu Phe Ile  
370

<210> 26

<211> 393

<212> PRT

<213> Homo sapiens

<400> 26

Met Glu Thr Thr Met Gly Phe Met Asp Asp Asn Ala Thr Asn Thr Ser  
1 5 10 15

Thr Ser Phe Leu Ser Val Leu Asn Pro His Gly Ala His Ala Thr Ser  
20 25 30

Phe Pro Phe Asn Phe Ser Tyr Ser Asp Tyr Asp Met Pro Leu Asp Glu  
35 40 45

Asp Glu Asp Val Thr Asn Ser Arg Thr Phe Phe Ala Ala Lys Ile Val  
50 55 60

Ile Gly Met Ala Leu Val Gly Ile Met Leu Val Cys Gly Ile Gly Asn  
65 70 75 80

Phe Ile Phe Ile Ala Ala Leu Val Arg Tyr Lys Lys Leu Arg Asn Leu  
85 90 95

Thr Asn Leu Leu Ile Ala Asn Leu Ala Ile Ser Asp Phe Leu Val Ala  
100 105 110

Ile Val Cys Cys Pro Phe Glu Met Asp Tyr Tyr Val Val Arg Gln Leu  
115 120 125

Ser Trp Glu His Gly His Val Leu Cys Thr Ser Val Asn Tyr Leu Arg  
130 135 140

Thr Val Ser Leu Tyr Val Ser Thr Asn Ala Leu Leu Ala Ile Ala Ile  
145 150 155 160

Asp Arg Tyr Leu Ala Ile Val His Pro Leu Arg Pro Arg Met Lys Cys  
165 170 175

Gln Thr Ala Thr Gly Leu Ile Ala Leu Val Trp Thr Val Ser Ile Leu  
180 185 190

Ile Ala Ile Pro Ser Ala Tyr Phe Thr Thr Glu Thr Val Leu Val Ile  
195 200 205

Val Lys Ser Gln Glu Lys Ile Phe Cys Gly Gln Ile Trp Pro Val Asp  
210 215 220

Gln Gln Leu Tyr Tyr Lys Ser Tyr Phe Leu Phe Ile Phe Gly Ile Glu  
225 230 235 240

Phe Val Gly Pro Val Val Thr Met Thr Leu Cys Tyr Ala Arg Ile Ser  
245 250 255

Arg Glu Leu Trp Phe Lys Ala Val Pro Gly Phe Gln Thr Glu Gln Ile  
260 265 270

Arg Lys Arg Leu Arg Cys Arg Arg Lys Thr Val Leu Val Leu Met Cys  
275 280 285

Ile Leu Thr Ala Tyr Val Leu Cys Trp Ala Pro Phe Tyr Gly Phe Thr  
290 295 300

Ile Val Arg Asp Phe Phe Pro Thr Val Phe Val Lys Glu Lys His Tyr  
305 310 315 320

Leu Thr Ala Phe Tyr Ile Val Glu Cys Ile Ala Met Ser Asn Ser Met  
325 330 335

Ile Asn Thr Leu Cys Phe Val Thr Val Lys Asn Asp Thr Val Lys Tyr  
340 345 350

Phe Lys Lys Ile Met Leu Leu His Trp Lys Ala Ser Tyr Asn Gly Gly  
355 360 365

Lys Ser Ser Ala Asp Leu Asp Leu Lys Thr Ile Gly Met Pro Ala Thr  
370 375 380

Glu Glu Val Asp Cys Ile Arg Leu Lys  
385 390

<210> 27  
<211> 389  
<212> PRT  
<213> Homo sapiens

<400> 27

Met Gly Phe Met Asp Asp Asn Ala Thr Asn Thr Ser Thr Ser Phe Leu  
1 5 10 15

Ser Val Leu Asn Pro His Gly Ala His Ala Thr Ser Phe Pro Phe Asn  
20 25 30

Phe Ser Tyr Ser Asp Tyr Asp Met Pro Leu Asp Glu Asp Glu Asp Val

35	40	45
Thr Asn Ser Arg Thr Phe Phe Ala Ala Lys Ile Val Ile Gly Met Ala		
50	55	60
Leu Val Gly Ile Met Leu Val Cys Gly Ile Gly Asn Phe Ile Phe Ile		
65	70	75
80		
Ala Ala Leu Val Arg Tyr Lys Lys Leu Arg Asn Leu Thr Asn Leu Leu		
85	90	95
Ile Ala Asn Leu Ala Ile Ser Asp Phe Leu Val Ala Ile Val Cys Cys		
100	105	110
Pro Phe Glu Met Asp Tyr Tyr Val Val Arg Gln Leu Ser Trp Glu His		
115	120	125
Gly His Val Leu Cys Thr Ser Val Asn Tyr Leu Arg Thr Val Ser Leu		
130	135	140
Tyr Val Ser Thr Asn Ala Leu Leu Ala Ile Ala Ile Asp Arg Tyr Leu		
145	150	155
160		
Ala Ile Val His Pro Leu Arg Pro Arg Met Lys Cys Gln Thr Ala Thr		
165	170	175
Gly Leu Ile Ala Leu Val Trp Thr Val Ser Ile Leu Ile Ala Ile Pro		
180	185	190
Ser Ala Tyr Phe Thr Thr Glu Thr Val Leu Val Ile Val Lys Ser Gln		
195	200	205
Glu Lys Ile Phe Cys Gly Gln Ile Trp Pro Val Asp Gln Gln Leu Tyr		
210	215	220
Tyr Lys Ser Tyr Phe Leu Phe Ile Phe Gly Ile Glu Phe Val Gly Pro		
225	230	235
240		
Val Val Thr Met Thr Leu Cys Tyr Ala Arg Ile Ser Arg Glu Leu Trp		
245	250	255
Phe Lys Ala Val Pro Gly Phe Gln Thr Glu Gln Ile Arg Lys Arg Leu		
260	265	270
Arg Cys Arg Arg Lys Thr Val Leu Val Leu Met Cys Ile Leu Thr Ala		
275	280	285
Tyr Val Leu Cys Trp Ala Pro Phe Tyr Gly Phe Thr Ile Val Arg Asp		
290	295	300
Phe Phe Pro Thr Val Phe Val Lys Glu Lys His Tyr Leu Thr Ala Phe		
305	310	315
320		
Tyr Ile Val Glu Cys Ile Ala Met Ser Asn Ser Met Ile Asn Thr Leu		
325	330	335
Cys Phe Val Thr Val Lys Asn Asp Thr Val Lys Tyr Phe Lys Lys Ile		
340	345	350

Met Leu Leu His Trp Lys Ala Ser Tyr Asn Gly Gly Lys Ser Ser Ala  
355 360 365

Asp Leu Asp Leu Lys Thr Ile Gly Met Pro Ala Thr Glu Glu Val Asp  
370 375 380

Cys Ile Arg Leu Lys  
385

<210> 28

<211> 9

<212> PRT

<213> Synthetic Substrate

<400> 28

Ala Pro Arg Thr Pro Gly Gly Arg Arg  
1 5

<210> 29

<211> 27

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 29

ttcaaagctt atggatccaa ccaccc

27

<210> 30

<211> 32

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 30

ttcactcgag ctacaccaga ctgcttctcg ac

32

<210> 31

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 31

taggcacagg tcatcacag

19

<210> 32

<211> 18

<212> DNA

<213> Artificial

<220>  
<223> Novel Sequence

<400> 32  
ttggacgcca ggaaggta

18

<210> 33  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 33  
gcctggagcc tgtctttct gttctc

26

<210> 34  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 34  
gttagatgagg gggttgatgg cactattc

28

<210> 35  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 35  
cctgatcata tttggaaaga ggacactg

28

<210> 36  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 36  
gatacccttg attttgccct ttgagatg

28

<210> 37  
<211> 30  
<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 37  
gcagcagaca atggccacca ggaagtcaga 30

<210> 38

<211> 30

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 38  
tgagcaggtt ggtgaggttg cgcagttct 30

<210> 39

<211> 22

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 39  
tttcctggct cttgacaatg ac 22

<210> 40

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Novel Sequence

<400> 40  
tccacttgtg ttcttgccc 19

<210> 41

<211> 1612

<212> DNA

<213> Homo sapiens

<400> 41  
cagtgagccg agatggtgcc attgcactct agcctggggc aacagagcc aactccatct 60  
ccaaaaaaaaa aaggccatcc tgaggatcaa ggcaccacta gcaacaggga gccccatggg 120  
tctcagaccc tctccccaca tctcctggtc cctggccca cctggcgtac agggaccagc 180  
cccacggaag gctcttgagg ccaggttaacc atggggaggg gaggaatggg gacaccttcc 240

tcctgagtgt	cttagggaag	agaagcttag	gtcaggtggc	tgagggtgga	aatgagagag	300
gggtctcctc	ctggagggtc	tcaccattcc	cttggtcacc	cacccaactc	tcatctcccc	360
tgatgtgggg	aggagcaggg	ggcatggatt	cctgagcccc	agactcaact	gttgtggttt	420
acaggggcat	caggagagag	agcgagcaga	acacactcct	gcagcatccc	ctggccccc	480
gccccatgt	ggagccaga	gaagctggac	agcacgtgg	ggccgccaac	ggcgcccagg	540
aggatgtggc	cttcaacctc	atcatccgt	ccctcaccga	ggggctcggc	ctcggtggc	600
tgctgggaa	tggggcagtc	ctctggctgc	tcagctccaa	tgtctacaga	aacccttcg	660
ccatctacct	cctggacgtg	gcctgcgcgg	atctcatctt	ccttggctgc	cacatggtgg	720
ccatcgccc	cgacttgcgt	caaggccggc	tggacttccc	gggcttcgtg	cagaccagcc	780
tggcaacgct	gcgcttcttc	tgctacatcg	tgggcctgag	tctcctggcg	gccgtcagcg	840
tggagcagtg	cctggccgccc	ctttcccaag	cctggtaactc	gtgcccggc	ccacgcccacc	900
tgaccacctg	tgtgtgcgcc	ctcacctggg	ccctctgcct	gctgctgcac	ctgctgctca	960
gccccgcctg	cacccagttc	ttcggggagc	ccagccgcca	cttgcgcgg	acgctgtggc	1020
tggtggcagc	ggtgctgctg	gctctgtgt	gttgcaccat	gtgtggggcc	agccttatgc	1080
tgctgctgcg	ggtggagcga	ggcccccagc	ggcccccacc	ccggggcttc	cctggctca	1140
tcctcctcac	cgtcctcctc	ttcctttct	gccccctgcc	cttcggcatac	tactggctgt	1200
cccgaaacct	gctctggta	atccccact	acttctacca	cttcagcttc	ctcatggccg	1260
ccgtgcactg	cgcggccaag	cccgtcgct	acttctgcct	gggcagtgcc	caggccgca	1320
ggctgcccct	ccggctggtc	ctccagcgag	cgctgggaga	cgaggctgag	ctggggcccg	1380
tcagggagac	ctcccgcccg	ggcctggtgg	acatagcagc	ctgagccctg	ggccccccga	1440
ccccagctgc	agccccctg	aggcaagagg	gtgacgtggg	gaaggtggtg	gggtcagagg	1500
ctggggccag	ccggacctgg	aggaggcctt	ggtgggtgac	ccggtcatgt	gctgtcaaag	1560
ttgtgaccct	tggtctggag	catgaggctc	ccctgggagg	cagctggaaa	gg	1612

<210> 42  
 <211> 530  
 <212> PRT  
 <213> Homo sapiens

<400> 42

Val Ser Arg Asp Gly Ala Ile Ala Leu Pro Gly Ala Thr Glu Pro Asp  
 1 5 10 15

Ser Ile Ser Lys Lys Lys Arg Pro Phe Gly Ser Arg His His Gln Gln  
 20 25 30

Gly Ala Pro Trp Val Ser Asp Pro Leu Pro Thr Ser Pro Gly Pro Cys  
35 40 45

Pro His Leu Ala Tyr Arg Asp Gln Pro His Gly Arg Leu Leu Arg Pro  
50 55 60

Gly Asn His Gly Glu Gly Arg Asn Gly Asp Thr Phe Leu Leu Ser Val  
65 70 75 80

Leu Gly Lys Arg Ser Leu Gly Gln Val Ala Glu Gly Gly Asn Glu Arg  
85 90 95

Gly Val Ser Ser Trp Arg Val Ser Pro Phe Pro Trp Ser Pro Thr Gln  
100 105 110

Leu Ser Ser Pro Leu Met Trp Gly Gly Ala Gly Gly Met Asp Ser Ala  
115 120 125

Pro Asp Ser Thr Val Val Tyr Arg Gly Ile Arg Arg Glu Ser Glu  
130 135 140

Gln Asn Thr Leu Leu Gln His Pro Leu Ala Pro Arg Pro Met Met Glu  
145 150 155 160

Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Gly Ala Gln Glu  
165 170 175

Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu Gly Leu Gly  
180 185 190

Leu Gly Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu Leu Ser Ser  
195 200 205

Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp Val Ala Cys  
210 215 220

Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile Val Pro Asp  
225 230 235 240

Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln Thr Ser Leu  
245 250 255

Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu Leu Ala Ala  
260 265 270

Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala Trp Tyr Ser  
275 280 285

Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala Leu Thr Trp  
290 295 300

Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Gly Ala Cys Thr Gln  
305 310 315 320

Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu Trp Leu Val  
325 330 335

Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys Gly Ala Ser

	340	345	350
Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg Pro Pro Pro	355	360	365
Arg Gly Phe Pro Gly Leu Ile Leu Leu Thr Val Leu Leu Phe Leu Phe	370	375	380
Cys Gly Leu Pro Phe Gly Ile Tyr Trp Leu Ser Arg Asn Leu Leu Trp	385	390	395
Tyr Ile Pro His Tyr Phe Tyr His Phe Ser Phe Leu Met Ala Ala Val	405	410	415
His Cys Ala Ala Lys Pro Val Val Tyr Phe Cys Leu Gly Ser Ala Gln	420	425	430
Gly Arg Arg Leu Pro Leu Arg Leu Val Leu Gln Arg Ala Leu Gly Asp	435	440	445
Glu Ala Glu Leu Gly Ala Val Arg Glu Thr Ser Arg Arg Gly Leu Val	450	455	460
Asp Ile Ala Ala Ala Leu Gly Pro Pro Thr Pro Ala Ala Ala Pro Val	465	470	475
Arg Gln Glu Gly Asp Val Gly Lys Val Val Gly Ser Glu Ala Gly Ala	485	490	495
Ser Arg Thr Trp Arg Arg Pro Trp Trp Val Thr Arg Ser Cys Ala Val	500	505	510
Lys Val Val Thr Leu Gly Leu Glu His Glu Ala Pro Leu Gly Gly Ser	515	520	525
Trp Lys	530		
<210> 43			
<211> 1612			
<212> DNA			
<213> Homo sapiens			
<400> 43			
cagtggccg agatggtgcc attgcactct agcctggggc aacagagcca gactccatct			
ccaaaaaaaaa aaggccattc tgaggatcaa ggcaccacta gcaacaggg accccatggg			
tctcagaccc tctcccccaca tctcctggtc cctggccccc cctggcgta c agggaccaggc			
cccacggaag gctcttgagg ccaggttaacc atggggaggg gaggaatgg gacacccccc			
tcctgagtgt ctttaggaaag agaagcttag gtcagggtggc tgagggtgga aatgagagag			
gggtctccctc ctggagggtc tcaccatcc cttggtcacc cacccaaactc tcatctcccc			
tgatgtgggg aggagcaggg ggcattggatt cctgagcccc agactcaact gttgtggttt			
acaggggcat caggagagag agcgagcaga acacactct gcagcatccc ctggcccccc			
420			
480			

gccccatgtatggccaga	540
ggagctggac	
agcacgtggg	
ggccgccaac	
ggcgcggcagg	
aggatgtggc	600
cttcaacctc	
atcatctgt	
ccctcaccga	
ggggctcggc	
ctcgggtggc	
tgctgggaa	660
tggggcagtc	
ctctggctgc	
tcagctccaa	
tgtctacaga	
aacccttcg	
ccatctacct	720
cctggacgtg	
gcctgcgcgg	
atctcatctt	
ccttggctgc	
cacatggtgg	
ccatcgccc	780
cgacttgctg	
caaggccggc	
tggacttccc	
gggcttcgtg	
cagaccagcc	
tggcaacgct	840
gcgcttcttc	
tgctacatcg	
tgggcctgag	
tctcctggcg	
gccgtcagcg	
tggagcagtg	900
cctggccgccc	
ctttcccaag	
cctggtaactc	
gtgccgcgc	
ccacgcccacc	
tgaccacctg	960
tgtgtgcgccc	
ctcacctggg	
ccctctgcct	
gctgctgcac	
ctgctgctca	
gccccgcctg	1020
cacccagttc	
ttcggggagc	
ccagccgcctt	
cttgcgcgg	
acgctgtggc	
tggtggcagc	1080
ggtgctgctg	
gctctgtgt	
gttgcaccat	
gtgtggggcc	
agccttatgc	
tgctgctgcg	1140
ggtggagcga	
ggcccccagc	
ggccccccacc	
ccggggcttc	
cctgggctca	
tcctcctcac	1200
cgtcctcctc	
ttcctcttc	
gcggcctgccc	
cttcggcattc	
tactggctgt	
cccggaacct	1260
gctctggta	
atccccact	
acttctacca	
cttcagcttc	
ctcatggccg	
ccgtgcactg	1320
cgcggccaag	
cccgtcgct	
acttctgcct	
gggcagtgcc	
cagggccgca	
ggctgcccct	1380
ccggctggtc	
ctccagcgag	
cgctggaga	
cgaggctgag	
ctggggcccg	
tcagggagac	1440
ctcccgccgg	
ggcctggtgg	
acatagcagc	
ctgagccctg	
gggcccccg	
ccccagctgc	1500
agccccctgt	
aggcaagagg	
gtgacgtggg	
gaaggtggtg	
gggtcagagg	
ctggggccag	1560
ccggacactgg	
aggaggcctt	
ggtgggtgac	
ccggtcatgt	
gctgtcaaag	
ttgtgaccct	1612
tggtctggag	
catgaggttc	
ccctgggagg	
cagctggaaa	
gg	

<210> 44  
 <211> 311  
 <212> PRT  
 <213> Homo sapiens  
 <400> 44

Met Met Glu Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Gly  
 1 5 10 15

Ala Gln Glu Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu  
 20 25 30

Gly Leu Gly Leu Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu  
 35 40 45

Leu Ser Ser Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp  
 50 55 60

Val Ala Cys Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile  
 65 70 75 80

Val Pro Asp Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln  
 85 90 95

Thr Ser Leu Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu  
 100 105 110

Leu Ala Ala Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala  
 115 120 125

Trp Tyr Ser Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala  
 130 135 140

Leu Thr Trp Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Gly Ala  
 145 150 155 160

Cys Thr Gln Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu  
 165 170 175

Trp Leu Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys  
 180 185 190

Gly Ala Ser Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg  
 195 200 205

Pro Pro Pro Arg Gly Phe Pro Gly Leu Ile Leu Leu Thr Val Leu Leu  
 210 215 220

Phe Leu Phe Cys Gly Leu Pro Phe Gly Ile Tyr Trp Leu Ser Arg Asn  
 225 230 235 240

Leu Leu Trp Tyr Ile Pro His Tyr Phe Tyr His Phe Ser Phe Leu Met  
 245 250 255

Ala Ala Val His Cys Ala Ala Lys Pro Val Val Tyr Phe Cys Leu Gly  
 260 265 270

Ser Ala Gln Gly Arg Arg Leu Pro Leu Arg Leu Val Leu Gln Arg Ala  
 275 280 285

Leu Gly Asp Glu Ala Glu Leu Gly Ala Val Arg Glu Thr Ser Arg Arg  
 290 295 300

Gly Leu Val Asp Ile Ala Ala  
 305 310

<210> 45  
 <211> 939  
 <212> DNA  
 <213> Homo sapiens

<400> 45  
 atgatggagc ccagagaagc tggacagcac gtggggggccg ccaacagcgc ccaggaggat 60  
 gtggcttca acctcatcat cctgtccctc accgaggggc tcggcctcgg tgggtgtctg 120  
 ggaaatgggg cagtcctctg gctgctcagc tccaatgtct acagaaaccc cttcgccatc 180

tacctcctgg acgtggcctg	240
cgcgatctc atcttccttg	
gctgccacat ggtggccatc	
gtccccact tgctgcaagg	300
ccggctggac ttcccggtct	
tcgtcagac cagcctggca	
acgctgcgt tcttcgtcta	360
catcgtggc ctgagtctcc	
tggcggccgt cagcgtggag	
cagtgcctgg ccgcctctt	420
cccagcctgg tactcgtgcc	
gccgcccacg ccacctgacc	
acctgtgtgt gcccctcac	480
ctggcccttc tgcctgctgc	
tgcacctgtct gctcagcggc	
gcctgcaccc agttttcgg	540
ggagcccagc cgccacttgt	
gccggacgt gtggctggtg	
gcagcggtgc tgctggctct	600
gctgtgttgc accatgtgtg	
gggccagcct tatgctgtg	
ctgcgggtgg agcgaggccc	660
ccagcggccc ccacccggg	
gcttcctgg gctcatcctc	
ctcaccgtcc tcctcttcct	720
cttctgcggc ctgccttcg	
gcatctactg gctgtcccg	
aacctgtct ggtacatccc	780
ccactacttc taccactca	
gcttcctcat ggccgcccgt	
cactgcgcgg ccaagcccgt	840
cgtctacttc tgctggca	
gtgcccaggg ccgcaggctg	
cccctccggc tggcctcca	900
gcgagcgttg ggagacgagg	
ctgagctggg ggccgtcagg	
gagacctccc gccggggcct	
ggtggacata gcagcctga	939

<210> 46  
 <211> 311  
 <212> PRT  
 <213> Homo sapiens

<400> 46

Met Met Glu Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Ser  
 1 5 10 15

Ala Gln Glu Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu  
 20 25 30

Gly Leu Gly Leu Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu  
 35 40 45

Leu Ser Ser Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp  
 50 55 60

Val Ala Cys Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile  
 65 70 75 80

Val Pro Asp Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln  
 85 90 95

Thr Ser Leu Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu  
 100 105 110

Leu Ala Ala Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala  
 115 120 125

Trp Tyr Ser Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala  
 130 135 140  
 Leu Thr Trp Ala Leu Cys Leu Leu Leu His Leu Leu Ser Gly Ala  
 145 150 155 160  
 Cys Thr Gln Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu  
 165 170 175  
 Trp Leu Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys  
 180 185 190  
 Gly Ala Ser Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg  
 195 200 205  
 Pro Pro Pro Arg Gly Phe Pro Gly Leu Ile Leu Leu Thr Val Leu Leu  
 210 215 220  
 Phe Leu Phe Cys Gly Leu Pro Phe Gly Ile Tyr Trp Leu Ser Arg Asn  
 225 230 235 240  
 Leu Leu Trp Tyr Ile Pro His Tyr Phe Tyr His Phe Ser Phe Leu Met  
 245 250 255  
 Ala Ala Val His Cys Ala Ala Lys Pro Val Val Tyr Phe Cys Leu Gly  
 260 265 270  
 Ser Ala Gln Gly Arg Arg Leu Pro Leu Arg Leu Val Leu Gln Arg Ala  
 275 280 285  
 Leu Gly Asp Glu Ala Glu Leu Gly Ala Val Arg Glu Thr Ser Arg Arg  
 290 295 300  
 Gly Leu Val Asp Ile Ala Ala  
 305 310

<210> 47  
 <211> 22  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Novel Sequence  
  
 <400> 47  
 ctgagcatgg atccaaccac cc

22

<210> 48  
 <211> 29  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Novel Sequence  
  
 <400> 48  
 ctctacacca gactgcttct cgacatctc

29

<210> 49  
<211> 25  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 49  
agatggagac caccatgggg ttcac 25

<210> 50  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 50  
gggttatttt agtctgatgc agtccacac 30

<210> 51  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 51  
gatcgaattc atgatggagc ccagagaagc tggac 35

<210> 52  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 52  
gatcctcgag tcaggctgct atgtccacca ggcc 34

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> Novel Sequence

<400> 53  
acagccccaa agccaaacac 20

<210> 54  
<211> 22  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Novel Sequence  
  
<400> 54  
ccgcaggagc aatgaaaatc ag

22

<210> 55  
<211> 22  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Novel Sequence  
  
<400> 55  
ctgagcatgg atccaaaccac cc

22

<210> 56  
<211> 29  
<212> DNA  
<213> Artificial  
  
<220>  
<223> Novel Sequence  
  
<400> 56  
ctctacacca gactgcttct cgacatctc

29

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
WO 01/48015 A3

(51) International Patent Classification<sup>2</sup>: C07K 14/72, C12N 15/12, 15/861, 15/863, 15/864, 15/867, 15/869, 5/10, C07K 16/28, G01N 33/53, C12Q 1/68

MI 49024 (US). HIEBSCH, Ronald, R.; 917 Lane Boulevard, Kalamazoo, MI 49001 (US). RUFF, Valerie; Portage, MI (US).

(21) International Application Number: PCT/US00/35456

(74) Agents: DELUCA, Mark et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(22) International Filing Date:

28 December 2000 (28.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language:

English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language:

English

(30) Priority Data:

60/173,339	28 December 1999 (28.12.1999)	US
60/184,305	23 February 2000 (23.02.2000)	US
60/188,880	13 March 2000 (13.03.2000)	US
60/200,534	27 April 2000 (27.04.2000)	US
60/219,492	20 July 2000 (20.07.2000)	US
60/224,321	11 August 2000 (11.08.2000)	US
60/239,062	9 October 2000 (09.10.2000)	US

Published:

— with international search report

(71) Applicant: PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(88) Date of publication of the international search report: 10 May 2002

(72) Inventors: LIND, Peter; Borjegatan 31C, S-751 29 Uppsala (SE). PARODI, Luis, A.; Grevgafan 24, S-115 43 Stockholm (SE). LINDBERG, Eleni; Nacka (SE). VOGELI, Gabriel; 2576 9th Avenue West, Seattle, WA 98119 (US). WOOD, Linda, Susan; 10193 Fox Hollow, Portage,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/48015 A3

(54) Title: G PROTEIN-COUPLED RECEPTORS

(57) Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/35456

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07K14/72	C12N15/12	C12N15/861	C12N15/863	C12N15/864
	C12N15/867	C12N15/869	C12N5/10	C07K16/28	G01N33/53
	C12Q1/68				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7	C12N	C07K	G01N	C12Q
-------	------	------	------	------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

GENSEQ, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE GENEMBL 'Online! 13 July 1997 (1997-07-13) TRENKLE ET AL.: "AF003828 human erythroleukemia RAP-PCR products Homo sapiens cDNA clone TF-1/A1-1, mRNA sequence" XP002170928</p> <p>Accession AF003828</p> <p>-----</p> <p>-/-</p>	<p>1-4, 7-9, 12-27, 29-34, 40, 44, 45, 47, 48, 50, 51, 53, 58-60</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 November 2001

Date of mailing of the international search report

04.12.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG., A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/35456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 46620 A (MILLENNIUM PHARM INC) 22 October 1998 (1998-10-22)  page 4, line 19 -page 7, line 3 page 28, line 6 -page 45, line 4 page 55, line 6 -page 62, line 14 ---	1-5, 7-10, 12-27, 29-38, 40-45, 47-53, 55-60, 86-88
A	WO 99 32519 A (FORTIN YVES ;LEMBO PAOLA (CA); AHMAD SULTAN (CA); BANVILLE DENIS () 1 July 1999 (1999-07-01) page 1, line 25 -page 5, line 20 figures 1,4; examples 1,2 SEQ ID NO: 3,7,9 ---	1-62, 64-89
P, X	WO 00 34334 A (SYNAPTIC PHARMA CORP) 15 June 2000 (2000-06-15)  page 3 -page 14 ---	1-5, 7-10, 12-27, 29-38, 40-45, 47-53, 55-60, 86-88
E	WO 01 19983 A (DELEERSNIJDER WILLY ;HEUVAERT NICOLE D (BE); NYS GUY (BE); SOLVAY) 22 March 2001 (2001-03-22)  page 11 -page 29 ---	1-5, 7-10, 12-27, 29-38, 40,44, 45,47, 48,50, 51,53, 55,56, 58-60, 86-88
E	WO 01 18206 A (LEXICON GENETICS INC) 15 March 2001 (2001-03-15) page 6, line 23 -page 7, line 25 page 10, line 31 -page 11, line 3 page 11, line 29 -page 12, line 7 page 13, line 25 -page 14, line 14 page 14, line 23 -page 24, line 17 page 26, line 7 -page 29, line 3 page 39, line 1 -page 57, last line ---	1-60, 73-86, 89
		-/-

## II INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/35456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>DATABASE WPI  Section Ch, Week 200123  Derwent Publications Ltd., London, GB;  Class B04, AN 2001-226684  XP002183350  &amp; WO 01 16309 A (TAKEDA CHEM IND LTD),  8 March 2001 (2001-03-08)</p> <p>abstract  -&amp; DATABASE GENSEQ 'Online!  29 May 2001 (2001-05-29)  WATANABE, T. ET AL.: "Human  G-protein-coupled receptor protein"  XP002183348  Accessions AAB70143  -&amp; DATABASE GENSEQ 'Online!  29 May 2001 (2001-05-29)  WATANABE, T. ET AL.: "DNA encoding human  G-protein-coupled receptor protein"  XP002183349  Accession AAF79502</p> <p>---</p> <p>WO 01 62797 A (PARODI LUIS A ;LIND PETER  (SE); UPJOHN CO (US); VOGELI GABRIEL (US)  30 August 2001 (2001-08-30)  see claims  SEQ ID NO:53,113</p> <p>---</p> <p>WO 01 72840 A (PE CORP NY)  4 October 2001 (2001-10-04)  page 6, last paragraph -page 44  SEQ ID NOs:3,4</p> <p>---</p>	1-5, 7-10, 12-27, 29-38, 40-45, 47-53, 55-60, 86-88
E		1-62, 64-89
E		1-62, 64-89

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/35456

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claim 44 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: 41-43, 49, 52, 57 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 41-43, 49,52,57

Present claims 41-43 relate to an antibody defined by reference to a desirable characteristic or property, namely, its ability to bind the polynucleotide of the invention. The claims cover all antibodies having this characteristic or property, whereas the application provides neither support within the meaning of Article 6 PCT nor disclosure within the meaning of Article 5 PCT for none of such antibodies. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the antibody by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for those claims.

Present claims 49,52,57 relate to compounds defined by reference to a desirable characteristic or property, namely, their ability to be identified by the methods of claims 45, 50 and 53, respectively. The claims cover all compounds having this characteristic or property, whereas the application provides neither support within the meaning of Article 6 PCT nor disclosure within the meaning of Article 5 PCT for none of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has not been carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5, 7-10, 12-27, 29-38, 40-45, 47-53, 55-60 and 86-88 (partially)

An isolated nucleic acid molecule (SEQ ID NO:11) encoding a polypeptide comprising an aminoacid sequence (SEQ ID NO:24) coding for the G-protein coupled receptor nGPCR-1003; expression vector and host cells containing said polynucleotide, a method for the recombinant production of the polypeptide of the invention; an antibody that binds to the polypeptide of the invention; methods to identify compounds that bind to the nGPCR-1003 polynucleotide or nGPCR-1003 polypeptide; a method of identifying an animal homolog of nGPCR-1000; a method to purify a G-protein from a sample by binding to nGPCR-1000.

2. Claims: 1-61, 64-86, 89 (partially) and 63 (complete).

As invention 1, but referring to the G-protein coupled receptor nGPCR-1007 (SEQ ID NOs: 25) encoded by the polynucleotide of SEQ ID NO: 12; in addition, the invention also claims methods to diagnose a brain disorder or a genetic predisposition to a mental disorder and by detecting mutations in nGPCR-1007; kits for carrying out above methods; a method for identifying a nGPCR-1007 allelic variant; a method for identifying a modulator of biological activity of nGPCR-1007; a method to identify compounds useful in the treatment of a mental disorder by identifying compounds which bind to nGPCR-1007.

3. Claims: 1-5, 7-10, 12-27, 29-38, 40-45, 47-53, 55-60 and 86-88 (partially)

As invention 1, but referring to the G-protein coupled receptor nGPCR-1006 (SEQ ID NOs: 26,27) encoded by the polynucleotide of SEQ ID NO: 13.

4. Claims: 1-61, 64-89 (partially) and 62 (complete).

As invention 1, but referring to the G-protein coupled receptor nGPCR-1002 (SEQ ID NO: 46) encoded by the polynucleotide of SEQ ID NO: 45; in addition, the invention also claims methods to diagnose a brain disorder or a genetic predisposition to a mental disorder and by detecting mutations in nGPCR-1002; kits for carrying out above methods; a method for identifying a nGPCR-1002 allelic variant; a method for identifying a modulator of biological activity of nGPCR-1002; a method to identify compounds

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

useful in the treatment of a mental disorder by identifying compounds which bind to nGPCR-1002.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/35456

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9846620	A	22-10-1998	US 5891720 A AU 6973698 A EP 1007536 A1 WO 9846620 A1	06-04-1999 11-11-1998 14-06-2000 22-10-1998
WO 9932519	A	01-07-1999	AU 1990499 A BR 9814335 A CN 1284966 T EP 1051434 A1 NO 20003221 A PL 341524 A1 WO 9932519 A1 SK 8752000 A3 TR 200001861 T2	12-07-1999 10-10-2000 21-02-2001 15-11-2000 10-08-2000 23-04-2001 01-07-1999 18-01-2001 21-11-2000
WO 0034334	A	15-06-2000	AU 2172300 A EP 1147136 A1 WO 0034334 A1	26-06-2000 24-10-2001 15-06-2000
WO 0119983	A	22-03-2001	AU 7777400 A WO 0119983 A1	17-04-2001 22-03-2001
WO 0118206	A	15-03-2001	AU 7475400 A WO 0118206 A1	10-04-2001 15-03-2001
WO 0116309	A	08-03-2001	AU 6728000 A WO 0116309 A1	26-03-2001 08-03-2001
WO 0162797	A	30-08-2001	AU 5787501 A WO 0148015 A2 WO 0162797 A2	09-07-2001 05-07-2001 30-08-2001
WO 0172840	A	04-10-2001	WO 0172840 A2	04-10-2001

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

**THIS PAGE BLANK (USPTO)**